58th Annual Meeting of the Scientific and Standardization Committee of the ISTH

LIVERPOOL
UNITED KINGDOM

EDUCATIONAL FORMAT
27-30 JUNE 2012

www.ssc2012.org
WE ARE
BIOGEN IDEC HEMOPHILIA
AND WE ARE RESEARCHING THE POTENTIAL
FOR LONG-LASTING FACTORS

With a team dedicated to improving the lives of people with hemophilia around the world

▶ United in our passion for making a difference on a global scale
▶ A dedicated team, including leaders from the hemophilia community
▶ Developing hemophilia factors with safety as our priority

With our development partner, Swedish Orphan Biovitrum, we are using forward-thinking technology to advance hemophilia research

LEARN MORE AT
www.Biogenidec.com

© 2012 Biogen Idec Inc. All rights reserved.
WE ARE BIOGEN IDEC HEMOPHILIA

AND WE ARE RESEARCHING THE POTENTIAL FOR LONG-LASTING FACTORS

With a team dedicated to improving the lives of people with hemophilia around the world

› United in our passion for making a difference on a global scale
› A dedicated team, including leaders from the hemophilia community
› Developing hemophilia factors with safety as our priority

With our development partner, Swedish Orphan Biovitrum, we are using forward-thinking technology to advance hemophilia research

LEARN MORE AT www.Biogenidec.com
Benjamin’s bravery amazes his parents and inspires us

When Benjamin was diagnosed with severe haemophilia A and an inhibitor, his parents thought their world was coming to an end. Yet, new therapies, effective support, and the bravery of their son, have shown them that anything is possible.

At Novo Nordisk, we are inspired by the courage we see in the haemophilia community, as well by our potential to deliver positive change for people affected by the condition. From our laboratories to our production line – and even beyond, in volunteer programmes that see our colleagues go out and make a difference for people with haemophilia in their local communities – we maintain a unique culture that is passionate about putting the needs of individuals at the heart of our actions.

Find out how Novo Nordisk is changing possibilities in haemophilia at changingpossibilities.com.
Table of Contents

3  Welcome Message from the Meeting President
3  Welcome Message from ISTH Council Chairman
4  Welcome Message from SSC Chairman
5  Committees
7  ISTH Future Meetings Calendar
8  Meeting Sponsors
9  Awards and Grants 2012
12 General Information
20 Programme at a Glance
21 Day by Day Scientific Schedule & Programme
22 Detailed Programme  Tuesday, 26 June 2012
25 Detailed Programme  Wednesday, 27 June 2012
33 Detailed Programme  Thursday, 28 June 2012
44 Detailed Programme  Friday, 29 June 2012
56 Detailed Programme  Saturday, 30 June 2012
68 Hot Topics Schedule
71 ePoster Sessions
97 Sponsor & Exhibitor Profiles
110 Exhibition Floor Plan
111 Congress Centre Floor Plan

www.isth.org
The

Roald Dahl Haemostasis & Thrombosis Centre, Liverpool

is privileged to welcome delegates of the

58th Scientific & Standardization Sub-Committee Meeting of the

International Society on Thrombosis and Haemostasis

in the shared aim of

Setting the best Standards of Care for our patients
Welcome Messages

Message from the ISTH SSC 2012
Meeting President

Dear Colleagues and Friends,

We warmly welcome you to the Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) at Liverpool’s UNESCO World Heritage Centre waterfront!

As setting standards is fundamental to all quality outcomes, our objective for this meeting in Liverpool will be to convey how the SSC is well-positioned to translate new knowledge into better patient care. Promoting cross-information exchange and engaging with external partners are key to deliver solutions for patients with haemostatic and thrombotic problems.

Developing future leaders is also key to the vitality of ISTH and this meeting will be rooted in the themes of Education, Engagement and Translation. I am therefore delighted that SSC 2012 offers a coherent programme with a Trainees’ Day on Consultative Coagulation, an Education Day on Setting Standards of Care, a Presidential Plenary on Translational Thrombosis & Haemostasis and enhanced opportunities to Meet-the-Experts.

I look forward to greeting you personally and wish you the best of experiences in Liverpool!

With best wishes.

CHENG-HOCK TOH
M.D., FRCP, FRCPath

Message from the ISTH
Chairman of Council

Dear Colleagues and Friends,

It is my distinct privilege to welcome you to Liverpool for our 2012 SSC meeting.

Dr. Cheng-Hock Toh and his colleagues have set up a great Programme aiming at making our off-congress year meeting especially attractive for our participants.

Since 2008, beside the usual in-depth work of the Subcommittees, our SSC meetings include a large educational programme that targets young basic and clinical scientists. Because of the smaller format of these meetings, compared to our biennial congresses, it also allows to experiment with innovations. With a very encouraging number of abstracts submitted, we will have stimulating “hot topic abstracts” reporting late-breaking results in basic and clinical science, and also regular abstracts featured as “e-posters”. These innovations will further foster the exchange of knowledge and the educational experience for our participants.

I look forward to meeting you in the course of the week and attending and actively participating in what looks like an outstanding program.

Thank you for attending our 58th SSC meeting to experience the “science, culture, and friendship!”. Welcome to Liverpool!

HENRI BOUNAMEAUX M.D.
Dear Colleagues and Friends,

Following the success of the SSC meeting in Kyoto, we are back in Europe and I warmly welcome you to a new and very innovative meeting in Liverpool.

As is the tradition of the SSC, the format of the 2012 meeting is designed to favor an active exchange of new important information and topics of research, and to stimulate cross-disciplinary collaborations. The conference will start with a strong educational programme, providing an opportunity of intensive training for our younger colleagues. Then the meetings of all sub-committees of the SSC will follow and the results of the new and on-going projects of each subcommittee will be extensively discussed. This will provide the new insights into the most challenging practical issues in thrombosis and hemostasis, and also will grant an expert view on the standardization of basic and clinical research methods, nomenclature, preparation of reference reagents, and evaluation of new tests and new drugs.

Professor Cheng-Hock Toh and his colleagues on the Local Organizing Committee have assembled a very high-level programme, which will also include for the first time “Hot topic abstracts” and regular abstracts that will be presented as e-posters. This novelty will help to highlight the most recent achievements in basic and clinical research and will be a great challenge for young investigators.

To maintain the high level reached by the SSC it is important that those who are not currently a member, not only participate in the meeting, but make an active contribution, participating in the working projects and registries, and become a member of one of the sub-committees.

The dynamic and energizing atmosphere of Liverpool will provide the perfect setting for the offspring of new projects and collaborations, and will guarantee a great success of the 2012 ISTH/SSC conference.

Welcome to Liverpool!

ANNA FALANGA  M.D.
Committees

Organizing Committee
Cheng-Hock Toh, President (United Kingdom)
Jecko Thachil (United Kingdom)
Simon Abrams (United Kingdom)
Tina Dutt (United Kingdom)
Ian Greer (United Kingdom)
Colin Downey (United Kingdom)

Officers of the Scientific and Standardization Committee
Anna Falanga (Italy)
Chairman (2010-2012)

David Lillicrap (Canada)
Secretary/Chairman-Elect (2010-2012 / 2012-2014)

Subcommittees of the Scientific and Standardization Committee
Animal, Cellular, and Molecular Models of Thrombosis
Susan S. Smyth (USA)

Biorheology
Michael R. King (USA)

Control of Anticoagulation
Walter Ageno (Italy)

Disseminated Intravascular Coagulation (DIC)
Hideo Wada (Japan)

Exogenous Hemostatic Factors, Registry of
Jan Rosing (The Netherlands)

Factor VIII & Factor IX
Flora Peyvandi (Italy)

Factor XI and the Contact System
Thomas Renne (Sweden)

Factor XIII and Fibrinogen
Hans P Kohler (Switzerland)

Fibrinolysis
Ann Gils (Belgium)

Hemostasis & Malignancy
Agnes Y Y Lee (Canada)

Lupus Anticoagulant/Phospholipid-dependent Antibodies
Thomas L Ortel (USA)

Perinatal/Pediatric Hemostasis
Paul Monagle (Australia)

Plasma Coagulation Inhibitors
Steven Kitchen (United Kingdom)

Platelet Immunology
Yves Gruel (France)

Platelet Physiology
Paul Harrison (United Kingdom)

Predictive Hemostatic Variables and Cardiovascular Disease
James Douketis (Canada)
Committees

Vascular Biology
Françoise Dignat-George (France)

Von Willebrand Factor
Jeroen CJ Eikenboom (The Netherlands)

Women’s Health Issues in Thrombosis and Haemostasis
Sabine Eichinger (Austria)

SSC Working Group on Coagulation Standards
Anthony Hubbard (United Kingdom)

Council of the International Society on Thrombosis and Haemostasis (ISTH)

Chairman of Council (2010-2012)
Henri Bounnameaux (Switzerland)

Secretary/Chairman-Elect of Council (2010-2012 / 2012-2014)
Michael Berndt (Ireland)

Treasurer (2011-2015)
Nuala Booth (United Kingdom)

Class of 2012
Michael Berndt (Ireland)
Henri Bounnameaux (Switzerland)
Alan Nurden (France)
Bjarne Østerud (Norway)
Pieter Reitsma (The Netherlands)

Class of 2014
Nuala Booth (United Kingdom)
Françoise Dignat-George (France)
Nigel Key (USA)
Robert Montgomery (USA)
Hugo ten Cate (The Netherlands)

Class of 2016
Marco Cattaneo (Italy)
Björn Dahlbäck (Sweden)
Andreas Greinacher (Germany)
Paula Tracy (USA)
Yukio Ozaki (Japan)

Ex-Officio Council Members

Bruce Furie (USA)

Secretary General (2010-2014)

Frits R. Rosendaal (The Netherlands)
President of the XXIV Congress (Amsterdam, 2013)
& Immediate Past Chairman of Council

Pieter Reitsma (The Netherlands)
Vice-President of the XXIV (Amsterdam, 2013) Congress

Yasuo Ikeda (Japan)
President of the XXIII Congress (Kyoto, 2011)

Mike Greaves and David Lane (United Kingdom)
Editors-in-Chief, Journal of Thrombosis and Haemostasis

Anna Falanga (Italy)
Chairman, Scientific and Standardization Committee
Committees

SSC 2012 Abstract Reviewers

Ken Bauer (USA)
Nuala Booth (United Kingdom)
James Crawley (United Kingdom)
Françoise Dignat-George (France)
Alison Goodall (United Kingdom)
Tilman Hackeng (The Netherlands)
Katherine Hajjar (USA)
Keith Hoots (USA)
Bendt Jilma (Austria)
Paul Kyrle (Austria)
Nigel Mackman (USA)
Andrew Mumford (United Kingdom)
Bjarne Østerud (Norway)
Evan Sadler (USA)
Hugo ten Cate (The Netherlands)
Jecko Thachil (United Kingdom)
Cheng-Hock Toh (United Kingdom)
Steve Watson (United Kingdom)

ISTH Future Meetings Calendar

XXIV ISTH Congress and 59th Annual SSC Meeting
Frits R. Rosendaal, President
Amsterdam, The Netherlands
29 June - 4 July, 2013
www.isth2013.com

60th Annual SSC Meeting
Robert R. Montgomery, President
Milwaukee, WI, USA
2014

XXV ISTH Congress and 61st Annual SSC Meeting
Sam Schulman, President
Toronto, Canada
2015

XXVI ISTH Congress and 63rd SSC Meeting
Johannes Oldenburg, President
Berlin, Germany
2017

XXVII ISTH Congress and 65th SSC Meeting
Robert Medcalf, President
Melbourne, Australia
2019
Meeting Sponsors

The ISTH and the SSC 2012 Local Organizing Committee would like to thank the following companies for their generous support of the 58th Annual Meeting of the Scientific and Standardization Committee of the ISTH.

**Platinum Level**

BAYER

**Gold Level**

Inspiration Biopharmaceuticals

**Silver Level**

Pfizer

Stago

**Bronze Level**

Daiichi Sankyo

SANOFI

**Sponsors, Exhibitors and Partners**

*List correct as at 22 May 2012*

4S DAWN Clinical Software

ACC Liverpool

Affinity Biologicals Inc.

Alexion

Amgen

Baxter Healthcare Inc.

Bayer

Biogen Idec & Swedish Orphan Biovitrum

Boehringer Ingelheim Limited

CSL Behring

Daiichi Sankyo Europe GmbH

Enzyme Research / r2 Diagnostics

GlaxoSmithKline

Haematologic Technologies, Inc.

Haemonetics Corporation

Helena Biosciences Europe

HPS Network UK

HemaCore LLC

Inspiration Biopharmaceuticals, Inc.

Instrumentation Laboratory

Microvsk Technologies

Mitsubishi Pharma

Multiplate - Verum Diagnostica GmbH

Novo Nordisk

Octapharma AG

Pathway Diagnostics Ltd.

Pentaplharm / DSM

Pfizer

Precision BioLogic

Sanofi

Schattauer GmbH

Siemens / Healthcare Diagnostics Products GmbH

Stago

Sysmex UK Ltd.

Technoclone
Awards and Grants 2012

ISTH Young Investigator Awards

The Young Investigator Awards were provided in the form of travel grants to medical trainees and young scientists (under 35 years of age as of 27 June, 2012) who submit highly rated abstracts. These awards have been made possible thanks to ISTH and the 58th Scientific and Standardization Committee meeting of the International Society on Thrombosis and Haemostasis.

Awardees

Simon Abrams
Yasir Alhamdi
Seamus Allen
Sandra Baker
Anna Balandina
Cecilia Becattini
Giselle Begue
Saartje Bloemen
Marc Blondon
Annamieke Bouman
Roza Chaireti
Katarzyna Czerwińska-Jelonkiewicz
Hugoline de Haan
Susanne de Witt
Jun Deng
Ming-Yang Deng
Erika Diani
Jonathan Douxfils
Natalia Dovlatova
Lizaveta Drozd
Lisa Duffett
Petra Erkens
Elena Maria Faioni
Giovanni Favuzzi
Lena Furmark
Ivona Geenen
Jayandharan Giridhara Rao
Wenjuan He
Ivana Horvat
Walter Janse van Rensburg
Jiang Jiang
Miao Jiang
Yosuke Kanno
Alev Karasu
Marie-Claire Kleinegris
Gerhardus Kuiper
Rinske Loeffen
Ana Lopez
Marie Lordkipanidze
Gillian Lowe
Yeling Lu
Stephen Macdonald
Ilaria Mancini
Maura Marucci
Olesya Matvienko
Alexandra Mazharian
Kate Monagle
Micah Mooberry
Christopher Moxon

Country

United Kingdom
United Kingdom
Ireland
USA
Russian Federation
Italy
Argentina
The Netherlands
USA
The Netherlands
Sweden
Poland
The Netherlands
The Netherlands
China
China
Italy
Belgium

ISTH 2012  11.6.2012  14:46  Page 9
Awards and Grants 2012

Omonivie Okaisabor
Abimbola Onasoga
Maria Teresa Pagliari
Leonid Parunov
Leonie Pelkmans
Rachel Roach
Nathan Schloemer
Henrike Schouten
Anish Sharda
Wie Shi
Jane Skov
Francesca Stufano
Carmen Tartari
Claudia Tersteeg
Thea Tilley
Jasmijn Timp
Julien Toh
Giacomo Tuana
Thomas Vanassche
Anyou Wang
Yan Xia
Guoling You
Jingyi Zhou
Xuemei Zhu
Xiaoyu Zhu
Stéphane Zuily
United Kingdom
USA
Italy
Russian Federation
The Netherlands
The Netherlands
USA
The Netherlands
USA
China
Denmark
Italy
Italy
The Netherlands
Ireland
The Netherlands
United Kingdom
Italy
Belgium
China
China
China
China
China
China
France

ISTH Reach the World Travel Awards

In recognition of the expanding educational format of ISTH’s SSC Annual Meetings, the ISTH is extending its “Reach the World” initiative to enable participation by scientists from all areas of the world in the educational and working sessions of the SSC.

Bayer HealthCare has partnered with ISTH to make possible these 2012 Awards through a generous unrestricted educational grant. Welcome to All! We hope that you will find attendance at SSC 2012 fruitful in your continued research and educational activities.

Awardees

Magy Abdelwahab
Xia Bai
Venina Barros
Munira Borhany
Qiulan Ding
Irina Gribkova
Tarandovskiy Ivan
Gwo-Ping Jong
Arshi Naz
Ira Puspitawati
Analía Sánchez-Luceros
Jianbo Wu

Country

Egypt
China
Brazil
Pakistan
China
Russian Federation
Russian Federation
Taiwan, China
Pakistan
Indonesia
Argentina
China
General Information

International Society on Thrombosis and Haemostasis

The International Society on Thrombosis & Haemostasis (ISTH) is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH is a global professional individual membership organization with over 3,000 members in more than 80 countries around the world. Among its highly regarded activities and initiatives are education and standardization programmes, research activities, meetings and conferences, peer-reviewed publications and expert committees.

ISTH offers 3 categories of membership:

• Regular: for active researchers, educators and clinicians in the field
• Associate: for students, trainees, research staff, post-doctoral fellows as well as allied health professionals
• Reach-the-World: for researchers, educators and clinicians in non-industrialized countries

Membership benefits include:

• A network of over 3,000 members in more than 80 countries
• Priority registration and discounted fees for ISTH meetings and congresses
• Complimentary print and online subscription to ISTH’s Journal of Thrombosis and Haemostasis
• Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
• Exclusive access and/or reduced fees for other educational activities, Programmes and publications
• The quarterly ISTH Newsletter and regular e-updates

• The right to nominate, elect and serve on ISTH committees. For more information, please visit www.isth.org

Contact Information

For general information about the Society, please contact ISTH at:

ISTH Headquarters
610 Jones Ferry Road Suite 205
Carrboro, NC 27510
USA
Phone: +1 919 929-3807
Fax: +1 919 929-3935
Email: headquarters@isth.org

For membership related questions, please contact ISTH at Email: membership@isth.org

For educational enquiries, please contact ISTH at: education@isth.org

Meeting Secretariat

SSC 2012
C/o MCI Suisse SA - Rue de Lyon 75
1211 Geneva 13 - Switzerland
Phone: +41 22 33 99 588
Fax: +41 22 33 99 631
Email: ssc2012@mci-group.com

Accommodation

The Mersey Partnership Conference Bureau
Phone: +44 (0) 151 237 3938
Fax: +44 (0) 151 227 2621
Email: conferences@merseyside.org.uk

A help desk for participants who have booked their accommodation in advance via The Mersey Partnership Conference Bureau is located in the registration area. The staff at this counter will also help you to find and book rooms, if required.
General Information

Annual Business Meeting of the SSC
Saturday, 30 June 2012, Room 12 on Level 1 at the Conference Centre
This business meeting is open to all interested participants. The agenda includes brief oral reports of the Scientific Subcommittees’ sessions, action on reports and recommendations resulting from the Subcommittees, reports of Working Parties, liaison activities, and collaborative work. For further information, contact the ISTH Secretariat at Room 11B on Level 1 at the Conference Centre.

Banks & Automatic Teller Machines (ATM)
A Barclays cash machine is situated on site, on the riverside of the building. Walk down the steps before the exit and the machine is on the left; there is no charge for using it.

Car Parking
The Liverpool Waterfront Car Park is sign-posted 'Waterfront' on the city wide 'available spaces' signage.

Climate
In late June, average temperatures in Liverpool vary between 18 and 23 degrees Celsius (approximately 64 - 73 degrees Farenheit). There is always a chance for occasional rain.

Cloakroom
A cloakroom facility will be provided by the ACC Conference Centre. Items can be left in the cloakroom at a price of £1.00 (GBP) per item.

Coffee Breaks
Complimentary coffee and tea will be served in the Exhibition Area on the lower ground floor. Coffee breaks are scheduled daily (10:00-10:30 and 16:00-16:30) from 27-29 June 2012 and in the morning only on the 30 June.

Conference Venue
BT Convention Centre (ACC)
Kings Dock
Liverpool Waterfront, L3 4FP UK
Phone: +44 151 475 8888
Email: info@accliverpool.com
Website: www.btconventioncentre.com

Continuing Medical Education
EACCME
The 58th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) Liverpool, United Kingdom (27-30 June 2012) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

The 58th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) is designated for a maximum of, or up to 20 European CME credits (ECMEC). Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
General Information

EHA

The European Hematology Association has accredited the 58th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) Liverpool, United Kingdom (27-30 June 2012) with 16 credit points. All participants may print a European Hematology Association CME System approved CME certificate indicating the number of EHA-CME Credit Points awarded, directly from the system on the CME section of the EHA website at www.ehaweb.org. An EHA-CME Credit Point account will be used by all interested participants. Participants will receive a login after the meeting which will allow them to complete the online evaluation in order to obtain the EHA credits.

BSHT

The British Society for Haemostasis & Thrombosis (BSHT) has accredited the 58th Scientific and Standardization Committee (SSC) meeting of the International Society on Thrombosis and Haemostasis (ISTH) Liverpool, United Kingdom (27-30 June 2012) with 16 credit hours as follows:

- Wednesday, 27 June: Educational Programme: 08:30-12.00 [3.5 hours] and 13:15-15:00: [1.75 hours] followed by Special Symposia: 15.30-17:30 [2.00 hours]
- Thursday, 28 June: Plenary Programme: 08:45-12:00 [2.75 hours]
- Friday, 29 June: Hot Topics Programme: 14:00-17:00 [3.00 hours] followed by Poster discussion: 17:30-1900 [2.00 hours]
- Saturday, 30 June: Technical Programme: 08:00-09:00 [1.00 hour]

Each medical specialist should claim only those hours of credit that she/he actually spends in the educational activity.

Certificate of Attendance

Certificates of attendance will be available from 14:00 on Friday, 29 June 2012 in the registration area. Participants will need to scan the bar-code on their badge in order to print out their certificate.

Cyber Café

A wired internet zone is located within the exhibition and is generously sponsored by Inspiration Biopharmaceuticals, Inc.

Delegate Bags

You will receive your delegate bag at the registration area. No replacements for lost bags are available.

Electricity

The UK, Scotland and Republic of Ireland use a 13 amp plug with 3 rectangular pins which is different to the rest of Europe. As such, an adaptor may be needed depending on the country you are coming from.

ePosters

ePosters are an electronic version of the traditional scientific Posters. The objective of the ePosters is to reach an audience beyond that of a traditional poster session. Attendees can view all posters during the dedicated ePoster session, throughout the meeting at designated touch-screen stations, or on their personal computer to interact with the poster author. From a single location attendees may browse posters on topic or keyword, provide comments, contact the author directly with questions or download the poster for later viewing (when allowed by presenter). Authors also have the option to keep their posters online after the meeting in Liverpool to reach even the non-attendee ISTH members.
General Information

The ePoster stations in the Exhibition Hall provide large touch-screens for easy reading and browsing. A new innovation for SSC meetings; kindly see for yourself the future of poster presentation!

Exhibition hours:
Wednesday, 27 June 2012 10.00 - 17.00
Thursday, 28 June 2012 10.00 - 17.00
Friday, 29 June 2012 10:00 - 19.00
Saturday, 30 June 2012 10.00 - 13.00

Important Local Numbers:
999 for fire, police, ambulance or coastguard services. Emergency calls are free from pay phones - you will be asked which service you require by the operator.

Industry Exhibition
The SSC 2012 Industry Exhibition is located on the lower ground level. Please see details on pages 97-110.

Insurance and Liability
Participants have been advised to obtain adequate insurance coverage for travel, health and accidents before departure from their countries of residence. ISTH and MCI as organisers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the conference participants and accompanying persons.

ISTH Secretariat
The ISTH Secretariat is located at Room 11B on Level 1 of the Conference Centre. It is open during the same hours as the Registration Desks (see “Registration Desk” for opening hours).

Language
The Official language of the meeting is English. There is no simultaneous translation service provided.

“Liverpool Now” Reception (supported by ACC Liverpool) & “...the Beat goes on” Social Events
On Wednesday, 27 June 2012, eligible delegates are invited to attend a reception which will be held on the lower ground level and +1 level of the Conference Centre. This reception is free to all eligible participants from 18.00-19.30. The beat then continues as of 20.00 at the PanAm, a venue within walking distance from the Conference Centre, where participants will experience an outstanding evening of Beatles music, dance and fun. Attendance to this 2nd part of the evening requires the payment of a fee of £25 per person. For additional tickets, please contact the Registration Desk located near the entrance of the Conference Centre. As the venue is centrally located, no transfers will be provided.

Dress code: Casual

Local Currency
The official currency in Liverpool is the British Pound (£). Conversion rates as of 1 June 2012:
1£ = 1,24 EUR
1£ = 1,54 USD

Lunches
Please note that lunch is not included in the delegate registration fee for SSC 2012. Participants can purchase their lunch on-site at the ACC from one of the food outlets available. Please note that lunch may be provided at some lunch-time Satellite Symposia.

Mobile Telephones
As a courtesy to speakers and other participants, all mobile phones and pagers must be switched off when attending sessions or symposia.
General Information

Name Badges
Participants will receive their name badges when collecting their meeting documents on site. You are kindly requested to wear your name badge during all meeting events, including the Liverpool Now Reception. Please note that admission to scientific sessions and the exhibition is restricted to participants wearing their badges.

Registration Desk
The registration desk is located on the ground floor, next to the main entrance of the venue.

Opening Hours:
- Tuesday, 26 June 2012: 12.00 - 19.00
- Wednesday, 27 June 2012: 07.00 - 18.00
- Thursday, 28 June 2012: 07.30 - 18.30
- Friday, 29 June 2012: 07.30 - 18.00
- Saturday, 30 June 2012: 07.30 - 13.00

Restaurants
Looking for a Restaurant in Liverpool? The restaurant scene in Liverpool has never been more lively and diverse with a fantastic mix to suit all taste buds. Go to: www.liverpool.com/listings/restaurants.html for more information.

Shopping
Liverpool shopping is world class, which is only fitting for a city that can shop till it drops. Shoppers are spoilt for choice between gleaming new city-centre shopping centres to boutique arcades, bohemian streets and farmers markets.
Liverpool ONE, right in the heart of the city, is the shiny new designer Liverpool shopping centre that is home to more than 160 famous high street names, from John Lewis to Apple, Topshop to Cath Kidston.

Smoking
Please note that this is a non-smoking meeting. Smoking is neither permitted in or outside the meeting halls nor in the exhibition area.

Transportation
No transportation is provided during the conference since the Conference Venue is very centrally located and most hotels are within walking distance. If you need to arrange for a transfer to the airport, please refer to the “Information” menu item on the conference website: www.ssc2012.org where you will find more information under “Transportation”.

Speaker Ready Room
Room 11A (Level +1)
Speakers are asked to upload their formatted presentations (PowerPoint presentations) at the Speaker Ready Room at least 2 hours before their session or the day before for an early morning presentation. All conference rooms feature state-of-the-art technical equipment. Audiovisual material will be available for your presentation.

Opening Hours:
- Wednesday, 27 June 2012: 07.30 - 18.00
- Thursday, 28 June 2012: 07.30 - 18.30
- Friday, 29 June 2012: 07.30 - 18.00
- Saturday, 30 June 2012: 07.30 - 13.00

Wireless Internet
Wireless internet will be available on-site. Each delegate will receive a username and password with their badge. This wireless connection is generously sponsored by Inspiration Biopharmaceuticals, Inc.
About Liverpool

Liverpool

Liverpool is one of Europe’s most vibrant and cosmopolitan cities offering both European Capital of Culture and UNESCO World Heritage Site Status. As well as its worldwide reputation for music (Beatles and Cavern Club), sport (Liverpool F.C. and Everton F.C.) and humour, it has an abundance of architectural treasures and more museums and galleries than any other UK city outside London, including; World Museum; Maritime Museum; International Slavery Museum; Tate Modern Art Gallery; Walker Art Gallery; and Lady Lever Art Gallery. Public art is right on our doorsteps and our rich cultural heritage is also exemplified by magnificent civic buildings, two iconic Anglican and Roman Catholic cathedrals as well as the oldest Chinatown in Europe. A huge regeneration Programme has transformed the city with one of the major development projects, Liverpool One (award winning retail, leisure and residential scheme) being the largest of its kind in Europe. Liverpool is a great city from which to explore the surrounding region, which offers miles of beautiful coastline, Championship links golf courses, ancient cities like Chester and the stunning scenery of North Wales and the Lake District.

Liverpool has long been regarded as the friendliest destination for delegates and visitors, a fact which is backed by numerous accolades including the city winning Condé Nast Traveller UK’s Friendliest Destination in 2010 and 2011, Group Leisure magazine’s Best UK City 2011, and Britain’s Best Nightlife Destination 2011 awarded by TripAdvisor.

Liverpool is set to become even more affable with its Delegate Goodnight campaign.

The Goodnight campaign will complete the experience of delegates in the city, providing recommendations for event spaces with panoramic views, restaurants and bars in which to wind down after a conference or host gala dinners, the best accommodation, as well as attractions from which to view the city’s skyline and sunsets as part of a social itinerary. Together, the innovative Delegate Welcome and Goodnight schemes will provide all delegates with exclusive discounts for Virgin Trains’ high speed service from London to Liverpool with on board welcome announcements, signage and flags at entry points into the city, and a free dedicated accommodation booking service.
Xarelto®
NOW AVAILABLE FOR

help put a stop to complicated anti-coagulation

Xarelto®: the first oral single-drug approach for DVT treatment
Xarelto® (rivaroxaban) Prescribing Information

**Indication(s):** Treatment of deep vein thrombosis (DVT) & prevention of recurrent DVT & pulmonary embolism (PE) following an acute DVT in adults.

**Dosage & method of administration:**
- **Dose:** 15mg bd for 3 weeks followed by 20mg od for continued treatment & prevention of recurrent DVT & PE, with food.
- **Take with food.** Refer to SmPC for information on duration of therapy & converting from Vitamin K antagonists (VKA) or parenteral anticoagulants.

**Renal impairment:** Mild (creatinine clearance 50–80ml/min) – no dose adjustment necessary; moderate (creatinine clearance 30–45ml/min) – 15mg bd for 3 weeks, reduce maintenance dose to 15mg od; severe (creatinine clearance <15ml/min) – limited data indicates rivaroxaban plasma concentrations are significantly increased, 15mg bd for 3 weeks, reduce maintenance dose to 15mg od & use with caution. Patients with creatinine clearance <15ml/min – use not recommended.

**Hepatic impairment:** Do not use in patients with hepatic disease associated with coagulopathy & clinically relevant bleeding risk including cirrhotic patients with Child Pugh B & C patients. Elderly, body weight & gender: No dose adjustment.

**Paediatrics:** Not recommended below 18 years of age. Contra-indications:**
- Hypersensitivity to active substance or any excipient; clinically significant active bleeding; hepatic disease associated with coagulopathy & clinically relevant bleeding risk including cirrhotic patients with Child Pugh B & C; pregnancy & breast feeding.

**Warnings & precautions:** Clinical surveillance in line with anticoagulant practice is recommended throughout the treatment period. In studies mucosal bleedings & anaemia were seen more frequently during long term rivaroxaban treatment compared with VKA treatment – haemoglobin/haematocrit testing may be of value to detect occult bleeding. Following sub-groups of patients are at increased risk of bleeding & should be carefully monitored after treatment initiation. Use with caution – in patients with severe renal impairment (creatinine clearance 15–29ml/min) or in patients with renal impairment concomitantly receiving other medicines that are potent inhibitors of CYP3A4 (PK models show increased rivaroxaban concentrations in these patients). In patients treated concomitantly with medicines affecting haemostasis; in patients with an increased bleeding risk such as congenital or acquired bleeding disorders, uncontrolled severe arterial hypertension, active ulcerative gastrointestinal disease (consider appropriate prophylactic treatment for at-risk patients), recent gastrointestinal ulcerations, vascular retinopathy, recent intracranial or intracerebral haemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain/spinal/ophthalmological surgery, bronchiectasis or history of pulmonary bleeding. Use is not recommended in patients with creatinine clearance <15ml/min; receiving concomitant systemic treatment with azole-antimycotics or HIV protease inhibitors; with prosthetic heart valves; for treatment of acute pulmonary embolism. If invasive procedures or surgical intervention are required, stop Xarelto use at least 24 hours beforehand. Restart use as soon as possible provided adequate haemostasis has been established. See SmPC for full details. Xarelto contains lactose. Interactions:**
- Concomitant use with strong inhibitors of both CYP3A4 & P-gp (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir) is not recommended as increased rivaroxaban plasma concentrations to a clinically relevant degree are observed (may increase risk of bleeding). Avoid co-administration with dalcetrone. Use with caution in patients concomitantly receiving other anticoagulants (e.g. enoxaparin), NSAIDs (including acetylsalicylic acid) or platelet aggregation inhibitors due to the increased bleeding risk. Strong CYP3A4 Inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) should be used concomitantly with caution as they may reduce rivaroxaban plasma concentrations. Pregnancy & breast feeding:
- Contra-indicated. Effects on ability to drive and use machines: Adverse reactions like syncope & dizziness are common. Patients experiencing these effects should not drive or use machines. Undesirable effects:

**Very common** urogenital tract haemorrhage (in women <65 years in DVT-T trials). Common anaemia, dizziness, headache, syncope, eye haemorrhage, tachycardia, hypotension, haematoma, epistaxis, GI tract haemorrhage, GI & abdominal pain, dyspepsia, nausea, constipation, diarrhoea, vomiting, pruritus, rash, ecchymosis, pain in extremity, urogenital tract haemorrhage, fever, peripheral oedema, decreased general strength & energy, increase in transaminases, post-procedural haemorrhage, contusion. Uncommon thrombocytopenia, allergic reaction, allergic dermatitis, cerebral & intracranial haemorrhage, haemoptysis, dry mouth, abnormal hepatic function, urticaria, cutaneous & subcutaneous haemorrhage, haemorrhatitis, renal impairment; feeling unwell, localised oedema, increased bilirubin, blood alkaline phosphatase, LDH, lipase, amylase, GGT; wound secretion. Rare jaundice, muscle haemorrhage, increased conjugated bilirubin. Frequency not known pseudoaneurysm formation following percutaneous intervention, compartment syndrome secondary to a bleeding, renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion. Occult or overt bleeding from any tissue or organ which may result in post-haemorrhagic anaemia and complications with variable severity (including fatal outcome). Prescribers should consult SmPC in relation to full side effect information.

**Overdose:** Rare cases of overdose up to 600mg have been reported without bleeding complications or other adverse reactions. Due to limited absorption a ceiling effect is expected at supratherapeutic doses of 50mg rivaroxaban or above. No specific antidote is available. Use of activated charcoal to reduce absorption may be considered. For management of bleeding complication associated with rivaroxaban please refer to the SmPC.

**Legal Category:** POM. **Package Quantities and Basic NHS Costs:** 15mg - 28 tablets: £58.80, 42 tablets: £88.20, 100 tablets: £210.00; 20mg - 28 tablets: £58.80. **MA Number(s):** EU/1/08/472/0011-21.


Xarelto® is a trademark of the Bayer Group.
## Programme at a Glance

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday 26 June</th>
<th>Wednesday 27 June</th>
<th>Thursday 28 June</th>
<th>Friday 29 June</th>
<th>Saturday 30 June</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>08:30 – 15:00</td>
<td>08:30 – 15:00</td>
<td>08:30 – 12:00</td>
<td>08:00 – 12:30</td>
<td>08:30 – 09:00</td>
</tr>
<tr>
<td>08:45</td>
<td>Trainees' Fringe Meeting</td>
<td>Educational Session</td>
<td>Presidential Plenary</td>
<td>Technical Session</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td>p. 34</td>
<td></td>
<td>p. 45</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td>p. 26</td>
<td></td>
<td>p. 57</td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td>p. 31</td>
<td></td>
<td>p. 57</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>16:30 – 17:30</td>
<td></td>
<td></td>
<td></td>
<td>14:00 – 16:30</td>
</tr>
<tr>
<td>16:30</td>
<td>The Mike Nesheim &quot;Meet the Expert&quot; Session</td>
<td></td>
<td></td>
<td></td>
<td>SSC Business Meeting</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>18:00 – 19:00</td>
<td>18:00 – 19:00</td>
<td>18:30 – 20:00</td>
<td>17:00 – 19:30</td>
<td>17:00 – 19:30</td>
</tr>
<tr>
<td>18:30</td>
<td>SSC 2012 Trainees' Reception</td>
<td>&quot;Liverpool Now&quot; Reception</td>
<td>Satellite Symposia</td>
<td>E-Poster Session</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td>p. 42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>20:00 –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td>and the Beat goes on</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Exhibition Hours

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday 26 June</th>
<th>Wednesday 27 June</th>
<th>Thursday 28 June</th>
<th>Friday 29 June</th>
<th>Saturday 30 June</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 17:00</td>
<td></td>
<td></td>
<td></td>
<td>19:00 – 16:00</td>
<td>10:00 – 13:00</td>
</tr>
</tbody>
</table>

### Registration Hours

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday 26 June</th>
<th>Wednesday 27 June</th>
<th>Thursday 28 June</th>
<th>Friday 29 June</th>
<th>Saturday 30 June</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 – 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00 – 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30 – 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30 – 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ePoster Viewing

<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday 26 June</th>
<th>Wednesday 27 June</th>
<th>Thursday 28 June</th>
<th>Friday 29 June</th>
<th>Saturday 30 June</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 – 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Programme Overview

Tuesday, 26 June 2012

**Trainees’ Fringe Meeting**

How to start a career in coagulation

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 13:00</td>
<td>Trainees in research</td>
<td>Ian Peake, Gill Lowe</td>
</tr>
<tr>
<td>14:15 - 18:00</td>
<td>Practical / on call issues in haemostasis and thrombosis</td>
<td>John Pasi, David Keeling</td>
</tr>
</tbody>
</table>

**18:00 - 19:00**  
SSC 2012 Trainees’ Welcome Drinks Reception
### Detailed Programme Tuesday, 26 June 2012

#### Trainees’ Fringe Meeting (supported by the British Society for Haemostasis and Thrombosis) 08:45 - 17:30

**How to start a Career in Coagulation**  
*Room 4A*

Chairpersons: *Ian Peake, Gill Lowe, John Pasi, David Keeling*

#### Trainees in research - part I

- **Ian Peake**
  - **Introduction**  
    Gill Lowe  
    *09:25 - 09:30*
  - **A beginners guide to laboratory coagulation**  
    Steve Kitchen (Sheffield)  
    *09:30 - 10:00*
  - **Setting up research studies / A beginners guide to ethics**  
    Gill Lowe (Birmingham)  
    *10:00 - 10:30*
  - **Research opportunities in non malignant haematology in the UK**  
    John Pasi (London)  
    *10:30 - 11:00*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:25 - 09:30</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>A beginners guide to laboratory coagulation</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Setting up research studies / A beginners guide to ethics</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Research opportunities in non malignant haematology in the UK</td>
</tr>
</tbody>
</table>

**Tea / Coffee Break**  
*Room 4B*

#### Trainees in research - part II

- **Gill Lowe**
  - **How to write a research grant / get a research fellowship**  
    Sam Machin (London)  
    *11:20 - 11:50*
  - **How to get a paper published**  
    Steve Watson (Birmingham)  
    *11:50 - 12:20*
  - **Planning a research career**  
    Mike Laffan (London)  
    *12:20 - 12:50*
  - **A historical perspective in researching von Willebrand’s disease - highs and lows**  
    Ian Peake (Sheffield)  
    *12:50 - 13:20*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20 - 11:50</td>
<td>How to write a research grant / get a research fellowship</td>
</tr>
<tr>
<td>11:50 - 12:20</td>
<td>How to get a paper published</td>
</tr>
<tr>
<td>12:20 - 12:50</td>
<td>Planning a research career</td>
</tr>
<tr>
<td>12:50 - 13:20</td>
<td>A historical perspective in researching von Willebrand’s disease - highs and lows</td>
</tr>
</tbody>
</table>
Detailed Programme Tuesday, 26 June 2012

**Practical / on call issues in haemostasis and thrombosis - part I**
*John Pasi*

*Clinical issues from abnormal coagulation tests*
David Keeling (Oxford)  
14:15 - 14:45

*Clinical and laboratory Issues in thrombophilia*
Trevor Baglin (Cambridge)  
14:45 - 15:15

*On call issues in obstetric haematology*
Beverly Hunt (London)  
15:15 - 15:45

**Tea / Coffee Break**  
Room 4B

**Practical / on call issues in haemostasis and thrombosis - part II**
*David Keeling*

*On call transfusion Issues with a focus on NAIT*
Mike Murphy (Oxford)  
16:15 - 16:45

*On call issues in inherited bleeding disorders*
Mike Markis (Sheffield)  
16:45 - 17:15

*Issues in diagnosis and management of antiphospholipid syndrome*
Mike Greaves (Aberdeen)  
17:15 - 17:45

**SSC 2012 Trainees’ Welcome Drinks Reception**  
18:00 - 19:30

Upper Galleria (sponsored by the Faculty of Health & Life Sciences, University of Liverpool)
Wednesday, 27 June 2012

**Educational Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 12:00</td>
<td><strong>Thrombosis &amp; haemostasis issues in cancer</strong> (Hall 2E)</td>
<td>Agnes Lee &amp; Jeffrey Zwicker</td>
</tr>
<tr>
<td></td>
<td><strong>Thrombosis &amp; haemostasis issues in critical infection and trauma</strong> (Hall 2F)</td>
<td>Jecko Thachil &amp; Hideo Wada</td>
</tr>
<tr>
<td></td>
<td><strong>Thrombosis &amp; haemostasis Issues in women’s health</strong> (Hall 2L)</td>
<td>Sabine Eichinger &amp; Flora Peyvandi</td>
</tr>
<tr>
<td></td>
<td><strong>Thrombosis &amp; haemostasis Issues in child health</strong> (Hall 2N)</td>
<td>Anthony Chan &amp; Paul Monagle</td>
</tr>
</tbody>
</table>

**Lunch Break - On Your Own**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 - 15:00</td>
<td><strong>Anti-phospholipid syndrome</strong> (Hall 2E)</td>
<td>Thomas Ortel</td>
</tr>
<tr>
<td></td>
<td><strong>Point-of-care &amp; personalised treatment</strong> (Hall 2F)</td>
<td>Steven Kitchen</td>
</tr>
<tr>
<td></td>
<td><strong>Thrombotic microangiopathies</strong> (Hall 2L)</td>
<td>Paul Harrison &amp; Changgeng Ruan</td>
</tr>
<tr>
<td></td>
<td><strong>Inherited bleeding disorders</strong> (Hall 2N)</td>
<td>Marco Cattaneo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:30 - 17:30</td>
<td><strong>The Mike Nesheim “Meet the Expert” Sessions</strong> Halls 2E, 2F, 2L, 2N</td>
<td></td>
</tr>
<tr>
<td>18:00 - 19:30</td>
<td>“Liverpool Now” Reception (supported by ACC Liverpool)</td>
<td></td>
</tr>
<tr>
<td>20:00 - 24:00</td>
<td>“... and the Beat goes on”</td>
<td></td>
</tr>
</tbody>
</table>
Detailed Programme Wednesday, 27 June 2012

Educational Session 08:30 - 12:00

Thrombosis & Haemostasis Issues in Cancer Hall 2E
Chairpersons: Agnes Lee (Canada), Jeffrey Zwicker (USA)
Overview with learning objectives
Agnes Lee (Canada) 08:30 - 08:45

Session one: State-of-the-art updates
Jeffrey Zwicker (USA)
Complexities in tissue factor measurement and standardization
Nigel Key (USA) 08:45 - 09:15
Roles of CRP and D-dimer in diagnosis, treatment and prognosis
Ingrid Pabinger (Austria) 09:15 - 09:45
Screening for occult malignancy: where does the evidence stand?
Marc Carrier (Canada) 09:45 - 10:15

Tea / Coffee Break Exhibition hall, lower level

Session two: Controversies & debate
Agnes Lee (Canada)
Debate: incidental VTE: to treat or not to treat
Yes: Howard Liebman (USA) - No: Menno Huisman (The Netherlands) 10:30 - 11:15
Debate: outpatient thrombo-prophylaxis in cancer patients
Yes: Lord Ajay Kakkar (United Kingdom) - No: Alok Khorana (USA) 11:15 - 12:00

Thrombosis & Haemostasis Issues in Critical Infection and Trauma Hall 2F
Chairpersons: Jecko Thachil (United Kingdom), Hideo Wada (Japan)
Overview with learning objectives
Jecko Thachil (United Kingdom), Hideo Wada (Japan) 08:30 - 08:45

Session one: Day-to-day dilemmas
How I manage thrombocytopenia in critically ill patients
Andreas Greinacher (Germany) 08:45 09:15
The relationship between inflammation and thrombosis in critically ill patients
Hugo Ten Cate (The Netherlands) 09:15 - 09:45
How I manage peri-operative coagulation issues
Sibylle Kozek-Langenecker (Austria) 09:45 - 10:15
Detailed Programme Wednesday, 27 June 2012

**Session two: Emerging translation**
Acute Coagulopathy of Trauma: Relevance of the Protein C pathway  
Karim Brohi (United Kingdom) 10:30 - 11:00

Malaria and thrombosis: relevance of vWF & platelets  
Alister Craig (United Kingdom) 11:00 - 11:30

Current perspectives in the management of atypical haemolytic uremic syndrome  
Tim Goodship (United Kingdom) 11:30 - 12:00

**Thrombosis & Haemostasis Issues in Women’s Health**  
Hall 2L

Chairpersons: Sabine Eichinger (Austria), Flora Peyvandi (Italy)

**Overview with learning objectives**  
Sabine Eichinger (Austria), Flora Peyvandi (Italy)

**Session one: Thrombotic tendency**
How I manage recurrent miscarriage in relation to thrombophilia  
Ian Greer (United Kingdom) 08:45 - 09:15

Shirley Johnson Memorial Lecture
How I manage women with mechanical heart valves during pregnancy  
Claire McLintock (New Zealand) 09:15 - 09:45

How I advise contraception in relation to thrombophilia  
Jacqueline Conard (France) 09:45 - 10:15

**Tea / Coffee Break**  
Exhibition hall, lower level
Detailed Programme Wednesday, 27 June 2012

Session two: Bleeding tendency
How I manage ITP in pregnancy
Drew Provan (United Kingdom)  10:30 - 11:00
How I manage and coordinate care of the haemophilia carrier in pregnancy
Claude Negrier (France)  11:00 - 11:30
How I treat menorrhagia in women with bleeding disorders
Rezan Abdul-Kadir (United Kingdom)  11:30 - 12:00

Thrombosis & Haemostasis Issues in Child Health  Hall 2N
Chairpersons: Anthony Chan (Canada), Paul Monagle (Australia)

Overview with learning objectives
Anthony Chan (Canada), Paul Monagle (Australia)

Session one: State-of-the-art updates
Can childhood stroke be prevented?
Fenalla Kirkham (United Kingdom)  08:45 - 09:15
Management of post-thrombotic syndrome in children
Shoshana Revel-Vilk (Israel)  09:15 - 09:45
Bleeding in children with major organ failure
Christine MaCartney (United Kingdom) 09:45 - 10:15

Tea / Coffee Break  Exhibition hall, lower level

Session two: Controversies & debate
Will the newer anticoagulants still require monitoring?
Adults Trevor Baglin (United Kingdom) - Children Christoph Male (Austria)  10:30 - 11:00
Debate: Thrombophilia testing in children, with a few specific exceptions, is a waste of time
Yes Suzan Williams (Canada) - No Elizabeth Chalmers (United Kingdom)  11:00 - 11:30
Chronic severe ITP in children. Rituximab should be offered before splenectomy
Yes Paula Bolton-Maggs (United Kingdom) No Jenny Despotovic (USA)  11:30 - 12:00
Detailed Programme Wednesday, 27 June 2012

Educational Session 13:15 - 15:00

Anti-Phospholipid Syndrome (APS) Hall 2E

Chairperson: Thomas Ortel (USA)

Overview with learning objectives 13:15 - 13:30
Thomas Ortel (USA)

Session: from laboratory to patient
New mechanistic understanding in APS
PG de Groot (The Netherlands) 13:30 - 14:00
Guidance in laboratory testing to diagnose APS
Katrien Devreese (Belgium) 14:00 - 14:30
Novel therapies in addition to anticoagulation for APS
Munther Khamashta (United Kingdom) 14:30 - 15:00

Point-of-Care & Personalised Treatment Hall 2F

Chairperson: Steven Kitchen (United Kingdom)

Overview with learning objectives 13:15 - 13:30
Steven Kitchen (United Kingdom)

Session: from laboratory to patient
Assessing quality in point-of-care haemostasis testing
Dianne Kitchen (United Kingdom) 13:30 - 14:00
Point-of-care global haemostasis testing in operating theatres
Alastair Nimmo (United Kingdom) 14:00 - 14:30
Pharmacogenetics of warfarin in personalising treatment at point-of-care
Munir Pirmohamed (United Kingdom) 14:30 - 15:00
Detailed Programme Wednesday, 27 June 2012

Thrombotic Microangiopathies  Hall 2L

Chairpersons: Paul Harrison (United Kingdom), Changgeng Ruan (China)

Overview with learning objectives
Paul Harrison (United Kingdom), Changgeng Ruan (China)  13:15 - 13:30

Session: from laboratory to patient

Understanding vWF-ADAMTS13 in vivo
Karen Vanhoorelbeke (Belgium)  13:30 - 14:00

Diagnosing and treating Thrombotic Thrombocytopenic Purpura (TTP)
Marie Scully (United Kingdom)  14:00 - 14:30

Translational approaches to TTP
Flora Peyvandi (Italy)  14:30 - 15:00

Inherited Bleeding Disorders  Hall 2N

Chairperson: Marco Cattaneo (Italy)

Overview with learning objectives
Marco Cattaneo (Italy)

Session: from laboratory to patient

Advances in diagnosing congenital platelet disorders
Alan Nurden (France)  13:30 - 14:00

Safety, efficacy issues with haemophilia factor concentrates and the emerging treatments
Mike Makris (United Kingdom)  14:00 - 14:30

New considerations and treatment paradigms for von Willebrand disease
David Lillicrap (Canada)  14:30 - 15:00

Tea / Coffee Break  Exhibition hall, lower level
Detailed Programme Wednesday, 27 June 2012

Meet the Experts 15:30 - 16:30 / 16:30 - 17:30

The Mike Nesheim “Meet the Expert” Sessions

Chairpersons: Johanthan Foley (USA), Hugh Hoogendoorn (Canada), Paul Kim (Canada), Fletcher B. Taylor (USA), Paula Tracy (USA), Yotis Senis (United Kingdom), Cheng Hock Toh (United Kingdom), David Lillicrap (Canada)

Protein C pathway
Hugh Hoogendoorn (Canada)  
Björn Dahlbäck (Sweden)  
Hall 2E  
15:30 - 16:30

Venous thromboembolism
Fletcher B. Taylor (USA)  
Sam Schulman (Canada)  
Hall 2F  
15:30 - 16:30

Atrial fibrillation & arterial thrombotic disease
Paul Kim (Canada)  
Gregory Lip (United Kingdom)  
Hall 2N  
15:30 - 16:30

Fibrinolysis
Johanthan Foley (USA)  
Nuala Booth (United Kingdom)  
Hall 2L  
15:30 - 16:30

Von Willebrand disease
David Lillicrap (Canada)  
Robert Montgomery (USA)  
Hall 2  
16:30 - 17:30

Platelets
Yotis Senis (United Kingdom)  
Steve Watson (United Kingdom)  
Hall 2F  
16:30 - 17:30

Haemophilia
Cheng Hock Toh (United Kingdom)  
Pier Mannuccilli (Italy)  
Hall 2N  
16:30 - 17:30

Tissue factor
Paula Tracy (USA)  
Bjarne Østerud (Norway)  
Hall 2L  
16:30 - 17:30

SSC 2012 “Liverpool Now” Reception 18:00 - 19:30

Upper and Lower Galleria (supported by ACC Liverpool)

“... and the Beat goes on” 20:00 - 24:00

PanAm - Albert Docks (tickets available for purchase from registration area)
See you in Amsterdam!
Thursday, 28 June 2012

**Presidential Plenary: SSC in Translation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:00</td>
<td>Relevance of the SSC to translational medicine</td>
<td>Cheng-Hock Toh</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>Marion Barnhart Memorial Lecture</td>
<td>Garret FitzGerald</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Translational medicine in thrombosis and haemostasis</td>
<td>Edward Tuddenham</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>Arthur Bloom Memorial Lecture</td>
<td>Kenneth Kaushansky</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>Pia Glas Greenwalt Memorial Lecture</td>
<td>Markus Huber-Lang</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Kenneth M. Brinkhouse Memorial Lecture</td>
<td>Denisa Wagner</td>
</tr>
</tbody>
</table>

**Satellite Symposia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 - 13:45</td>
<td>Novo Nordisk</td>
<td>Pharmacokinetics in haemophilia: guiding patient care (Hall 2E)</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td>Clinical leadership in haemophilia - setting new standards? (Hall 2F)</td>
</tr>
<tr>
<td></td>
<td>Sanofi</td>
<td>VTE prophylaxis in 2012: where we are and where we are going (Hall 2L)</td>
</tr>
</tbody>
</table>

**SSC Session**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 - 15:30</td>
<td>Pro-thrombotic markers and global hemostatic tests (Auditorium 1)</td>
<td>Anna Falanga &amp; David Lillicrap</td>
</tr>
<tr>
<td>15:30 - 18:00</td>
<td>Disseminated Intravascular Coagulation (DIC) (Hall 2L)</td>
<td>Hideo Wada</td>
</tr>
<tr>
<td></td>
<td>Factor XI and the contact system (Hall 2F)</td>
<td>Thomas Renne</td>
</tr>
<tr>
<td></td>
<td>Predictive variables in cardiovascular disease (Room 3A)</td>
<td>James Douketis</td>
</tr>
<tr>
<td></td>
<td>Fibrinolysis (Room 3B)</td>
<td>Ann Gils</td>
</tr>
<tr>
<td></td>
<td>Plasma coagulation inhibitors (Room 12)</td>
<td>Steven Kitchen</td>
</tr>
<tr>
<td></td>
<td>ISTH BAT standing committee public session (Hall 2E)</td>
<td>Francesco Rodeghiero</td>
</tr>
</tbody>
</table>

**Satellite Symposia**

<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 - 19:45</td>
<td>Bayer HealthCare</td>
<td>Novel oral anticoagulant for the management of venous (Hall 2E)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>thromboembolism - a practical consideration</td>
</tr>
</tbody>
</table>

**Symposium on Widening Participation**

<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 - 19:45</td>
<td>University of Liverpool</td>
<td>Little big medicine (Hall 2N)</td>
</tr>
</tbody>
</table>
# Detailed Programme Thursday, 28 June 2012

## Presidential Plenary 08:30 - 12:00

### Presidential Plenary: SSC in Translation  
**Auditorium 1**

**Chairpersons:**  
*Cheng Hock Toh (United Kingdom), Henri Bounnameaux (Switzerland)*

**Welcome and introduction**  
08:30 - 08:45

**Relevance of the SSC to translational medicine**  
Cheng-Hock Toh (United Kingdom)  
08:45 - 09:00

**Marion Barnhart Memorial Lecture**  
*Translational medicine in thrombosis and haemostasis*  
Garret FitzGerald (USA)  
09:00 - 09:30

**Arthur Bloom Memorial Lecture**  
*From gene to therapy I: haemophilia*  
Edward Tuddenham (United Kingdom)  
09:30 - 10:00

**Pia Glass Greenwalt Memorial Lecture**  
*From gene to therapy II: thrombocytopaenia*  
Kenneth Kaushansky (USA)  
10:00 - 10:30

**Tea / Coffee Break**  
Exhibition hall, lower level

**Collen Foundation - Life Sciences Research Partners Award**

**Emerging translation I: complement & coagulation**  
Markus Huber-Lang (Germany)  
11:00 - 11:30

**Kenneth M. Brinkhouse Memorial Lecture**

**Emerging translation II: NETs & thrombosis**  
Denisa Wagner (USA)  
11:30 - 12:00
Detailed Programme Thursday, 28 June 2012

**Satellite Symposia**

**Novo Nordisk**

**Chairpersons:** Steven Pipe (USA), Stephanie Seremetis (Denmark)

**Pharmacokinetics in haemophilia: guiding patient care**

**Welcome and introduction**
Steven Pipe (USA) Stephanie Seremetis (Denmark) 12:15 - 12:20

**Assessment of recombinant glycoPEGylated FVIII (N8-GP): pathfinder™1 - a first human dose trial**
Andreas Tiede (Germany) 12:20 - 12:40

**Characterising the PK profile of turoctocog alfa: results from the GUARDIAN™ trials**
Camilla Buøen Stenmo (Denmark) 12:40 - 13:00

**Exploring the clinical application of recombinant glycoPEGylated FIX (N9-GP): population PK modelling and simulations**
Peter Collins (United Kingdom) 13:00 - 13:20

**Panel discussion**
All 13:20 - 13:35

**Concluding remarks**
Steven Pipe (USA) 13:35 - 13:45

**Pfizer**

**Chairperson:** David Keeling (United Kingdom)

**Clinical leadership in haemophilia - setting new standards?**

**Welcome and introduction**
David Keeling (United Kingdom) 12:15 - 12:20

**Specialised services in haemophilia - a national policy perspective**
Alison Rylands (United Kingdom) 12:20 - 12:35

**Developing an evidence base to support best practice**
Gerry Dolan (United Kingdom) 12:35 - 12:50

**Defining clinical outcomes - optimising existing resources**
John Pasi (United Kingdom) 12:50 - 13:05

**Delivering best clinical practice through partnerships**
Susan Mather (United Kingdom) 13:05 - 13:20

**Panel discussion**
All 13:20 - 13:40

**Concluding remarks**
David Keeling (United Kingdom) 13:40 - 13:45
## Detailed Programme Thursday, 28 June 2012

**Sanofi**

**Hall 2L**

Chairpersons: *Job Harenberg (Germany), Lord Kakkar (United Kingdom)*

### VTE prophylaxis in 2012: where we are and where we are going

**Welcome and introduction**  
*Job Harenberg (Germany)*  
12:15 - 12:20

**New understanding of heparin properties**  
*Ludovic Drouet (France)*  
12:20 - 12:35

**Anticoagulants: from clinical trials to real life**  
*Russell D. Hull (Canada)*  
12:35 - 12:50

**Anticoagulants in medical prophylaxis: where do we stand?**  
*Roger D. Yusen (USA)*  
12:50 - 13:05

**Biosimilar LMWHs: regulatory perspectives**  
*Job Harenberg (Germany)*  
13:05 - 13:20

**Anticoagulation: challenges in the coming years**  
*Lord Kakkar (United Kingdom)*  
13:20 - 13:35

**Questions and answers and closing remarks**  
*Lord Kakkar (United Kingdom)*  
13:35 - 13:45

### SSC Sessions  
**14:00- 15:30**

**Pro-thrombotic Markers and Global Hemostatic Tests**

**Auditorium 1**

Chairpersons: *Anna Falanga (Italy), David Lillicrap (Canada)*

### Part I

**Advantages and limitations of clot-lysis assays**  
*Jonathan Foley (USA)*  
14:05 - 14:20

**Elevated fibrin related markers in patients with malignant diseases associated with DIC or DVT**  
*Hideo Wada (Japan)*  
14:20 - 14:35

**Overall discussion part I**  
*Anna Falanga (Italy), David Lillicrap (Canada)*  
14:35 - 14:45
Detailed Programme Thursday, 28 June 2012

Part II

The use of global coagulation assays to evaluate: treatments with LMWHs and VKA in patients with acquired hypercoagulable state
Grigoris Gerotziafas (France) 14:45 - 15:00

The use of global coagulation assays to evaluate: treatments with by-passing agents in haemophilia
Armando Tripodi (Italy), Elena Santagostino (Italy) 15:00 - 15:15

Overall discussion part II
Anna Falanga (Italy), David Lillicrap (Canada) 15:15 - 15:30

SSC Sessions 15:30- 18:00

Disseminated Intravascular Coagulation (DIC)

Chairpersons: Hideo Wada (Japan), Satoshi Gando (Japan), Hyun Kyung Kim (Republic of Korea), Jorn Nielsen (Denmark), Jecko Thachil (United Kingdom)

Fibrin related markers
Carl-Erik Dempfle (Germany) 15:30 - 15:55

Treatment of DIC with rh thrombomodulin
Yun Mimuro, Hoyu Takahashi, Isao Kitajima, Hajime Tsuji, Yutaka Eguchi, Tadashi Matsushita, Tatsuhiko Kuroda Yoichi Sakata (Japan) 15:55 - 16:20

Chairman’s report
16:20 - 16:30

DIC and COT/ACOTS in trauma
Satoshi Gando (Japan) 16:30 - 16:45

DIC and thrombotic microangiopathy: what are the differences and the shared features?
Shinichiro Kurosawa (USA) 16:45 - 17:00

Fibrinogen, pathological coagulation and DIC’?
Jecko Thachil (United Kingdom) 17:00 - 17:15

Topics on diagnosis of DIC
Jorn Nielsen (Denmark) 17:15 - 17:30

The prognostic value of thrombomodulin expression on monocytes subset?
Hyun Kyung Kim (Republic of Korea) 17:30 - 17:45

DAMPs/PAMOs in DIC
Ikuro Maruyama (Japan) 17:45 - 18:00
**Detailed Programme Thursday, 28 June 2012**

**Factor XI and the Contact System**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bleeding in FXI deficiency</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Factor XI -setting the scene</td>
<td>Paula Bolton-Maggs (United Kingdom)</td>
<td>15:30 - 15:50</td>
</tr>
<tr>
<td><strong>Genetics and genomics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genetic variations of complement factors and phenotypic effects</td>
<td>Christine Mannhalter (Austria)</td>
<td>15:50 - 16:05</td>
</tr>
<tr>
<td>Epidemiology and genetics of aPTT and contact factors</td>
<td>Gordon Lowe (United Kingdom)</td>
<td>16:05 - 16:20</td>
</tr>
<tr>
<td><strong>Tea / Coffee Break</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Activation of factor XII</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structure of the FXII protease domain</td>
<td>Jonas Emsley (United Kingdom)</td>
<td>16:30 - 16:45</td>
</tr>
<tr>
<td>Functional insights into FXII contact activation</td>
<td>Coen Maas (The Netherlands)</td>
<td>16:45 - 17:00</td>
</tr>
<tr>
<td><strong>Novel functions of FXI and the contact system in thrombosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Characterization of factor XII autoactivation by a physiological</td>
<td>Nicola Mutch (United Kingdom)</td>
<td>17:00 - 17:15</td>
</tr>
<tr>
<td>Contact system activation by microparticles</td>
<td>Helen Philippou (United Kingdom)</td>
<td>17:15 - 17:30</td>
</tr>
<tr>
<td>Contact pathway inhibition: characterization of effect on clot formation</td>
<td>Henry Spronk (The Netherlands)</td>
<td>17:30 - 17:40</td>
</tr>
<tr>
<td>Targeting factor XII inhibits the pathological process of thrombus formation on ruptured plaques in vivo and in vitro</td>
<td>Judith Cosemans (The Netherlands)</td>
<td>17:40 - 17:50</td>
</tr>
<tr>
<td>A chromogenic FXIa method with low interference for in-process and final testing of immunoglobulin preparations</td>
<td>Steffen Rosén (Sweden)</td>
<td>17:50 - 18:00</td>
</tr>
</tbody>
</table>
### Predictive Variables in Cardiovascular Disease

**Room 3A**

**Chairpersons:** James Douketis (Canada), Frederick Spencer (Canada), Alberto Tosetto (Italy), Richard White (USA), Alex Spyropoulos (USA), Shinya Goto (Japan), Karel Moons (The Netherlands)

**Part A: new project on the determinants of thrombosis and bleeding risk in the perioperative setting**

*Alex Spyropoulos (USA)*

**Sessions objectives**

- Managing patients on new oral anticoagulants who need surgery: how to minimize risk for thrombosis and bleeding?
  - Marc Samama (France) 15:30 - 15:35

- Managing patients on new oral anticoagulants who need surgery: how to use and interpret coagulation tests?
  - Beverly Hunt (United Kingdom) 15:35 - 15:50

- Managing patients on antiplatelet drugs who need surgery: can platelet function assays predict bleeding?
  - Jerrold Levy (USA) 15:50 - 16:10

- Weighting of thrombosis and bleeding risk in clinical trials: application to the perioperative setting
  - Alex Spyropoulos (USA) 16:10 - 16:30

**Tea / Coffee Break**

**Exhibition hall, lower level**

**Part B: update of SSC-Related activities**

*James Douketis (Canada)*

- The Austrian study on recurrent venous thromboembolism (AUREC): an update
  - Paul Kyrle (Austria) 17:00 - 17:15

- Assessing patients’ risk for stroke and bleeding: how this informs decisions about which anticoagulant to use
  - Shinya Goto (Japan) 17:15 - 17:30

- Patient risk scores: how to assess their usefulness in clinical practice?
  - Karel Moons (The Netherlands) 17:30 - 17:45

- CHADS2 and CHADS2VASc to determine stroke risk: one or both?
  - Scott Kaatz (USA) 17:45 - 18:00
Detailed Programme Thursday, 28 June 2012

**Fibrinolysis**

Chairpersons: Ann Gils (Belgium), Jonathan Foley (USA), Shirley Uitte de Willige (Netherlands), Paul Kim (Canada), Osamu Matsuo (Japan), Tetsumei Urano (Japan), Nicola Mutch (United Kingdom), Craig Thelwell (United Kingdom)

An update on WHO International Standards: a report on the Urokinase study; a proposal to replace the plasmin IS and other ongoing projects
Craig Thelwell (United Kingdom) 15:30 - 16:00

Measuring the mechanical properties and fibrinolytic potential of blood clots formed via the tissue factor pathway of coagulation
Jonathan Foley (USA) 16:00 - 16:20

**Tea / Coffee Break**

**Exhibition hall, lower level**

Alpha-2-antiplasmin: a heterogeneous fibrinolysis inhibitor
Shirley Uitte de Willige (The Netherlands) 16:40 - 17:00

Roles of kringle domains in plasminogen activation and plasmin activity
Paul Kim (Canada) 17:00 - 17:20

What’s in a name? An evaluation of TAFI/pro-CPU nomenclature
Jonathan Foley (USA) 17:20 - 17:40

**Plasma Coagulation Inhibitors**

Chairpersons: Steven Kitchen (United Kingdom); Piet Meijer (The Netherlands), Laurent Mosnier (USA), Elisabetta Castoldi (The Netherlands), Tilman Hackeng (The Netherlands), Richard Marlar (USA)

Welcome and update on subcommittee projects
Steven Kitchen (United Kingdom) 15:30 - 15:40

Session 1: effects of new oral anticoagulants on plasma coagulation inhibitor testing
Steven Kitchen (United Kingdom); Piet Meijer (The Netherlands) 15:40 - 15:55

The effect of rivaroxaban on laboratory testing for coagulation inhibitors: experience from ECAT surveys
Piet Meijer (The Netherlands) 15:40 - 15:55
Detailed Programme Thursday, 28 June 2012

Effects of dabigatran on PC, PS and AT assays
Bob Gosselin (USA)  15:55 - 16:10

Effects of rivaroxaban and dabigatran on plasma inhibitor testing
Andreas Hillarp (Sweden)  16:10 - 16:25

Session 2
Steven Kitchen (United Kingdom), Richard Marlar (USA)
The effect of CRP on clot based protein C and protein S assays
Jun Teruya (USA)  16:25 - 16:40

Stability of AT, PC and APC-R in whole blood
K Hickey (United Kingdom)  16:40 - 16:55

Total protein S assay system: clinical significance and pre-analytical quality control
Hiroko Tsuda (Japan)  16:55 - 17:10

Genotype and laboratory phenotype of hereditary protein S deficiency
Michael Spannagl (Germany)  17:10 - 17:25

Session 3
Laurent Mosnier (USA), Tilman Hackeng (The Netherlands)
Novel assays for EPCR encryption and cellular APC resistance
Eveline A. Bouwens (USA), Laurent Mosnier (USA)  17:25 - 17:40

Thrombin generation as an intermediate phenotype for genetic studies on venous thrombosis
Elisabetta Castoldi (The Netherlands)  17:40 - 18:00
Detailed Programme Thursday, 28 June 2012

ISTH BAT Standing Committee Public Session

Chairperson: Francesco Rodeghiero (Italy)

Introduction
Presentation of the ISTH-Bleeding Assessment Tool (BAT) Standing Committee operative rules and projects
Francesco Rodeghiero (Italy) 16:05 - 16:20

Rockefeller University repository
Barry Coller (USA) 16:20 - 16:35

Ongoing/planned projects
Jeroen Eikenboom (The Netherlands), Paul Monagle (Australia)

Bleeding phenotype of severe VWD3 versus milder VWD forms: current experiences and future perspectives
Augusto Federici (Italy) 16:35 - 17:35

Preliminary data on bleeding manifestations in adult controls and adults with Type 1 VWD
Paula James (Canada) 16:35 - 17:35

Defining the incidence of bleeding in normal adults
Alberto Tosetto (Italy) 16:35 - 17:35

Towards harmonization of different BATs in rare congenital bleeding disorders
K Mussallam (Italy), Flora Peyvandi (Italy) 16:35 - 17:35

Proposals and suggestions from the attendees
David Lillicrap (Canada), Sabine Eichinger (Austria) 17:35 - 17:55

Conclusions
Francesco Rodeghiero (Italy) 17:55 - 18:00
### Satellite Symposia

**Chairperson:** Ander Cohen (United Kingdom)

**Novel oral anticoagulant for the management of venous thromboembolism - a practical consideration**

<table>
<thead>
<tr>
<th>Session</th>
<th>Speaker(s)</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>Ander Cohen (United Kingdom)</td>
<td>18:15 - 18:20</td>
</tr>
<tr>
<td><strong>EINSTEIN PE results and their impact on VTE treatment</strong></td>
<td>Ander Cohen (United Kingdom)</td>
<td>18:20 - 18:45</td>
</tr>
<tr>
<td><strong>Treating VTE: the single drug approach</strong></td>
<td>Gerry Dolan (United Kingdom)</td>
<td>18:45 - 19:05</td>
</tr>
<tr>
<td><strong>Orthotep Presentation</strong></td>
<td>Jan Beyer-Westendorf (Germany)</td>
<td>19:05 - 19:15</td>
</tr>
<tr>
<td><strong>Novel anticoagulants in clinical practice – panel discussion and close</strong></td>
<td>Ander Cohen (United Kingdom), Gerry Dolan (United Kingdom), Jan Beyer-Westendorf (Germany), Simon Nobel (United Kingdom), Raj Patel (United Kingdom)</td>
<td>19:15 - 19:45</td>
</tr>
</tbody>
</table>

### Symposium on Widening Participation

**Chairperson:** Mike Parker (Liverpool Vision)

**Little Big Medicine**

<table>
<thead>
<tr>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome to school students</td>
<td>Mike Parker (Liverpool Vision)</td>
</tr>
<tr>
<td><strong>Nourishing the creative mind</strong></td>
<td>Richard Piper (Roald Dahl Foundation)</td>
</tr>
<tr>
<td><strong>The emerging importance of nanomedicine</strong></td>
<td>Andrew Owen (University of Liverpool)</td>
</tr>
<tr>
<td><strong>Panel discussion with scientist, clinician and industry</strong></td>
<td>Andrew Owen (University of Liverpool), Saye Khoo (Royal Liverpool University Hospital), Geoff Wainwright (2Bio)</td>
</tr>
</tbody>
</table>
Programme Overview

Friday, 29 June 2012

SSC Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:30</td>
<td>Joint session Von Willebrand Factor and Factor VIII and IX (Hall 2E)</td>
<td>Flora Peyvandi &amp; Paula James</td>
</tr>
<tr>
<td>09:30 - 12:00</td>
<td>Von Willebrand Factor, part I (Hall 2E)</td>
<td>Jeroen Eikenboom</td>
</tr>
<tr>
<td></td>
<td>Factor VIII and IX, part I (Hall 2F)</td>
<td>Flora Peyvandi</td>
</tr>
<tr>
<td></td>
<td>Perinatal/pediatric (Hall 2L)</td>
<td>Paul Monagle</td>
</tr>
<tr>
<td></td>
<td>Animal models (Hall 2N)</td>
<td>Susan Smyth</td>
</tr>
<tr>
<td>08:00 - 12:00</td>
<td>Lupus anticoagulant (Room 3A)</td>
<td>Thomas Ortel</td>
</tr>
<tr>
<td></td>
<td>Platelet physiology (Room 3B)</td>
<td>Paul Harrison</td>
</tr>
<tr>
<td></td>
<td>Vascular biology (Room 4)</td>
<td>Françoise Dignat-George</td>
</tr>
<tr>
<td></td>
<td>Biorheology (Room 12)</td>
<td>Michael King</td>
</tr>
</tbody>
</table>

Satellite Symposia

<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 - 13:45</td>
<td><strong>Daiichi Sankyo</strong></td>
<td>Novel anticoagulation for venous thromboembolism - (Hall 2E) new perspectives and treatment strategies</td>
</tr>
<tr>
<td></td>
<td><strong>Stago</strong></td>
<td>DIC - The next frontier in thrombosis and haemostasis (Hall 2F)</td>
</tr>
</tbody>
</table>

14:00 - 17:00 Hot Topics

Halls 2L and 2N

17:00 - 19:00 ePoster Session

20:00 - 22:00 Football Match - Europe versus the World
Detailed Programme Friday, 29 June 2012

SSC Sessions 08:00 - 12:00

Joint Session: Von Willebrand Factor and Factor VIII and IX Hall 2E

Chairpersons: Flora Peyvandi (Italy), Paula James (Canada)

Bleeding scores

Introduction
Paula James (Canada) 08:00 - 08:05

Update from the standing committee on Bleeding Assessment Tool
Francesco Rodeghiero (Italy) 08:05 - 08:25

Web based Bleeding Assessment Tool (BAT)
Barry Coller (USA) 08:25 - 08:45

What type of scoring system is necessary in hemophilia
Alberto Tosetto (Italy) 08:45 - 09:05

Bleeding score in rare bleeding disorders
Khaled Musallam (Italy) 09:05 - 09:25

General discussion

Von Willebrand Factor, part I Hall 2E

Chairpersons: Jeroen Eikenboom (The Netherlands), Daniel Hampshire (United Kingdom), Thomas Abshire (USA), Jorge DiPaola (USA), Yoshihiro Fujimura (Japan), Paula James (Canada), Imre Bodo (Hungary), Johanna Kremer Hovinga (Switzerland)

Standardization of assays

Thomas Abshire (USA)

Review of the available WHO IS for all VWF-related analytes, and VWFpp calibration
Anthony Hubbard (United Kingdom) 10:00 - 10:15

Standardization of the high quality multimer assay: a Hamburg-Budapest project
Imre Bodo (Hungary) 10:15 - 10:30

International reference preparation for ADAMTS13 activity
Johanna Kremer Hovinga (Switzerland) 10:30 - 10:40

Gene mutation analysis for Upshaw-Schulman syndrome
Koichi Kokame (Japan) 10:40 - 10:55

Comparison of VWF activity assays
Imre Bodo (Hungary) 10:55 - 11:05
Detailed Programme Friday, 29 June 2012

VWF, VWD and TTP registries

Jorge DiPaola (USA)

VWF database
Daniel Hampshire (United Kingdom) 11:05 - 11:20

Platelet type- VWD registry/database
Maha Othman (Canada) 11:20 - 11:35

International registry on acquired von Willebrand syndrome
Augusto Federici (Italy) 11:35 - 11:45

Hereditary TTP registry
Johanna Kremer Hovinga (Switzerland) 11:45 - 12:00

Factor VIII and IX, part I

Chairpersons: Flora Peyvandi (Italy), Leonard Valentino (USA), Claude Negrier (France), Midori Shima (Japan), Jan Astermark (Sweden), Kathelijn Fischer (The Netherlands), Steven Pipe (USA)

Report on SSC-FVIII&FIX activity 2010-2011
Flora Peyvandi (Italy) 09:30 - 09:40

Projects reports I

Guy Young (USA), Alok Srivastava (India)

Standardization of whole blood viscoelastic measurement of clot formation and clot stability
Meera Chitlur (USA) 09:40 - 09:50

Standardization of methods for performing the thrombin generation test
Claude Negrier (France) 09:50 - 10:00

Standardization of methods for performing the clot wave form analysis
Midori Shima (Japan) 10:00 - 10:10

General discussion

Projects reports II: FDA and EMEA regulatoryies: clinical trial requirements

Flora Peyvandi (Italy), Mike Makris (United Kingdom)

New regulation of FDA for rare disorders
Nisha Jain (USA) 10:20 - 10:30

New European guidelines for clinical trials in rare disorders
Anneliese Hilger (Germany) 10:30 - 10:40

Clinical trial design for haemophilia
Donna DiMichele (USA) 10:40 - 10:50
### Detailed Programme Friday, 29 June 2012

#### Projects reports III

*Steven Kitchen (United Kingdom), Leonard Valentino (USA)*

**Using pharmacokinetics to individualize treatment: update**
Peter Collins (United Kingdom)  
11:10 - 11:20

**Potency labelling of clotting factor concentrates: update**
Anthony Hubbard (United Kingdom)  
11:20 - 11:30

**Consensus definitions in haemophilia**
Alok Srivastava (India)  
11:30 - 11:40

**Consensus definitions in rare bleeding disorders**
Flora Peyvandi (Italy)  
11:40 - 11:50

**General discussion**

#### Perinatal/Pediatric

*Chairpersons: Paul Monagle (Australia), Paolo Simioni (Italy), Mariana Bonduel (Argentina), Elizabeth Chalmers (United Kingdom), Anthony Chan (Canada), Christoph Male (Austria), Janna Journeycake (USA), Guy Young (USA)*

**Introduction and update on the work of the SSC**
Paul Monagle (Australia)  
08:00 - 08:15

**IVC filters in children**
Suzan Williams (Canada)  
08:15 - 08:45

**Measurement of long term consequences of specific organ thrombosis**
Madhvi Rajpurkar (USA)  
08:45 - 09:15

**Systematic assessment of PTS of the upper venous system**
Shoshana Revel-Vilk (Israel)  
09:15 - 09:45

**Evidence for FFP use in neonates and children**
John Puetz (USA)  
09:45 - 10:15

#### Tea / Coffee Break

*Exhibition hall, lower level*

---

**Establishment of a registry of homozygous protein C**
Vicky Price (Canada)  
10:30 - 11:00
### Detailed Programme Friday, 29 June 2012

#### Brief updates on ongoing SSC projects

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiplatelet therapy in children</td>
<td>Janna Journeycake (USA)</td>
<td>11:00 - 11:10</td>
</tr>
<tr>
<td>HIT in children</td>
<td>Guy Young (USA)</td>
<td>11:10 - 11:20</td>
</tr>
<tr>
<td>Point-of-care testing in children</td>
<td>Paul Monagle (Australia)</td>
<td>11:20 - 11:30</td>
</tr>
<tr>
<td>Investigation of the bleeding child</td>
<td>Paolo Simioni (Italy)</td>
<td>11:30 - 11:45</td>
</tr>
<tr>
<td>Conclusion and planning</td>
<td>Paul Monagle (Australia)</td>
<td>11:45 - 12:00</td>
</tr>
</tbody>
</table>

#### Animal Models

**Chairpersons:** Susan Smyth (USA), Cecile Denis (France), Nigel Mackman (USA), Toshiyuki Miyata (Japan), David Motto (USA), Hugo Ten Cate (The Netherlands), Timothy Nichols (USA), Eva-Maria Muchitsch (Austria), Tom Knudsen (Denmark)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARFI ultrasound method of detecting bleeding and documenting hemostasis in the hemophilic and VWD dogs</td>
<td>Timothy Nichols (USA)</td>
<td>08:05 - 08:30</td>
</tr>
<tr>
<td>Pharmacokinetics and pharmacodynamics of recombinant canine FVIIa in dogs</td>
<td>Tom Knusden (Denmark, Novo Nordisk AS)</td>
<td>08:30 - 08:55</td>
</tr>
<tr>
<td>Pro-hemostatic agents in a pig model of coagulopathy</td>
<td>Henry Spronk (The Netherlands)</td>
<td>08:55 - 09:20</td>
</tr>
<tr>
<td>Assessment of thrombogenicity</td>
<td>Eva-Maria Muchitsch (Austria, Baxter Innovations GmbH)</td>
<td>09:20 - 09:45</td>
</tr>
</tbody>
</table>

**Tea / Coffee Break**

**Exhibition hall, lower level**
Detailed Programme Friday, 29 June 2012

Coagulant proteins in murine models of atherosclerosis
Hugo Ten Cate (The Netherlands) 10:00 - 10:25

Platelet signatures in mice and humans
Andy Weyrich (USA) 10:25 - 10:50

Contributions of platelet TGF-β1 in vitro and in vivo to plasma TGF-β1 and its biologic effects
Jasimuddin Ahamed (USA) 10:50 - 11:15

Bleeding phenotype and coagulation variables of BALB/c, C57BL/6 and 129S1/Sv mice
Alexandra Schiviz (Austria, Baxter Innovations GmbH) 11:15 - 11:40

Planning for the 59th Annual SSC Meeting with XXIV ISTH Congress:
Amsterdam, The Netherlands, June 29 - July 4, 2013 11:40 - 12:00

Lupus Anticoagulant

Chairpersons: Thomas Ortel (USA), Katrien Devreese (Belgium), Armando Tripodi (Italy), Silvia Pierangeli (USA), Bas de Laat (The Netherlands), Tatsuya Atsumi (Japan), Guido Reber (Switzerland), Vittorio Pengo (Italy)

Anticardiolipin, anti-beta-2-glycoprotein I, and antiprothrombin antibodies
Update on criteria antiphospholipid task force and establishing units of measurement for anti-beta-2-glycoprotein I antibodies
Silvia Pierangeli (USA) 08:00 - 08:30

Conformation of beta-2-glycoprotein I
Bas de Laat (The Netherlands) 08:30 - 09:00

Phosphatidylserine dependent antiprothrombin antibodies: significance and international standardization
Tatsuya Atsumi (Japan) 09:00 - 09:30

Standardization of the antiphospholipid antibody assays
Katrien Devreese (Belgium), Thomas Ortel (USA) 09:30 - 10:00

Lupus anticoagulants
Diagnosis of lupus anticoagulants in the presence of new anticoagulant therapies
PG de Groot (The Netherlands) 10:00 - 10:30

Problems and possible solutions in the detection of antiphospholipid antibodies
Guido Reber (Switzerland) 10:30 - 11:00
New assays
Update on the annexin A5 resistance assay and proposal for an SSC trial analogous to the anti-D1 study
Jacob Rand (USA) 11:00 - 11:30

Proposal for new guidelines for diagnosis of APS
Proposed guidelines for the diagnosis of antiphospholipid syndrome
Vittorio Pengo (Italy) 11:30 - 12:00

Platelet Physiology

Chairpersons: Paul Harrison (United Kingdom), Paolo Gresele (Italy), Christian Gachet (France), Dermot Kenny (Republic of Ireland), Diego Mezzano (Chile), Andrew Mumford (United Kingdom), Marco Cattaneo (Italy), Alan Nurden (France)

Introduction and overview
Paul Harrison (United Kingdom) 08:00 - 08:15

Guidelines for the diagnosis of platelet disorders
Survey update
Paolo Gresele (Italy) 08:15 - 08:40

Consensus of working group
Paolo Gresele (Italy) 08:40 - 09:05

Platelet type VWD
Maha Othman (Canada) 09:05 - 09:30

Therapeutic monitoring of anti-P2Y12 drugs
Dirk Sibbing (Germany) 09:30 - 10:00

Tea / Coffee Break

Analysis of the platelet transcriptome
New generation sequencing, transcription profiling and whole exome analysis of platelet disorders
Kathleen Freson (Belgium) 10:30 - 11:00

Thrombogenetics
Graham Kiddle (United Kingdom) 11:00 - 11:30

In vitro microfluidic devices
Johan Heemskerk (The Netherlands) 11:30 - 12:00
### Vascular Biology

**Room 4**

Chairpersons: Françoise Dignat-George (France), Michael Berndt (Ireland, Republic of), John Griffin (USA), Peter Newman (USA), Florence Toti-Orfanoudakis (France), Nigel Key (USA), Rienk Nieuwland (The Netherlands), Elizabeth Gardiner (Australia)

#### Shed proteins/receptors

*Elizabeth Gardiner (Australia), Peter Newman (USA)*

- **Shear-induced release of platelet receptors by metalloproteinases**
  - Elizabeth Gardiner (Australia)
  - 08:00 - 08:15
- **Metalloproteinase shedding influencing leukocyte function**
  - Elaine Raines (USA)
  - 08:15 - 08:30
- **ADAMs mediated shedding in vascular biology**
  - Andreas Ludwig (Germany)
  - 08:30 - 08:45
- **Function of GPV and its utility as a marker of thrombosis in cardiovascular disorders**
  - François Lanza (France)
  - 08:45 - 09:00

#### Detection and characterization of circulating endothelial cells and their progenitors

*Françoise Dignat-George (France), John Griffin (USA)*

- **Endothelial progenitor cell measurement for assessment of cardiovascular risk**
  - Gianpaolo Fadini (Italy)
  - 09:00 - 09:15
- **Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells**
  - Jamie Case (USA)
  - 09:15 - 09:30
- **Changes in circulating endothelial cells and their progenitors during percutaneous coronary intervention: a reflect of endothelial response to injury with prognosis significance.**
  - Florence Sabatier (France)
  - 09:30 - 09:45

#### Tea / Coffee Break

Exhibition hall, lower level

#### Determination and characterization of (circulating) microparticles

*Nigel Key (USA), Florence Toti-Orfanoudakis (France)*

- **Challenges and opportunities for multiparameter analysis of cell derived microvesicle by flow cytometry**
  - John Nolan (USA)
  - 10:15 - 10:30
- **Characterization of microparticles from blood plasma and activated platelets by cryo-electron microscopy**
  - Alain Brisson (France)
  - 10:30 - 10:45
Detailed Programme Friday, 29 June 2012

Is decrease of microparticles related to improvement of hemostasis after the treatment in hemophilia A
Jovan Antovic (Sweden) 10:45 - 11:00
Effect of different triggering techniques on MP analysis by flow cytometry
Micah Mooberry (USA) 11:00 - 11:15
Flow cytometry-based standardized microparticle counting: forward or side scatter
Philippe Poncelet (France) 11:15 - 11:30
Development of standards for MP determination
Rienk Niewland (The Netherlands) 11:30 - 11:45
Closing remarks
Françoise Dignat-George (France) 11:45 - 12:00

Biorheology Room 12

Chairpersons: Michael King (USA), Lawrence Brass (USA), Shaun Jackson (Australia), Armin Reininger (Switzerland), Mitsuhiko Sugimoto (Japan), Keith Neeves (USA), Owen McCarty (USA)

Part 1: in vitro assays of thrombosis and haemostasis under flow
Michael King (USA)
Platelet aggregates as prerequisite for fibrin polymerization under flow
Armin Reininger (Switzerland) 08:05 - 08:25
Fibrin generation within thrombi generated in antibody-induced hemophilic whole blood under flow condition: In vitro evaluation for hemostatic effects of anti-hemophilic agents
Mitsuhiko Sugimoto (Japan) 08:25 - 08:45
Fibrin formation under flow correlates to FVIII levels in hemophilia A in a tissue factor-collagen flow assay
Keith Neeves (USA) 08:45 - 09:05
Characterization of the physical parameters of mass, volume and density of platelet aggregates and thrombus formation
Owen McCarty (USA) 09:05 - 09:25
Methods and readouts for investigating the effects of fluid shear stress on haemostatic and inflammatory responses of endothelial cells
Gerard Nash (United Kingdom) 09:25 - 09:45

Tea / Coffee Break Exhibition hall, lower level
Detailed Programme Friday, 29 June 2012

Part 2: multiscale modeling and high throughput assays of thrombus growth under flow
Armin Reininger (Switzerland), Mitsuhiko Sugimoto (Japan)
High throughput microfluidics and platelet phenotyping for patient-specific simulation of thrombosis and bleeding
Scott Diamond (USA)
Multiparameter assessment of thrombus formation: a systems biology approach
Johan Heemskerk (The Netherlands)
A novel platform for multiscale modeling of human thrombi
Tom Diacovo (USA)
Modeling platelet deposition and coagulation under flow: transport of platelets and proteins to and within the thrombus
Aaron Fogelson (USA)
Estimating the robustness and fragility of the coagulation cascade using a population of mathematical models
Jeff Varner (USA)
Multiscale simulation of platelet tethering and translocation
Michael King (USA)

Satellite Symposia 12:15 - 13:45

Daiichi Sankyo Hall 2E

Chairpersons: Gregory YH Lip (United Kingdom), Henri Bounaumeaux (Switzerland)

Novel anticoagulation for venous thromboembolism - new perspectives and treatment strategies

Welcome and introduction
Gregory YH Lip (United Kingdom), Henri Bounaumeaux (Switzerland) 12:15 - 12:20
Venous thromboembolism - a clinician’s view
Henri Bounaumeaux (Switzerland) 12.20 - 12:40
New perspectives with novel anticoagulants, beyond venous thromboembolism
Gregory YH Lip (United Kingdom) 12:40 - 13:00
Edoxaban - current evidence of a new once-daily factor Xa inhibitor
Sebastian M Schellong (Germany) 13:00 - 13:20
Detailed Programme Friday, 29 June 2012

Edoxaban in venous thromboembolism - what can the HOKUSAI-VTE study tell us?
Harry Büller (The Netherlands)  13:20 - 13:35
Panel discussion / Q&A
All 13:35 -13:40
Meeting close
Gregory YH Lip (United Kingdom), Henri Bounnameaux (Switzerland) 13:40 - 13:45

Stago 

Chairpersons: Cheng-Hock Toh (United Kingdom), Fletcher B. Taylor Jr. (USA)

DIC - The next frontier in thrombosis and haemostasis
Welcome and introduction
Cheng-Hock Toh (United Kingdom), Fletcher B. Taylor, Jr. (United Kingdom) 12:15 - 12:20
Mission: impossible-DIC protocol
Cheng-Hock Toh (United Kingdom)  12:20 - 12:45
Platelets in DIC and severe sepsis
Bernd Jilma (Austria)  12:45 - 13:10
Laboratory innovation in the management of patients with severe sepsis
Françoise Dignat-George (France) 13:10 - 13:35
Concluding remarks
Cheng-Hock Toh (United Kingdom)  13:35 - 13:45

Hot Topics 14:00 - 17:00

Basic Science (see page 68)  Hall 2 L
Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands)

Clinical Science (see page 69)  Hall 2 N
Chairpersons: Anna Falanga (Italy), Henri Bounnameaux (Switzerland)

ePoster Session 17:00 - 19:00

Football Match - Europe versus the World 20:00 - 22:00
join ISTH!

Benefits of membership in ISTH include:

- An international network of over 3,000 members in more than 80 countries
- Priority registration and discounted fees for ISTH meetings and congresses
- Complimentary print subscription for regular members and online subscription for all membership categories to ISTH's *Journal of Thrombosis and Haemostasis*
- Access to the ISTH members-only online resources, including educational materials, e-learning and membership directory
- Exclusive access and/or reduced fees for other educational activities, programs and publications
- The quarterly ISTH Newsletter and regular e-updates
- The right to nominate, elect and serve on ISTH committees

The International Society on Thrombosis and Haemostasis is the leading worldwide organization dedicated to the advancement of the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders.

ISTH provides a forum for discussion, encourages research and fosters the dissemination and exchange of ideas through scientific meetings and publications, education initiatives, research activities, expert committees and standardization of nomenclature and methods.

www.isth.org
### Programme Overview

#### Saturday, 30 June 2012

#### Technical Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 09:00</td>
<td><strong>Inspiration Biopharmaceuticals, Inc.</strong></td>
<td>Assay techniques for recombinant porcine FVIII and recombinant human FIX (Hall 2E)</td>
</tr>
</tbody>
</table>

#### SSC Session

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chairpersons</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 13:00</td>
<td>Von Willebrand Factor, part II (Hall 2E)</td>
<td>Jeroen Eikenboom</td>
</tr>
<tr>
<td></td>
<td>Women’s health issues in thrombosis and haemostasis (Hall 2F)</td>
<td>Sabine Eichinger</td>
</tr>
<tr>
<td></td>
<td>Control of anticoagulation (Hall 2L)</td>
<td>Walter Ageno</td>
</tr>
<tr>
<td></td>
<td>Hemostasis and Malignancy (Hall 2N)</td>
<td>Agnes Lee</td>
</tr>
<tr>
<td></td>
<td>Factor VIII and IX, part II (Room 3)</td>
<td>Flora Payvandi</td>
</tr>
<tr>
<td></td>
<td>Platelet immunology (Room 12)</td>
<td>Yves Gruel</td>
</tr>
<tr>
<td></td>
<td>Factor XIII and fibrinogen (Room 4A)</td>
<td>Hans Kohler</td>
</tr>
</tbody>
</table>

#### 14:00 - 16:30 SSC Business Meeting

Room 12
### Detailed Programme Saturday, 30 June 2012

#### Technical Session 08:00 - 09:00

**Inspiration Biopharmaceuticals, Inc.**

**Chairperson:** Dougald Monroe (USA)

**Assay techniques for recombinant porcine FVIII and recombinant human FIX**

- **Welcome and introduction**
  - Dougald Monroe (USA) 08:00 - 08:05

- **Recombinant porcine FVIII**
  - Martin L Lee (USA) 08:05 - 08:20

- **Factor IX assay**
  - Elaine Gray (United Kingdom) 08:20 - 08:35

- **Recombinant human FIX**
  - Dougald Monroe (USA) 08:35 - 08:50

- **Questions and answers**
  - Elaine Gray (United Kingdom), Martin L Lee and Dougald Monroe (USA) 08:50 - 09:00

#### SSC Sessions 09:00 - 13:00

**Von Willebrand Factor, part II**

**Chairpersons:** Jeroen Eikenboom (The Netherlands), Daniel Hampshire (United Kingdom), Thomas Abshire (USA), Paula James (Canada), Johanna Kremer Hovinga (Switzerland), Imre Bodo (Hungary), Jorge DiPaola (USA), Yoshihiro Fujimura (Japan)

**Multicenter studies on VWD**

- Daniel Hampshire (United Kingdom), Imre Bodo (Hungary)

  - **European project on type 3 VWD**
    - Augusto Federici (Italy) 09:00 - 09:15

  - **EUVWD cooperative group**
    - Anne Goodeve (United Kingdom), Carlo Castaman (Italy) 09:15 - 09:30

  - **Zimmerman project (ZPMCB-VWD)**
    - Robert Montgomery (USA) 09:30 - 09:45

  - **VWD international prophylaxis (VIP) study**
    - Thomas Abshire (USA) 09:45 - 10:00
Detailed Programme Saturday, 30 June 2012

WIN (Willebrand in Netherlands)
Frank Leebeek (The Netherlands) 10:00 - 10:15

Canadian type 3 VWD study
Paula James (Canada) 10:15 - 10:30

Belgian-Czech cooperation in the Brno-VWD study
Alain Gadisseur (Belgium) 10:30 - 10:45

Tea / Coffee Break

Genetic modifiers of VWF levels
Johanna Kremer Hovinga (Switzerland), Jeroen Eijkenboom (The Netherlands) 11:15 - 11:30

Potential role of novel VWF clearance pathways
David Lillicrap (Canada) 11:30 - 11:45

Genetic variability as a determinant of in vivo release of VWF
Frank Leebeek (The Netherlands) 11:45 - 12:00

Genetic modifiers of VWF antigen levels in healthy young adults
Karl Desh (USA) 12:00 - 12:15

Genetic modifiers of VWD in large pedigrees: association and linkage
Jorge DiPaola (USA) 12:15 - 12:30

Animal studies

Mouse modifiers of VWF
Jordan Shavit (USA) 12:30 - 12:45

Modifier screens in zebrafish and possible application to VWF
Jordan Shavit (USA)

General discussion and concluding remarks

Women’s Health Issues in Thrombosis and Haemostasis

Chairpersons: Sabine Eichinger (Austria), Takao Kobayashi (Japan), Claire Phillip (USA), Andra James (USA), Barbara Konkle (USA), Rezan Abdul-Kadir (United Kingdom), Claire McLintock (New Zealand), Saskia Middeldorp (The Netherlands)

Educational activities

Educational program of SSC meetings: overview and future perspectives
Sabine Eichinger (Austria) 09:05 - 09:10
Report on the women’s health issues in thrombosis and haemostasis
symposium 2011
Benjamin Brenner (Israel) 09:10 - 09:15

**ACCP guidelines on “venous thromboembolism, thrombophilia, antithrombolic therapy, and pregnancy” 2012: panelists update of relevant changes**
1. 
**Thromboprophylaxis after caesarean section**
Ian Greer (United Kingdom) 09:15 - 10:15

2. 
**Prevention of VTE in pregnant women at increased risk**
Saskia Middeldorp (The Netherlands) 09:15 - 10:15

3. 
**Thrombophilia and pregnancy complications**
Ian Greer (United Kingdom) 09:15 - 10:15

**Update on investigator initiated trials in women’s issues (Highlow study, ALIFE II)**
Saskia Middeldorp (The Netherlands) 10:15 - 10:30

**Tea / Coffee Break**

<table>
<thead>
<tr>
<th>Exhibition hall, lower level</th>
</tr>
</thead>
</table>

**Hormone use and the risk of venous thrombosis: clinical issues**
Astrid van Hylckama-Vlieg (The Netherlands) 10:50 - 11:15

**Heparanase procoagulant assay in women on hormonal therapy**
Yona Nadir (Israel), Benjamin Brenner (Israel) 11:15 - 11:30

**Spotlight on “malignancy and women’s health issues in thrombosis and haemostasis”**
**Pregnancy and malignancy**
Benjamin Brenner (Israel) 11:30 - 12:00

**Menorrhagia working group**
*Claire Phillip (USA)*
**Recombinant activated factor VII (rFVIIa/NovoSeven) in the management of severe postpartum hemorrhage:**
Initial report of a multicenter case series in Japan
Takao Kobayashi (Japan) 12:00 - 12:30

**Report from the bleeding assessment tool standing committee - what is relevant for women and girls**
Sabine Eichinger (Austria) 12:30 - 12:50

**Closing remarks**
Detailed Programme Saturday, 30 June 2012

Control of Anticoagulation

Chairpersons: Walter Ageno (Italy), Rebecca Beyth (USA), Elaine Hylek (USA), John Olson (USA), Gualtiero Palareti (Italy), Henry Watson (United Kingdom), Trevor Baglin (United Kingdom)

Update on the laboratory monitoring of the vitamin K antagonists
Validation of certified plasmas for ISI calibration and INR derivation
Ton van den Besselaar (The Netherlands) 09:00 - 09:15

INR simplified: the PT/INR line
S. Ibrahim (United Kingdom) 09:15 - 09:30

Intra-individual variation of INR in warfarin-treated patients: consequences for desirable analytical precision
Ton van den Besselaar (The Netherlands) 09:30 - 09:45

WHO-SSC collaborative study on low molecular weight heparin
Results of the 3rd international standard for low molecular weight heparin
Elaine Gray (United Kingdom) 09:45 - 10:00

The laboratory monitoring of the new oral anticoagulant drugs (NOACs)
Which tests should we use?
Armando Tripodi (Italy), Marc Samama (France) 10:00 - 10:35

When and how to measuring new oral anticoagulants (NOAC): working towards a recommendation from the subcommittee on control of anticoagulation
Trevor Baglin (United Kingdom) 10:35 - 10:50

Update on SSC activities: dabigatran
Elaine Gray (United Kingdom) 10:50 - 11:00

Clinical experiences with the NOACs
Major orthopaedic surgery, venous thromboembolism, atrial fibrillation: reports from daily clinical practice
J. Beyer (Germany) 11:00 - 11:15

Atrial fibrillation: gaps in trials and current practice
Elaine Hylek (USA) 11:15 - 11:30

Venous thromboembolism: gaps in trials and current practice
Giancarlo Agnelli (Italy) 11:30 - 11:45
Proposal of an SSC project: an international register on anticoagulated patients
Gualtiero Palareti (Italy)  11:45 - 12:00

Bleeding in patients receiving NOACs: problems and possible management
Update on current evidences from the real world and presentation of ongoing studies
Peter Kamphuisen (The Netherlands)  12:00 - 12:15

Suggestions for the management of invasive procedures and bleeding events with the NOACs
Sam Schulman (Canada)  12:15 - 12:30

Management of obese patients with the old and new anticoagulants
Henry Watson (United Kingdom)  12:30 - 12:45

Proposal for an SSC recommendation for the guidance on the management of patients treated with the NOACs
Walter Ageno (Italy)  12:45 - 12:55

Update on research activity on unusual site thrombosis
Splanchnic vein thrombosis
Walter Ageno (Italy)  12:55 - 13:00

Hemostasis and Malignancy  Hall 2N

Chairpersons: Agnes Lee (Canada), Marina Marchetti (Italy), Dominique Farge (France), Alok Khorana (USA), Howard Liebman (USA), Ingrid Pabinger (Austria), Wolfram Ruf (USA), Marc Carrier (Canada), Jeffrey Zwicker (USA)

Session one: update on current projects and clinical trials
Agnes Lee (Canada)

Standardization of tissue factor assays
Marina Marchetti (Italy)  09:00 - 09:20

Defining VTE in oncology trials
Marc Carrier (Canada)  09:20 - 09:40

International guidelines for antithrombotics in cancer patients
Dominique Farge (France)  09:40 - 10:00

2012 ACCP guidelines on cancer-associated thrombosis
Alok Khorana (USA)  10:00 - 10:20

Updates on clinical trials and registries
Agnes Lee (Canada)  10:20 - 10:40
Detailed Programme Saturday, 30 June 2012

Tea / Coffee Break

Exhibition hall, lower level

Session two: new proposals and hypotheses
Alok Khorana (USA)
Prothrombotic state and metastasis in preclinical models
Wolfram Ruf (USA)  11:00 - 11:20
The role of genetic polymorphisms in thrombosis and colorectal cancer
Carla Vossen (The Netherlands)  11:20 - 11:40
Biomarkers in clinical practice
Cihan Ay (Austria)  11:40 - 12:00
Competing risks in oncology trials
Jeffrey Zwicker (USA)  12:00 - 12:20
Registry on incidental PE
Marcello Dinisio (Italy)  12:20 - 12:40
New oral anticoagulants in CAT
Agnes Lee (Canada)  12:40 - 13:00

Factor VIII and IX, part II

Room 3

Chairpersons: Flora Peyvandi (Italy), Marilyn Manco-Johnson (USA), Raimondo De Cristofaro (United Kingdom), Donna DiMichele (USA), Anthony Hubbard (United Kingdom), Steven Pipe (USA), Carmen Escuriola (Germany)

Clinical issues
Marilyn Manco-Johnson (USA), Carmen Escuriola (Germany)
The incidence of inhibitors in long terms experience in prophylaxis
Erik Berntorp (Sweden)  09:00 - 09:10
Research of determinants of inhibitor development among previously untreated patients with haemophilia (RODIN study)
Marijke van den Berg (The Netherlands)  09:10 - 09:20
Extending prophylaxis around the world - What doses can we start with?
Alok Srivastava (India)  09:20 - 09:30
Immunotolerance induction using plasma derived products
Carmen Escuriola (Germany)  09:30 - 09:40
ITI International study project
Charles Hay (United Kingdom)  09:40 - 09:50
General discussion
**Detailed Programme Saturday, 30 June 2012**

**Standardisation issues**
*Raimondo De Cristofaro (United Kingdom), Anthony Hubbard (United Kingdom)*

4th international standard for FII and X, concentrate
Elaine Gray (United Kingdom) 10:10 - 10:20

A report on the collaborative study to calibrate the WHO 2nd international standard for factor VII concentrate
Craig Thelwell (United Kingdom) 10:20 - 10:30

FVIII Inhibitors assay (SMIA): a new approach in measurement
Sanj Raut (United Kingdom) 10:30 - 10:40

General discussion

---

**Critical issues on evaluation of efficacy of treatment in hemophilia**
*Donna DiMichele (USA), Steven Pipe (USA)*

Measuring clinical efficacy and laboratory parameters in patients treated with porcine factor VIII
Martin Lee (Inspiration Biopharmaceuticals) 11:00 - 11:10

Development of new rFVIII and rFIX molecules: clinical and laboratory evaluation of safety and efficacy
Stephanie Seremetis (Novo Nordisk) 11:10 - 11:20

Evolution of clinical trials in haemophilia: from simple replacement to pharmacological evidence
Rupert Sandbrink (Bayer) 11:20 - 11:30

Correlation of potency assignment and clinical performance of rFVIII-Fc and rFIX-Fc fusion proteins through field studies, ex vivo coagulation and global hemostasis assays
Jurg Sommer (Biogen Idec) 11:30 - 11:40

Clinical research challenges in developing novel compounds to treat hemophilia: the rIX-FP and rVIII-SingleChain experience
Debbie Bensen-Kennedy (CSL Behring) 11:40 - 11:50

Standardised specific assays or general tests of haemostatic potential?
Pfizer’s view on precise science or clinical relevance
Brian Colvin (Pfizer) 11:50 - 12:00

Novel assays for novel hemophilia therapies - practice of clinical testing during clinical studies 2012 and beyond
Peter Turecek (Baxter) 12:00 - 12:10
Detailed Programme Saturday, 30 June 2012

A clinically validated technology for elongating the half life of coagulation factors, enabling a prolonged haemostatic activity in hemophilic animal models
Gili Hart (Prolor Biotech) 12:10 - 12:20

General discussion

Platelet Immunology

Chairpersons: Yves Gruel (France), Andreas Greinacher (Germany), Hartmut Kroll (Germany), Yoshiaki Tomiyama (Japan), Donald Arnold (Canada), Beng Chong (Australia)

Drug-induced and autoimmune thrombocytopenia
Donald Arnold (Canada), Beng Chong (Australia)

Standardization of methods/ evaluation of drug-induced ITP testing
Donald Arnold (Canada) 09:05 - 09:20

Animal model of drug-induced ITP
Beng Chong (Australia) 09:20 - 09:35

In vivo animal model of drug-induced thrombocytopenia: the clinical relevance of anti-protamine sulfate antibodies
Tamam Bakchoul (Germany) 09:35 - 09:50

Drug-induced antibody effects on megakaryocytes
Beng Chong (Australia) 09:50 - 10:05

Application of PLT antibody testing in ITP trials: the effect of rituximab on PLT antibodies in ITP
Donald Arnold (Canada) 10:05 - 10:20

Alloimmune and isoimmune thrombocytopenia
Yves Gruel (France)

Usefulness and biological aspects of a national registry of donors for the treatment and prevention of alloimmune thrombocytopenia
Françoise Boehlen (Switzerland) 10:20 - 10:35

Usefulness of surface plasmon resonance technology for monitoring pregnancies with expected NAIT
Tamam Bakchoul (Germany) 10:35 - 10:50

Development of antibodies to \( \alpha_{IIb}\beta_3 \) in a French cohort of Glanzmann thrombasthenia patients
Mathieu Fiore (France) 10:50 - 11:00
Detailed Programme Saturday, 30 June 2012

Tea / Coffee Break

Exhibition hall, lower level

Heparin-induced thrombocytopenia - pathogenesis of HIT
Andreas Greinacher (Germany)
Binding study of HIT antibodies to PF4 modified by enoxaparin oligosaccharides using SPR
D Leroux (France), Yves Gruel (France)
Gene variations and modulation of FcRlla- dependent platelet activation
J Rollin

Heparin-induced thrombocytopenia - diagnosis of HIT
Andreas Greinacher (Germany)
Validation of the multiplate assay for HIT diagnosis
Greifswald Group
Functional assays for HIT in Australia: where do they fit in current algorithms?
Christopher Ward (Australia)
Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients
Lorenzo Alberia (Switzerland)
Prospective evaluation of a lateral flow immunoassay
Yves Gruel (France)
AcuStar HIT-IgG and HIMEA for rapid diagnosis of type-II HIT
François Mullier (Belgium)
Difference between enzyme immunoassays in the high heparin step are independent of the source of PF4
Greifswald Group (Germany)
Final discussion and perspective

Factor XIII and Fibrinogen

Room 4A

Chairpersons: Hans Kohler (Switzerland), Sanj Raut (United Kingdom), Marguerite Neerman-Arbez (Switzerland), Helen Philippou (United Kingdom), Verena Schroeder (Switzerland), Aida Inbal (Israel), Moniek de Maat (The Netherlands), John Weisel (USA)

International collaborative study for the value assignment of the 2nd International Standard for fibrinogen, concentrate - an update
Sanj Raut (United Kingdom)
Modeling fibrinogen deficiency in the zebrafish
Marguerite Neerman-Arbez (Switzerland) 09:25 - 09:45

An international, collaborative study on the standardisation of the permeability measurement of fibrin clot structure: methodological considerations and implications for healthy control values
Moniek de Maat (The Netherlands), John Weisel (USA), Marlien Pieters (South Africa), Anettes Undas (Poland), Rita Marchi (Venezuela), Colin Longstaff (United Kingdom), Robert A.S. Ariëns (United Kingdom) 09:45 - 10:05

Fibrinogen gamma measurements
Moniek de Maat (The Netherlands) 10:05 - 10:25

In vivo measurement of FXIII activity and fibrin formation in real time
Helen Philippou (United Kingdom) 10:25 - 10:45

Tea / Coffee Break

Current practice in investigation of FXIII deficiency;
data from UK NEQAS (blood coagulation)
Ian Jennings, Isobel Walker, Timothy Woods, Steven Kitchen, Dianne Kitchen (United Kingdom) 11:00 - 11:20

First case of FXIII-A type II deficiency
Vytautas Ivaskevicius (Germany) 11:20 - 11:40

Project on value assignment for FXIII B-subunit (total & free)
to the WHO 1st IS Factor XIII plasma (2/206)
Hans Kohler, Verena Schroeder (Switzerland), Sanj Raut (United Kingdom) 11:40 - 12:00

Factor XIII B: just a carrier of factor XIII A subunit or a plasma protein of its own right?
Laszlo Muszbek (Hungary) 12:00 - 12:20

Japanese criterion 2012 for the diagnosis and treatment of acquired hemorrhaphilia XIII/13
Akitada Ichinose (Japan) 12:20 - 12:40

A novel point-of-care test for the detection of anti-factor XIII antibodies in patients with autoimmune hemorrhaphilia XIII/13, by using immunochromatography
Yasuo Magari, Shoichi Kawato, Keiko Ninomiya, Masayoshi Souri, Akitada Ichinose (Japan) 12:40 13:00

SSC Business Meeting - Room 12 14:00 - 16:30
Hot Topics Schedule

Friday, 29 June 2012

Hot Topics 14:00 - 17:00

Basic Science  Hall 2 L

Chairpersons: Michael Berndt (Ireland), Pieter Reitsma (The Netherlands)

HTB01 14:00 - 14:15

THE ITIM RECEPTOR G6B-B IS A CRITICAL REGULATOR OF MEGAKARYOCYTE ACTIVATION, PLATELET PRODUCTION AND FUNCTION

A. Mazharian* (United Kingdom) - Y. J. Wang - J. Mori - S. Heising - B. G. Neel - S. P. Watson - Y. A. Senis

HTB02 14:15 - 14:30

PLATELET GENE THERAPY CORRECTS THE HEMOPHILIC PHENOTYPE IN IMMUNOCOMPROMISED HEMOPHILIA A MICE TRANSPLANTED WITH GENETICALLY MANIPULATED HUMAN CORD BLOOD STEM CELLS

Q. Shi* (USA) - E. L. Kuether - J. A. Schroeder - S. A. Fahs - R. R. Montgomery

HTB03 14:30 - 14:45

NUCLEAR FACTOR (NF)-"B IS A MAJOR REGULATOR OF BLOOD INDUCED JOINT DAMAGE IN A MURINE MODEL OF HEMOPHILIA A


HTB04 14:45 - 15:00

STRUCTURE OF FACTOR XI IN COMPLEX WITH A HIGH MOLECULAR WEIGHT KININOGEN PEPTIDE

S. S. Wong* (United Kingdom) - G. Hall - H. Stennicke - J. Emsley

HTB05 15:00 - 15:15

INVOLVEMENT OF 2-ANTIPLASMIN IN DENDRITIC GROWTH DURING MEMORY FORMATION


HTB06 15:15 - 15:30

MODULATION OF TAFI-DEPENDENT REGULATION OF FIBRINOLYSIS BY EXTRACELLULAR HISTONES

L. O. Mosnier* (USA) - D. Rozenshteyn

HTB07 16:00 - 16:15

TISSUE FACTOR EXPRESSING NEUTROPHILS INITIATE COAGULATION ON INJURED VESSEL WALLS

R. Darbousset - G. Thomas - S. Mezouar - T. Renne - N. Mackman - F. Dignat-George - L. Panicot-Dubois — C. Dubois* (France)

HTB08 16:15 - 16:30

EGFP-EGF1 PROTEIN CONJUGATED PEG-PLGA NANOPARTICLES FOR CEREBRAL THROMBI TARGETING DRUG DELIVERY

## Hot Topics Schedule

### HTB09 16:30-16:45

**LOSS OF PROTEIN C RECEPTORS LINKS COAGULATION AND INFLAMMATION TO PARASITE SEQUESTRATION IN CEREBRAL MALARIA**


### HTB10 16:45-17:00

**EXTRACELLULAR HISTONES ARE ELICITING FACTORS FOR DIC**

T. Ito* (Japan) - M. Nakahara - I. Maruyama

---

### Clinical Science Hall 2 N

#### HTC01 14:00 -14:15

**PREVENTION OF VENOUS THROMBOEMBOLISM AFTER AN ISOLATED, NON-SURGICAL BELOW-KNEE INJURY. BENEFIT/RISK OF FONDAPARINUX VersUS LOW MOLECULAR WEIGHT HEPARIN: THE FONDACAST STUDY**

C. M. Samama* (France) - B. Riou - P.-M. Roy - A. Sautet - P. Mismetti and the FONDACAST study group

### HTC02 14:15-14:30

**MULTIPLE SNP TESTING IMPROVES RISK PREDICTION OF FIRST VENOUS THROMBOSIS**


### HTC03 14:30-14:45

**A RANDOMIZED-CONTROLLED PHASE II TRIAL OF PRIMARY THROMBOPROPHYLAXIS WITH ENOXAPARIN IN CANCER PATIENTS WITH ELEVATED TISSUE FACTOR BEARING MICROPARTICLES (THE MICROTEC STUDY)**

**Hot Topics Schedule**

**HTC04** 14:45-15:00

**INDIRECT COMPARISON OF EFFICACY AND SAFETY OF DABIGATRAN S RE-LY, RIVAROXABAN S ROCKET-AF, AND APIXABAN S ARISTOTLE TRIAL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION**

J. Harenberg* (Germany) - S. Marx - H.-C. Diener - G. Lip - V. Marder - C. Weiss - M. Wehling

**HTC05** 15:00-15:15

**AUTOANTIBODIES DIRECTED AGAINST DOMAIN I OF BETA2-GLYCO-PROTEIN I INDICATE AN INCREASED RISK FOR THROMBOEMBOLIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES. A PROSPECTIVE COHORT STUDY**


**HTC06** 15:15-15:30

**WHOLE-EXOME SEQUENCING IDENTIFIES NOVEL RISK VARIANTS FOR THROMBOTIC STORM**


**HTC07** 16:00-16:15

**A NOVEL GENETIC VARIANT OF THE CYTOSOLIC PHOSPHOLIPASE A2 ALPHA ASSOCIATED WITH BLEEDING DIATHESIS AND DUODENAL ULCERS IN AN ITALIAN FAMILY**

E. M. Faioni* (Italy) - C. Razzari - G. Podda - M. Trinchera - G. Fontana - M. Cattaneo

**HTC08** 16:15-16:30

**NOVEL MHC PEPTIDE- T CELL RECEPTOR INTERFACES ARE NECESSARY FOR INHIBITOR FORMATION IN MILD/MODERATE HAEMOPHILIA A SECONDARY TO MIS-SENSE MUTATION GENOTYPES**

D. P. Hart* (United Kingdom) - S. Skelton - D. S. Moss - K. Gomez - C. Sansom - A. Shepherd

**HTC09** 16:30-16:45

**SPATIAL BLOOD COAGULATION IN THE PRESENCE OF ANTI-TFPI APTAMER BAX499 IN HEMOPHILIA A PATIENTS AFTER FVIII INFUSION**


**HTC10** 16:45-17:00

**THE INCIDENCE OF FACTOR VIII INHIBITORS IN SEVERE HAEMOPHILIA A FOLLOWING A MAJOR PRODUCT SWITCH IN THE UK: APROSPECTIVE CONTROLLED STUDY IN 1214 PREVIOUSLY TREATED PATIENTS**

C. R. M. Hay* (United Kingdom) - P. Collins - B. Palmer - R. Liesner - E. Chalmers - D. Hart - S. Rangarajan - S. Ragarajan - K. Talks - M. Williams -
**ePoster Session**

Exhibition hall lower level  
17:00 - 19:00

### Antithrombotic therapy

**Chairperson: Nigel Key (USA)**

**ATT01**  
**XAMOS: A NON-INTERVENTIONAL STUDY COMPARING THROMBOPROPHYLAXIS USING ORAL RIVAROXABAN WITH CONVENTIONAL REGIMENS AFTER MAJOR ORTHOPAEDIC SURGERY OF THE HIP AND KNEE**  

**ATT02**  
**RISK OF THROMBOEMBOLISM, RECURRENT BLEEDING AND DEATH AFTER WARFARIN INTERRUPTION FOR GASTROINTESTINAL BLEEDING**  

**ATT03**  
**DESPITE PHARMACOLOGICAL EQUIVALENCE, GENERIC VERSIONS OF ENOXAPARIN MAY DIFFER IN THEIR PHARMACODYNAMIC ACTIONS. POTENTIAL THERAPEUTIC IMPLICATIONS**  

**ATT04**  
**PERCEIVED STRESS REDUCES THE STABILITY OF VITAMIN K-ANTAGONIST TREATMENT**  
J. Skov* (Denmark) - A. Leppin - E.-M. Bladbjerg - J. J. Sidelmann - J. Gram

**ATT05**  
**ONE WEEK VERSUS FOUR WEEK HEPARIN PROPHYLAXIS AFTER LAPAROSCOPIC SURGERY FOR COLORECTAL CANCER. THE PRO-LAPS PILOT FEASIBILITY STUDY**  

**ATT06**  
**THE SAFETY AND EFFICACY OF INFERIOR VENA CAVA FILTERS: THE EXPERIENCE OF THE OTTAWA HOSPITAL**  
A. Forster - P. Wells

**ATT07**  
**EVALUATION OF A COMMUNITY PHARMACY ANTICOAGULATION MANAGEMENT SERVICE UTILISING POINT-OF-CARE TESTING AND ONLINE COMPUTERISED DECISION SUPPORT**  
P. Harper* (New Zealand) - J. Shaw - J. Harrison - J. Harrison

**ATT08**  
**IS THERE A GREATER ROLE FOR THROMBOLYSIS IN THE ACUTE MANAGEMENT OF DEEP VEIN THROMBOSIS (DVT)? REVIEW OF THE MANAGEMENT AND OUTCOME OF PATIENTS PRESENTING WITH PROXIMAL DVT TO A SINGLE UK CENTRE OVER A 2-YEAR PERIOD**  
D. Jayakody Arachchillage* (United Kingdom) - S. Chattree - B. Robinson - L. Rivett - P. Kesteven - K. Talks

**ATT09**  
**ENDOGENOUS THROMBIN POTENTIAL IN PATIENTS WITH LOW INTENSITY VITAMIN K ANTAGONISTS TREATMENT**  
V. Shmeleva* (Russian Federation) - Y. Namestnikov - O. Matvienko - L. Papayan - V. Soldatenkov
<table>
<thead>
<tr>
<th>ATT10</th>
<th>PROPHYLAXIS OF POSTOPERATIVE VENOUS THROMBOEMBOLISM: PURSUIT OF A RATIONAL SYSTEMATIC APPROACH</th>
<th>ATT16</th>
<th>EMERGENCY REVERSAL OF VITAMIN K ANTAGONISTS WITH PROTHROMBIN COMPLEX CONCENTRATE: THE EVERYDAY PRACTICE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATT11</td>
<td>SAFETY AND EFFICACY OF BRIDGING WITH LOW MOLECULAR WEIGHT HEPARINS: A SYSTEMATIC REVIEW</td>
<td>ATT17</td>
<td>BIOSIMILAR ENOXAPARINS AVAILABLE FOR CLINICAL USE IN BRAZIL: STRUCTURE AND HAEMOSTATIC EFFECTS</td>
</tr>
<tr>
<td></td>
<td>P. Eijgenraam* (The Netherlands) - H. ten Cate - A. ten Cate-Hoek</td>
<td></td>
<td>B. F. Glauser* (Brazil) - B. C. Vairo - S. N. Oliveira - L. P. Cinelli - M. S. Pereira - P. S. Mourão</td>
</tr>
<tr>
<td>ATT12</td>
<td>VARIANCE GROWTH RATE: A SUPERIOR METHOD TO MONITOR ORAL ANTICOAGULATION THERAPY</td>
<td>ATT18</td>
<td>DABIGATRAN EXPERIENCE IN NEW ZEALAND</td>
</tr>
<tr>
<td></td>
<td>A. V. Sharda* (USA) - G. Johnson - M. Kuskowski</td>
<td></td>
<td>M. Stephens - D. Pollock - P. Harper* (New Zealand)</td>
</tr>
<tr>
<td>ATT13</td>
<td>EUROPEAN ACTION ON ANTICOAGULATION (EAA) EVALUATION OF THE UK NATIONAL HEALTH SERVICE (NHS) IMPROVEMENT GUIDELINES FOR SAFETY INDICATORS IN ANTICOAGULATION OF ATRIAL FIBRILLATION (AF)</td>
<td>ATT19</td>
<td>ROLE OF SULFATED GALACTANS ON THROMBOSIS AND ANTITHROMBIN INTERACTION</td>
</tr>
<tr>
<td></td>
<td>L. Poller* (United Kingdom) - S. Ibrahim - T. Baglin - J. Jespersen</td>
<td></td>
<td>S. N. M. De Oliveira* (Brazil) - R. C. Fonseca - P. D. S. Mourao</td>
</tr>
<tr>
<td>ATT14</td>
<td>INFREQUENT REMOVAL OF RETRIEVABLE IVC FILTERS</td>
<td>ATT20</td>
<td>DEVELOPING AN IPHONE APP FOR THE MANAGEMENT OF THE ANTICOAGULANT DABIGATRAN</td>
</tr>
<tr>
<td></td>
<td>L. Furmark* (USA) - J. El Amm - D. Mobarek - C. Faselis - F. Rickles - A. Aggarwal</td>
<td></td>
<td>P. Harper* (New Zealand)</td>
</tr>
<tr>
<td>ATT15</td>
<td>PREDICTION OF OPTIMAL WARFARIN MAINTENANCE DOSE USING ADVANCED ARTIFICIAL NEURAL NETWORKS</td>
<td>ATT21</td>
<td>THE ROLE OF LMWH IN PREVENTION OF DEEP VEINS THROMBOSIS AND PULMONARY EMBOISI IN PATIENTS WITH SEVERE MULTIPLE TRAUMA</td>
</tr>
</tbody>
</table>
Coagulation factors Basic Science

Chairperson: *Henry Spronk (The Netherlands)*

CFBS01  FIBRIN FORMATION UNDER FLOW ON BIOMIMETIC TISSUE FACTOR RICH SURFACES
A. Onasoga* (USA) - K. Neeves

CFBS02  PRE-ANALYTICAL Routines IN COAGULATION TESTING: Are GUIDELINES FOLLOWED?
A.-H. Kristoffersen* (Norway) - A. V. Stavelin - S. Vannes - G. B. Kristensen

CFBS03  THE ATOMIC FORCE MICROSCOPY A SUITABLE TECHNIQUE TO CHARACTERIZE PROCOAGULANT VESICLES IN THE NANOmeter SCALE
J. Hardij* (Belgium) - J.-M. Dogn - B. Chatelain - F. Mullier

CFBS04  CFBS08  ADAMTS13 IN VON WILLEBRAND FACTOR (VWF) CONCENTRATES: Is an INTACT VWF TRIPLETT STRUCTURE IMPORTANT FOR VWF FUNCTION?
C. Kannicht - B. Solecka - M. Kroening - B. Fuchs* (Germany)

CFBS09  SMIA: A NEW APPROACH IN FVIII INHIBITOR MEASUREMENT AND STANDARDISATION
S. Raut* (United Kingdom)

CFBS10  THROMBIN INHIBITION Activity AND IN VITRO STABILITY IN HUMAN PLASMA OF TWO APTAMERS
I. Gribkova* (Russian Federation) - V. Spiridonova - A. Gorbatenko - E. Sinauridze

CFBS11  TECHNOCLOT® DTI AND TECHNOVIEW® DABIGATRAN - EVALUATION OF ASSAY PERFORMANCE MONITORING THE DIRECT THROMBIN INHIBITOR DABIGATRAN
L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner

CFBS12  TECHNOCHROM ANTI-XA AND TECHNOVIEW RIVAROXABAN - EVALUATION OF ASSAY PERFORMANCE ON DIFFERENT ANALYZERS
L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner - A. Siegemund - E. Lindhoff-Last

CFBS13  STAPHYLOTHROMBIN-MEDIATED FIBRIN FACILITATES S. AUREUS-PLATELET INTERACTIONS
T. Vanassche* (Belgium) - M. Hoylaerts - P. Verhamme
### ePoster Session

**Exhibition hall lower level**  
**17:00 - 19:00**

| CFBS14 | ACUTE PHASE PROTEINS REDUCE HISTONE-INDUCED PLATELET AGGREGATION AND COAGULATION ACTIVATION  
| CFBS15 | CTP - A CLINICALLY VALIDATED TECHNOLOGY FOR ELONGATING THE HALF LIFE OF COAGULATION FACTORS, ENABLING A PROLONGED HAEMOSTATIC ACTIVITY IN HEMOPHILIC ANIMAL MODEL  
| G. Hart* (Israel) - M. Zakar - P. E. Monahan - A. Bar-Ilian - O. Hershkovitz - E. Fima |
| CFBS16 | INFLUENCE OF CRYSTALLOID DILUENTS CONCENTRATION ON THROMBIN GENERATION: COMPARISON OF NAACL AND MANNITOL  
| G. O. Ogweno* (Kenya) - N. K. Gikonyo - W. Mwanda - F. Bukachi - T. Peters |
| CFBS17 | SPATIAL FIBRIN CLOT FORMATION IN PLASMA INDUCED BY SURFACE-IMMobilIZED TISSUE FACTOR: ASSAY DEVELOPMENT AND STANDARDIZATION  
| CFBS18 | INTERIM RESULTS FROM A GERMAN PROSPECTIVE POST-MARKETING SURVEILLANCE OF TREATMENT OF VON WILLEBRAND S DISEASE WITH A NEW GENERATION VWF/FVIII CONCENTRATE  
| I. Scharrer - M. v. Depka - S. Alesci - J. Feddern - O. Hegener* (Switzerland) - J. Kadar - W. Miesbach |
| CFBS19 | IMPACT OF THROMBIN AND FXA INHIBITORS (DAIGATRAN, APIXABAN, AND RIVAROXIBAN) ON PT/APTT ASSAYS ON IL INSTRUMENT/REAGENT SYSTEMS  
| J. Hammelburger* (USA) - R. Bottenuus - M. Triscott |
| CFBS20 | STRUCTURE OF THE FXII PROTEASE DOMAIN  
| J. Emsley* (United Kingdom) - M. Pathak |
| CFBS21 | INFLUENCE OF VKA, UFH OR LMWH TREATED PLASMA IN RIVAROXABAN MEASUREMENT WITH DIFFERENT METHODS BASED ON FX OR FXA ACTIVITY  
| M. M. Samama* (France) - C. Guinet - L. Le Flem - J. Amiral |
| CFBS22 | PHARMACODYNAMIC OF BOVINE AND PORCINE HEPARINS  
| CFBS23 | SEMULOPARIN AND IT'S COMPONENT Oligosaccharides Release Endogenous TFPi in a Molecular Weight Dependent Fashion. Pharmacodynamic Implications  
| J. Fareed* (USA) - H. Khan - E. Litinas - J. Cunanan - D. Hoppensteadt - C. Viskov |
| CFBS24 | DIFFERENTIATION OF NEWER ORAL ANTI-XA AND ANTI-IIA AGENTS WITH A REFERENCE TO THE REGULATORY FUNCTIONS OF THROMBIN  
ePoster Session

Exhibition hall lower level  
17:00 - 19:00

CFBS25  COMPARISON OF THE ANTICOAGULANT AND ANTITHROMBOTIC ACTIVITIES OF FUCOSYLATED CHONDROITIN SULFATE WITH THE DIRECT THROMBIN INHIBITOR DABIGATRAN ETEXILATE
R. J. C. Fonseca* (Brazil) - R. Cortez - P. A. D. S. Mourão

CFBS26  STANDARDIZATION OF ROTATION THROMBOELASTOMETRY (ROTEM®): EVALUATION OF RECOMBINANT FACTOR VIII PRODUCTS IN A MULTI-NATIONAL CLINICAL TRIAL

CFBS27  THE CONDENSED MCMDM-1 VWD BLEEDING QUESTIONNAIRE AS A PREDICTOR OF BLEEDING DISORDERS IN WOMEN WITH UNEXPLAINED MENORRHAGIA

CFBS28  GENETIC DEFECTS IN VON WILLEBRAND DISEASE TYPE 3 IN SOUTH WEST IRAN
B. Keikhaei* (Islamic Republic of Iran) - M. Nasiri - H. Galehdari - M. Yavarian

CFBS29  OCTANATE SHOWS LOW INHIBITOR INCIDENCE IN TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HAEMOPHILIA A
A. Klukowska - V. Komrska - M. Jansen - J. Bichler* (Switzerland) - P. Laguna

CFBS30  THE EFFECT OF CPB ON FXIII LEVELS IN CHILDREN
C. Cini - C. Attard - P. Monagle* (Australia) - V. Ignjatovic

CFBS31  DYSFIBRINOGENEMIA CAUSED BY TWO MUTATIONS PRESENT IN A SINGLE CHROMOSOME
L. Jiang* (China) - X. Wang

CFBS32  DETERMINATION OF FIBRINOGEN LEVEL TO GUIDE REPLACEMENT THERAPY IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS WITH DIRECT THROMBIN INHIBITORS

CFBS33  HOW DO HAEMOSTATIC VARIABLES AFFECT THROMBIN GENERATION DURING THE COURSE OF THE MENSTRUAL CYCLE?
R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CFBS34  DETECTING INTERACTION OF VWF A1 DOMAIN AND A3 DOMAIN USING SNAP/CL IP-TAG TECHNOLOGY
M. Jiang* (China) - Y. Zhao - C. Ruan

CFBS35  INFLUENCE OF TEMPERATURE ON FIBRIN CLOT FORMATION PROCESS IN THROMBODYNAMICS AND ROUTINE CLOTTING TESTS
CFBS36  ITI WITH A VWF-STABILISED FVIII CONCENTRATE IN HAEMOPHILIA A PATIENTS WITH INHIBITORS AND A POOR PROGNOSIS FOR ITI SUCCESS: PROGRESS REPORT ON OCTA-NATE IN THE OBSERVATIONAL OBSITI STUDY

CFBS37  EVALUATING THE PRECISION AND ACCURACY OF THE LABORATORY MEASUREMENT OF ANTI-PORCINE FACTOR VIII ANTIBODIES
M. L. Lee* (USA) - E. Gomperts - K. Biron - H. Levy

CFBS38  TISSUE FACTOR, A POTENT STIMULATOR OF CULTURED ENDOTHELIAL CELLS
M. M. Meiring* (South Africa) - W. Allers - E. Le Roux - P. Badenhorst

CFBS39  QUANTIFICATION OF MENORRHAGIA IN WOMEN WITH VON WILLEBRANDS DISEASE AND RARE BLEEDING DISORDERS
S. Halimeh* (Germany) - H. Rott - M. Siebert

CFBS40  STUDY OF THE EFFICACY OF ROUTINE USE OF RECTAL MISOPROSTOL IN THE PREVENTION OF POST-PARTUM HAEMORRHAGE IN RURAL NIGERIA
M. A.-R. Momoh* (Nigeria)

CFBS41  FREQUENCY OF FACTOR XIII DEFICIENCY AMONGST PATIENTS WITH RARE BLEEDING DISORDERS IN PAKISTAN: A MULTICENTER EXPERIENCE

CFBS42  DO HAEMOSTATIC PARAMETERS VARY DURING THE COURSE OF THE MENSTRUAL CYCLE?
R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CFBS43  HOW DO FEMALE HORMONE LEVELS AFFECT THE HAEMOSTASIS DURING THE COURSE OF THE MENSTRUAL CYCLE?
R. Chaireti* (Sweden) - K. Bremme - K. M. Gustafsson - T. L. Lindahl

CFBS44  COAGULATION AND FIBRINOLYTIC PARAMETERS IN NIGERIAN TYPE 2 DIABETICS WITH MICROVASCULAR COMPLICATIONS
O. Awodu* (Nigeria) - J. Obieche - M. Enosolease - C. Omoti

CFBS45  COAGULATION MARKERS AND REHEEOLOGY PROFILES IN SOME NIGERIAN PREGNANT WOMEN

CFBS46  IMMUNE TOLERANCE THERAPY IN CHILDREN WITH FVIII INHIBITORS: PROGRESS REPORT
ePoster Session

Exhibition hall lower level 17:00 - 19:00

Fibrinolysis and Vascular Biology

Chairperson: Françoise Dignat-George (France)

FVB01 EFFECTIVE TARGET THROMBOLYSIS MEDIATED BY RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR-CONJUGATED NANOPARTICLES
J. Deng* (China) - H. Mei - W. Shi - Y. Hu

FVB02 ALPHA2-ANTIPLASMIN REGULATES THE DEVELOPMENT OF FIBROSIS BY PGF2A SYNTHESIS THROUGH ATGL/IPLA2

FVB03 REDUCED FIBRINOLYTIC RESPONSE TO TISSUE PLASMINOGEN ACTIVATOR DEMONSTRATED BY THROMBOELASTOGRAPHY IN A PATIENT WITH HYPO-DYSFIBRINOPENEMIA AND A NOVEL FIBRINOGEN MUTATION

FVB04 EFFECT OF DABIGATRAN AND RIVAROXIBAN ON THROMBOMODULIN MEDIATED ACTIVATION OF PROTEIN C AND THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR (TAI)
D. Hoppensteadt* (USA) - J. Cunanan - J. Fareed - B. Lewis

FVB05 THE ANTICOAGULANT EFFECT OF BROMELAIN: AN IN VITRO STUDY USING THROMBOELASTOGRAPHY
M. Toukh* (Canada) - H. S. Elbatarny - M. Othman

FVB06 D-DIMER LEVEL, FACTOR XII ACTIVITY AND XIIA-DEPENDENT FIBRINOLYSIS IN NORMAL PREGNANCY
N. Silina* (Russian Federation) - O. Golovina - A. Nikolaeva - L. Papayan

FVB07 TECHNICAL AND CLINICAL VALIDATION OF A MODIFIED THROMBOELASTOMETRY APPROACH ON A ROTEM DEVICE FOR THE IDENTIFICATION OF PATIENTS AT RISK FOR HYPO- AND HYPERFIBRINOLYSIS

FVB08 B CELL-DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR A PROMOTES LYMPHANGIOGENESIS AND HIGH ENDOTHELIAL VENULE EXPANSION IN LYMPH NODES

FVB09 ROLES FOR TRANSGLUTAMINASE 2 AND BLOOD CLOTTING FACTOR XIII-A IN THE MAINTENANCE OF BLOOD VESSEL STRUCTURE
L. M. Newell* (United Kingdom) - K. F. Standeven - P. J. Grant - R. J. Pease - C. L. Jackson

FVB10 RELATIONSHIP OF PLATELET MICROPARTICLES TO COMPLICATIONS AND OUTCOME OF ACUTE LIVER INJURY/ACUTE LIVER FAILURE (ALI/ALF)
D. A. Gabriel* (USA) - S. Glover - R. Bowling - R. T. Stravitz
<table>
<thead>
<tr>
<th>FVB11</th>
<th>ACTIVATED PROTEIN C (APC) AND THROMBIN MODULATE CARDIOMYOCYTES CONTRACTILITY VIA A PROTEASE ACTIVATED RECEPTOR -1 (PAR1)- CARDIAC TROTONIN I (CTI) PATHWAY</th>
<th>FVB17</th>
<th>THROMBIN GENERATION ON ENDOTHELIAL CELLS IS INITIATED BY BOTH INTRINSIC AND EXTRINSIC ACTIVATION AND SHOULD BE CARRIED OUT IN LOW SERUM CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVB12</td>
<td>NITRIC OXIDE FROM ENOS REDUCES ABDOMINAL AORTIC ANEURYSMS DEVELOPMENT IN A MOUSE MODEL WITH HUMAN-LIKE HYPERCHOLESTEROLEMIA</td>
<td>FVB18</td>
<td>THE RESEARCH OF INTER-RELATIONSHIP BETWEEN ADAMTS13 AND HUMAN MICROVASCULAR ENDOTHELIAL CELLS</td>
</tr>
<tr>
<td></td>
<td>S. Momi* (Italy) - P. Gresele</td>
<td></td>
<td>A. Wang* (China) - Z. Yu - Z. Ma - K. Ding - X. Liu - J. Wu - Z. Sun - C. Ruan</td>
</tr>
<tr>
<td>FVB13</td>
<td>CILOSTAZOL IMPROVES AN ACCUMULATION OF Aμ BY LRP-1 EXPRESSION ON ENDOTHELIAL CELLS</td>
<td>FVB19</td>
<td>ANALYSIS OF SYNTHETIC AND BIOLOGICAL MICROPARTICLES ON SEVERAL FLOW CYTOMETRIC PLATFORMS</td>
</tr>
<tr>
<td>FVB14</td>
<td>PROCOAGULANT PHOSPHOLIPIDS ACTIVITY IN CEREBROSPINAL FLUID FROM PATIENTS WITH INTRACEREBRAL HAEMORRHAGE</td>
<td>FVB20</td>
<td>STANDARDIZATION OF FLOW CYTOMETRY-BASED MICROPARTICLE ANALYSIS FOR CYTOMETERS USING SIDE SCATTER FOR SIZE MEASUREMENTS</td>
</tr>
<tr>
<td>FVB15</td>
<td>CLEAVED HIGH MOLECULAR WEIGHT KININOGEN STIMULATES JNK/FOXO/MNDSOD PATHWAY FOR INDUCTION OF ENDOTHELIAL PROGENITOR CELL SENESCENCE</td>
<td>FVB21</td>
<td>THE ANGIOGENESIS AND ANTI-FIBROSIS EFFECTS OF HUMAN ADIPOSE-DERIVED STEM CELLS OVEREXPRESSING HUMAN HGF ON ACUTE MYOCARDIAL INFARCTION</td>
</tr>
<tr>
<td></td>
<td>X. Zhu* (China) - M. C. Yoder - R. W. Colman - Y. Wu</td>
<td></td>
<td>X. Zhu* (China) - J. Wu - Z. Sun - X. Cai - W. Zhu - X. Liu</td>
</tr>
<tr>
<td>FVB16</td>
<td>IS PROTHROMBIN TIME A PREDICTOR OF NEW-ONSET DIABETES IN HYPERTENSIVE AND CORONARY HEART DISEASE PATIENTS?</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>G.-P. G.-P. Jong - T. Ma* (Taiwan) - L. Tien</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ePoster Session

Exhibition hall lower level 17:00 - 19:00

Haemorrhagic Disorders (Clinical)

Chairperson: Mike Makris (United Kingdom)

HDC01 FACTOR XIII IN HAEMOPHILIA A - EFFECT ON CLOT STRUCTURE AND PERMEABILITY
O. O. Okaisabor* (United Kingdom) - J. Foley - B. Sorenson - C. Rea

HDC02 FACTOR ? A1 DOMAIN SUBSTITUTION HIS99ARG RESULTS IN SUPER-INSTABILITY OF FACTOR ? AND DISCREPANCY BETWEEN ONE-STAGE AND TWO-STAGE F?:C ASSAY IN A MILD HEMOPHILIA A PATIENT
G. You* (China) - X. Wang

HDC03 USE OF NEXT-GENERATION DNA SEQUENCING FOR GENE DISCOVERY IN BLEEDING SYNDROMES WITH DEFECTS OF PLATELET FUNCTION: A PILOT STUDY
L. A. Lotta* (Italy) - G. Tuana - A. Maino - A. Artoni - A. Lecchi - F. Peyvandi

HDC04 HEAD-TO-HEAD COMPARISON OF THE OPTIMUL ASSAY (96-Well PLATE AGGREGOMETRY) WITH GOLD STANDARD LIGHT TRANSMISSION AGGREGOMETRY FOR DETECTION OF ACQUIRED AND INHERITED PLATELET DEFECTS

HDC05 HEMOSTATIC PROPERTIES OF RED CELL DERIVED MICROPARTICLES (RMP): PROMISE OF UNIVERSAL HEMOSTATIC AGENT
Y. S. Ahn* (USA) - W. Jy - M. E. Johansen - L. L. Horstman - C. J. Bidot

HDC06 FVIII:C ASSAY DISCREPANCY AND GENOTYPE-PHENOTYPE CORRELATION IN A GROUP OF MILD HAEMOPHILIA A PATIENTS

HDC07 DEVELOPMENT OF AN ALTERNATIVE ASSAY FOR THE ASSESSMENT OF FACTOR VIII INHIBITOR BETHESDA TITRES
S. Daniels* (United Kingdom) - A. Heath - N. McMullan - S. Raut

HDC08 GENETIC ANALYSIS OF TWENTY EGYPTIAN PATIENTS WITH CONGENITAL AFIBRINOGENEMIA
M. Abdelwahab* (Egypt) - M. Neerman-Arbez - J. Koegel - O. Shaker

HDC09 MUTATIONS CAUSING SEVERE FACTOR XIII DEFICIENCY IN PAKISTAN
M. Borhany* (Pakistan) - T. Shamsi - A. Cairo - F. Peyvandi

HDC10 VWF EXERTS A PROTECTIVE EFFECT ON FVIII FROM INHIBITOR INACTIVATION BOTH IN VITRO AND IN VIVO
Q. Shi* (USA) - E. L. Kuether - J. A. Schroeder - C. L. Perry - S. A. Fahs - J. C. Gill - R. R. Montgomery

HDC11 VON WILLEBRAND FACTOR PROPEPTIDE (VWFP) TO VON WILLEBRAND FACTOR ANTIGEN (VWF:Ag) RATIO IN DIFFERENT SUBTYPES OF CONGENITAL AND ACQUIRED VON WILLEBRAND DISEASE (VWD)
F. Stufano* (Italy) - M. T. Canciani - L. Baronciani - G. Cozzi - S. La Marca - M. T. Pagliari - I. Garcia Oya - S. M. Siboni - F. Peyvandi
ePoster Session
Exhibition hall lower level 17:00 - 19:00

HDC12 COMBINED APTT AND WAVEFORM ANALYSIS INCREASES THE DIAGNOSTIC CAPABILITY OF STANDARD APTT ASSAYS
L. Leong* (USA) - P. Ramsey - L. Tang - D. Sim - J. E. Murphy - V. Laux - T. Myles

HDC13 PRESENTATION AND MANAGEMENT OF ACUTE CORONARY SYNDROMES (ACS) AMONG ADULT PERSONS WITH HEMOPHILIA (PWH): INITIAL RESULTS OF AN INTERNATIONAL, RETROSPECTIVE, TEN-YEAR SURVEY
P. F. Fogarty* (USA) - M. E. Mancuso - R. S. Kasthuri and GEHEP, Global Emerging Hemophilia Experts Panel

HDC14 FLUORESCENT QUANTITATION PCR METHOD APPLIED TO DO CARRIER AND PREGNATAL DIAGNOSIS IN HAEMOPHILIA A AND B FAMILIES WITH LARGE DELETION MUTATIONS
Y. Lu* (China)

HDC15 THROMBIN GENERATION, THROMBOBIOLOGY AND THROMBOELASTOGRAPHY IN THE PATIENTS WITH DIFFERENT BLEEDING PHENOTYPE OF SEVERE HEMOPHILIA A
I. Tarandovskiy* (Russian Federation) - A. Balandina - M. Panteleev - M. Kumskova - K. Kopylov - F. Ataullahkanov

HDC16 GENETIC DEFECT OF F9 GENE AND POLYMORPHISMS IN IMMUNE RESPONSE GENES ASSOCIATED WITH HIGH TITER INHIBITOR DEVELOPMENT AND ANAPHYLAXIS IN ONE HEMOPHILIA B CASE
J. Zhou* (China) - Q. Ding - Y. Lu - J. Dai - H. Wang - X. Wang

HDC17 MATERNAL HETERODISOMY/ISODISOMY OF CHROMOSOME 4 IN A CHILD WITH CONGENITAL AFIBRINOGENEMIA CONTAINING A NOVEL TRP293X MUTATION IN FIBRINOGEN B\(\mu\)-CHAIN GENE
Q. Ding* (China) - Q. Ouyang - X. Xi - X. Wang - H. Wang

Laboratory studies
Chairperson: Steve Kitchen (United Kingdom), Meyer-Michel Samama (France)

LSPE01 DIFFERENCES IN EXPOSURE OF THE DOMAIN I EPITOPE OF BETA2-GLYCOPROTEIN I IN COMMERCIAL ELISA KITS FOR THE DIAGNOSIS OF THE ANTIPHOSPHOLIPID SYNDROME

LSPE02 MEASUREMENT OF ANTI-ADAMTS13 NEUTRALISING AUTOANTIBODIES: A COMPARISON BETWEEN CBA AND FRET ASSAYS
I. Mancini* (Italy) - C. Valsecchi - R. Palla - M. T. Bajetta - G. Casoli - L. A. Lotta - F. Peyvandi

LSPE03 MODELING PHYSIOLOGICAL AND CYTOKINE DATA TO PREDICT OUTCOME
H. Hardway - D. Stearns-Kurosawa* (USA) - S. Kurosawa
ePoster Session

Exhibition hall lower level 17:00 - 19:00

LSPE04 PREDICTIVE VALUE OF HIGH FACTOR VIII LEVELS FOR RECURRENT VENOUS THROMBOSIS

LSPE05 ACUSTAR HIT-IGG AND HEPARIN-INDUCED MULTIPLE ELECTRODE AGGREGOMETRY: A USEFUL COMBINATION FOR RAPID DIAGNOSIS OF TYPE-II HIT

LSPE06 DETERMINATION OF DABIGATRAN IN PLASMA, SERUM, AND URINE SAMPLES FROM PATIENT WITH ATRIAL FIBRILLATION
J. Harenberg* (Germany) - S. Marx - R. Kraemer

LSPE07 DETERMINATION OF RIVAROXABAN IN PLASMA, SERUM, AND URINE FROM PATIENTS UNDERGOING TOTAL HIP AND KNEE REPLACEMENT SURGERY
J. Harenberg* (Germany) - A. Schulze - S. Marx - R. Krmer - C. Weiss

LSPE08 PREVALENCE OF FACTOR V LEIDEN IN 318 IRANIAN INDIVIDUAL REFERRED CASES AND THE DIAGNOSTIC POWER OF TWO DIFFERENT APC-R SCREENING TESTS

LSPE09 HEPARIN-INDUCED MULTIPLE ELECTRODE AGGREGOMETRY IS A PROMISING AND USEFUL FUNCTIONAL TOOL FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: CONFIRMATION IN A PROSPECTIVE STUDY
G. Gerotziafas* (France) - V. Galea - F. Robert - I. Elalamy - I. Elalamy

LSPE10 PREANALYTICAL VARIABLES OF THE CALIBRATED AUTOMATED THROMBOGRAM: TOWARDS A STANDARDIZED AND VALIDATED PROCEDURE

LSPE11 LABORATORY MONITORING TECHNIQUES FOR DABIGATRAN AND RIVAROXABAN - METHOD SUITABILITY AND VARIABILITY BETWEEN EUROPEAN LABORATORIES
T. Helin* (Finland) - A. Pakkanen - R. Lassila - L. Joutsi-Korhonen

LSPE12 IN VITRO ASSESSMENT OF THE APPLICABILITY OF PROTHROMBIN COMPLEX CONCENTRATE AS ANTIDOTE FOR THE DIRECT FACTOR XA INHIBITOR RIVAROXABAN
A. Leyte* (The Netherlands) - J. Dinkelaar - P. J. Molenaar

LSPE13 VALIDATION OF TWO AGE ADAPTED D-DIMER CUT-OFF VALUES FOR EXCLUSION OF DEEP VENOUS THROMBOSIS IN SUSPECTED ELDERLY PRIMARY CARE PATIENTS
**ePoster Session**

**Exhibition hall lower level**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>LSPE14</td>
<td>THE COST-EFFECTIVENESS OF &quot;POINT OF CARE  D-DIMER TESTS TO RULE OUT DEEP VENOUS THROMBOSIS IN PRIMARY CARE</td>
<td>J. Hendriksen* (The Netherlands) - G. J. Geersing - S. van Voorthuizen - A. ten Cate-Hoek - M. Joore - K. Moons - E. Koffijberg</td>
</tr>
<tr>
<td>LSPE15</td>
<td>FIBRIN-RELATED MARKER COMPARISON IN SEPSIS: CORRELATION TO GLOBAL AND MOLECULAR PARAMETERS OF HAEMOSTATIC DYSFUNCTION</td>
<td>J. M. H. Toh* (United Kingdom) - G. Ken-Dror - C. Downey</td>
</tr>
<tr>
<td>LSPE16</td>
<td>LARGE INTER-INDIVIDUAL VARIATION OF THE PHARMACODYNAMIC EFFECT OF ANTICOAGULANT DRUGS ON THROMBIN GENERATION</td>
<td>S. Bloemen* (The Netherlands) - C. H. Hemker - R. Al Dieri</td>
</tr>
<tr>
<td>LSPE17</td>
<td>LABORATORY RECOMMENDATIONS FOR THE MONITORING OF RIVAROXABAN</td>
<td>J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - S. Robert - B. Chatelain - J.-M. Dogn</td>
</tr>
<tr>
<td>LSPE18</td>
<td>LABORATORY RECOMMENDATIONS FOR THE MONITORING OF DABIGATRAN</td>
<td>J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - S. Robert - B. Chatelain - J.-M. Dogn</td>
</tr>
<tr>
<td>LSPE19</td>
<td>COMPARISON OF PROTHROMBINASE-BASED APC RESISTANCE ASSAY AND FV LEIDEN GENOTYPING</td>
<td>I. Horvat* (Croatia) - D. Coen Herak - R. Zadro</td>
</tr>
<tr>
<td>LSPE20</td>
<td>EVALUATION OF PRO C GLOBAL ASSAY AS A SCREENING TEST FOR THROMBOPHILIA IN WOMEN WITH ADVERSE PREGNANCY OUTCOME</td>
<td>A. Naz* (Pakistan) - N. Hossain - T. S. Shamsi - N. Khan</td>
</tr>
<tr>
<td>LSPE24</td>
<td>LYOPHILIZED NORMAL AND ABNORMAL LUPUS CONTROL PLASMA CAN BE USED FOR ASSAY CONTROL IN DRVV AND APTT BASED LUPUS ANTICOAGULANT TESTS</td>
<td>L. Wagner* (Austria) - V. Kaufmann - J. Mager - S. Geiter - M. Leitner</td>
</tr>
</tbody>
</table>
ePoster Session

Exhibition hall lower level

17:00 - 19:00

LSPE25  VON WILLEBRAND FACTOR LEVEL IN NEWLY DIAGNOSED PATIENT WITH MULTIPLE MYELOMA AFTER THE FIRST CYCLES OF INDUCTION THERAPY
E. Hait* (Russian Federation) - K. Abdulkadyrov - L. Papayan - O. Golovina

LSPE26  UNFRACTIONATED HEPARIN (UFH) AND LOW MOLECULAR WEIGHT HEPARINS (LMWH) COUNTERACT THROMBIN GENERATION (TG) AND PROANGIOGENIC PROPERTIES OF MDA.MB.231 BREAST CANCER CELLS
E. Diani* (Italy) - M. Marchetti - A. Vignoli - A. Falanga

LSPE27  THE EUROPEAN ACTION ON ANTICOAGULATION (EAA) PROTHROMBIN TIME /INTERNATIONAL NORMALISED RATIO (PT/INR) LINE - A RAPID METHOD OF DERIVING LOCAL INTERNATIONAL SENSITIVITY INDEX (ISI) AND MEAN NORMAL PT (MNPT) FOR USE WITH COAGULOMETERS
L. Poller* (United Kingdom) - S. Ibrahim - J. Jespersen

LSPE28  EUROPEAN ACTION ON ANTICOAGULATION (EAA). LOCAL INR DERIVATION SIMPLIFIED BY THE PT/INR LINE AND A SPREADSHEET FROM THE WORLD WIDE WEB
L. Poller* (United Kingdom) - S. Ibrahim - J. Jespersen

LSPE29  CHARACTERIZATION OF THROMBIN GENERATION (TG) BY THE CALIBRATED AUTOMATED THROMBOGRAPHY (CAT) IN ATRIAL FIBRILLATION (AF) PATIENTS ON PERMANENT ORAL ANTICOAGULATION THERAPY (OAT) WITH WARFARIN
M. Marchetti* (Italy) - C. Giaccherini - T. Lerede - A. Maggioni - M. Cefis - A. Falanga

LSPE30  THE EFFECT OF PREANALYTICAL AND ANALYTICAL VARIABLES ON SPATIAL FIBRIN CLOT FORMATION (THE THROMBODYNAMICS ASSAY) IN HEALTHY SUBJECTS

LSPE31  ASSESSMENT OF HAEMOSTASIS IN THE PRIMARY MULTIPLE MYELOMA PATIENTS USING DIFFERENT LABORATORY METHODS

LSPE32  INHIBITORY EFFECTS OF BORTEZOMIB ON PLATELET AGGREGATION INDUCED BY ADP, COLLAGEN AND RISTOCETIN IN PATIENTS WITH MULTIPLE MYELOMA
J. Rupa-Matysek* (Poland) - L. Gil - E. Wijasinska - K. Zajdel - A. Nowicki - D. Dytfeld - M. Komarnicki
ePoster Session

Exhibition hall lower level 17:00 - 19:00

**LSPE33** COMPARISON OF THE USE OF TFPI BLOCKAGE AND PLASMA DILUTION TO INCREASE THE SENSITIVITY OF THROMBIN GENERATION ASSAY TO MEASURE THE PROCOAGULANT ACTIVITY OF MICROVESICLES
D. Gheldof* (Belgium) and Mullier François, Chatelain Bernard, Dogn Jean-Michel, Chatelain Christian

**LSPE34** LUPUS ANTICOAGULANT SCREEN AND CONFIRM REAGENTS UTILIZING THE FX ACTIVATING VENOM FROM VIPERA LEBETINA
M. D. Goldford* (USA)

**LSPE35** CORRELATION OF PEAK THROMBIN RESULTS OBTAINED BY TGA MEASUREMENT ON CEVERONα ALPHTA TGA USING FAST SETTING AND STANDARD SETTING
L. Wagner* (Austria) - V. Kaufmann - J. Mager - G. Unzeitig

**LSPE36** IMPACT OF CYP3A4*1G POLYMORPHISM ON PLASMAC CONCENTRATION PROFILE OF RIVAROXABAN (XARELTO®) ASSESSED BY COAGULATION ASSAYS
J. Douxfils* (Belgium) - F. Mullier - C. Chatelain - B. Chatelain - J.-M. Dogn

---

**Platelet basic science**

Chairperson: Yotis Senis (United Kingdom)

**PBS01** DISCODO PLATELET AGGREGATIONS WITHOUT ENDOTHELium DISRUPTION VISUALIZED BY IN VIVO MOLECULAR IMAGING, AND CONTRIBUTION OF INFAMMATORY CYTOKINES
S. Nishimura* (Japan) - M. Nagasaki

---

**PBS02** RAPID RECRUITMENT AND MICROAGGREGATE FORMATION OF HUMAN PLATELETS BY THE COLONIZING BACTERIUM STREPTOCOCCUS ORALIS UNDER SHEAR RATES THAT MIMIC PHYSIOLOGICAL CONDITIONS
D. Tilley* (Ireland) - C. Douglas - S. W. Kerrigan

**PBS03** THREE DIMENSIONAL RECONSTRUCTION OF INTACT HUMAN INTEGRIN ALPHAIIIBBETA3 IN A PHOSPHOLIPID BILAYER NANODISC
W.-S. Choi* (USA) - W. J. Rice - B. S. Collier

**PBS04** PLATELET FLOW-INDUCED PROTRUSION (FLIPR) FORMATION IS A SHEAR AND CALPAIN INDUCED PROCESS LEADING TO PLATELET DISINTEGRATION AND THE FORMATION OF PROCOAGULANT MICROPARTICLES

**PBS05** SYNERGY OF PLATELET RECEPTORS IN THROMBUS FORMATION: A MICROARRAY APPROACH
S. M. De Witt* (The Netherlands) and Moniek M. Lamers, Frauke Swieringa, Roger Kruchten, Richard, W. Farndale, Kenneth J. Clemetson, Judith M. E. M. Cosemans, Johan W. M. Heemskerk

**PBS06** DEPLETION OF PLATELETS IN B16/F10 MELANOMA TUMOR BEARING MICE PREVENTS MATURATION OF NEWLY FORMED TUMOR BLOOD VESSELS
J. Wu* (China) - R. Li - M. Ren - N. Chen - M. Luo
ePosters

Exhibition hall lower level 17:00 - 19:00

PBS07 Exacerbation of GPVI-Dependent Platelet Responses in a Rhesus Monkey Model of Type I Diabetes

PBS08 A New Microfluidic Point-of-Care Test for Multi-Shear Platelet Thrombosis
D. N. Ku* (USA) - M. Li - C. Forest - K. Hefelfinger - S. Gurnani - O. Martinez - N. Turturro - P. Gandhi

PBS09 Nitric Oxide Enhances The Anti-Inflammatory and Anti-Atherogenic Activity of Atorvastatin In A Mouse Model of Accelerated Atherosclerosis
S. Momi* (Italy) - E. Falcinelli - V. Conti - E. Ongini - P. Gresele

PBS10 Morpho-Functional Characterization of Platelets by Atomic Force Microscopy
L. Drozd* (Belarus) - L. Kuharenko - S. Syroezhkin - L. Gelis - E. Medvedeva - I. Lazareva - S. Chizhik

PBS11 Shorter Carotid Artery Occlusion in A Thalassemic Mouse Model: A Potential Role for Oxidative Stress Affecting Both RBCS and Platelets
Z. Malyutin - E. Shai - M. Dana - E. Rachmilewitz - E. Fibach - D. Varon* (Israel)

PBS12 Isothermal Titration Calorimetry Confirms Protein-Protein Interactions in the Human Platelet

PBS13 Two Types of PhosphatidylSerine-Expressing Platelets Are Formed Upon Physiological Activation and Are Controlled by Integrin αLPHAIIβ3 Signaling

PBS14 Molecular Mechanisms Involved in The Antithrombotic Activity of Aegyptin, A Novel Mosquito-Derived Collagen-Binding Protein
D. Mizurini* (Brazil) - E. Calvo - I. Francischetti - R. Monteiro

PBS15 Comparison of The New Flow Cytometric Bead Assay for VASP-Phosphorylation to A Commercially Available Test in Assessment of Platelet Inhibition by P2Y12 Antagonists
N. Dovlatova* (United Kingdom) - J. Glenn - S. Heptinstall - S. Fox

PBS16 Multiplate Analyzer As A Valid Tool For Platelet (PLT) Aggregation Studies in Acid-Citrate-Dextrose (ACD) Donor Blood Bags
**ePoster Session**

**Exhibition hall lower level**

**17:00 - 19:00**

**PBS17**

**CHANGES IN PLATELET (PLT) AGGREGATION AND ACTIVATION STATUS DURING STORAGE IN PLATELET CONCENTRATES (PC) FOR TRANSFUSION USE**


**PBS18**

**EVALUATION OF BABOON PLATELET AGGREGATION IN A MULTIPLATE® PLATELET FUNCTION ANALYZER**

W. J. Janse Van Rensburg* (South Africa) - R. van Zyl - J. Roodt - S. Lamprecht

**Platelet clinical**

**Chairperson:** Beng Chong (Australia)

**PC01**

**A MUTATION IN ANKRD18A, ANKYRIN REPEAT DOMAIN 18A, CAUSES A SEVERE FORM OF CONGENITAL THROMBOCYTOPENIA**


**PC02**

**ACQUIRING AN INHERITED THROMBOCYTOPENIA: CLONAL CHROMOSOME ANOMALIES AFFECTING FLI1 MIMIC INHERITED THROMBOCYTOPENIA OF THE PARIS-TROUSSEAU TYPE**

P. Noris* (Italy) - R. Valli - B. Pressato - A. Pecci - C. Marletta - R. Invernizzi - L. Mare - C. L. Balduini - F. Pasquali - E. Maserati

**PC03**

**STICKY PLATELET SYNDROME AND THE GENETIC VARIABILITY OF THE GLYCOPROTEIN 6 GENE IN PATIENTS WITH VENOUS THROMBOSIS AND PULMONARY EMBOLISM**

P. Kubisz* (Slovakia) - D. Kotulíčková - P. Chudý - M. Škereňová - R. Pullmann, Sr. - J. Staško

**PC04**

**IDENTIFICATION OF 61 NOVEL MUTATIONS IN THE ITGA2B AND ITGB3 GENES OF 90 PATIENTS WITH GLANZMANN THROMbasthenia: AN ANALYSIS OF STRUCTURE-FUNCTION RELATIONSHIPS**

X. Pillois* (France) - C. Vinciguerra - R. Heilig - P. Nurden - M. Fiore - A. Nurden

**PC05**

**PLATELET SURFACE HIGH MOBILITY GROUP BOX PROTEIN-1 BINDS RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS IN PLASMA OR ON MONOCYTES IN SEPTIC PATIENTS**


**PC06**

**A NOVEL MECHANISM OF P-SELECTIN INDEPENDENT MONOCYTE-PLATELET AGGREGATION IN CHILDREN**

C. Yip - V. Ignjatovic - P. Monagle* (Australia) - C. Attard - M. D. Linden

**PC07**

**A NOVEL D235Y MUTATION IN THE GP1BA GENE ENHANCES PLATELET INTERACTION WITH VWF IN AN IRANIAN FAMILY WITH PLATELET TYPE VON WILLEBRAND DISEASE**

S. Enayat* (Iran) - S. Ravanbod - M. Rassoulzadegan - M. Jazebi - S. Tarighat - F. Ala - J. Emsley - M. Othman
## ePoster Session

**Exhibition hall lower level**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC08</td>
<td>MACROTHROMBOCYTOPENIA ASSOCIATED WITH PHYTOSTEROLEMA: A POTENTIAL NEW PLATELET DISORDER</td>
<td>Z. Wang* (China) - G. Wang - L. Cao - C. Ruan</td>
</tr>
<tr>
<td>PC09</td>
<td>PRETREATMENT ADAMTS13 ANTIBODY CONCENTRATION AND AGE PREDICTS RELAPSE IN PATIENTS WITH NEWLY DIAGNOSED ACQUIRED THROMBOTIC THROMBOCYTOPENIC PUPURA (TPP)</td>
<td>S. R. Cataland* (USA) - S. Yang - H. Wu</td>
</tr>
<tr>
<td>PC10</td>
<td>ANTI-PLATELET MEDICATION FOR THE PROGRESSING STROKE WITH SMALL VESSELS OCCLUSION</td>
<td>T. Nakase* (Japan) - M. Sasaki - S. Yoshioka - Y. Ikeda - A. Suzuki</td>
</tr>
<tr>
<td>PC12</td>
<td>A NOVEL PLATELET ASSAY THAT MEASURES THE EFFECT OF CLOPIDOGREL IN VIVO</td>
<td>A. Lopez* (Ireland) - D. Kenny - L. Basabe-Desmonts - S. Ramstrom - B. Jose - M. Somers</td>
</tr>
<tr>
<td>PC13</td>
<td>GLOBAL HEMOSTASIS TESTS IN PATIENTS WITH CIRRHOSIS BEFORE AND AFTER PROPHYLACTIC PLATELET TRANSFUSION</td>
<td>V. Chantarangkul* (Italy) - M. Primignani - L. Lemma - M. Clerici - M. Jovani - P. Rebull - P. M. Mannucci - A. Tripodi</td>
</tr>
<tr>
<td>PC14</td>
<td>UTILITY OF TEG AND FLOWCYTOMETRY TO GUIDE PLATELET TRANSFUSION REQUIREMENT IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES</td>
<td>S. Debono* (Malta) - F. Bonello - R. Buttigieg - P. Brincat - C. Grima - T. Lofaro - S. Laspina - A. Gatt</td>
</tr>
<tr>
<td>PC17</td>
<td>TOLERABILITY AND EFFICACY OF ROMIPLOSTIM AS MANAGEMENT OF SEVERE, REFRACTORY IMMUNE THROMBOCYTOPENIA (ITP) DURING PREGNANCY</td>
<td>A. Giermasz* (USA) - J. Knoche - P. F. Fogarty</td>
</tr>
<tr>
<td>PC18</td>
<td>EVALUATION OF PLATELET DYSFUNCTION IN VIRAL LIVER DISEASE: RELATIONSHIP TO DISEASE SEVERITY</td>
<td>M. F. Ghozlan* (Egypt) - A. A. Saad - D. S. Mohamed - E. A. Husseen - H. A. Abdella</td>
</tr>
<tr>
<td>PC19</td>
<td>RELATIONSHIP BETWEEN VON WILLEBRAND FACTOR AND PLATELET PARAMETERS IN ADULT DENGUE INFECTION PATIENTS</td>
<td>U. Sukorini* (Indonesia) - S. Setyawati - R. El Khair</td>
</tr>
</tbody>
</table>
**ePoster Session**

Exhibition hall lower level 17:00 - 19:00

**PC20**  
**THROMBIN GENERATION TEST IN THE MONITORING OF ANTIPLATELET THERAPY EFFECTIVENESS**  
O. Smirnova* (Russian Federation) - Y. Namestnikov - O. Matvienko - G. Berezovskaya - O. Golovina - L. Papayan

**PC21**  
**THROMBOELASTOGRAPHIC TESTING TO DETERMINE INDIVIDUAL RESPONSE TO CLOPIDOGREL**  
B. J. Bryant* (USA) - J. Treat - F. Scalia - I. McQueen - P. Sharks

**PC22**  
**EFFECT OF CYTOCHROME P450 POLYMORPHISM ON PLATELET REACTIVITY AFTER TREATMENT WITH CLOPIDOGREL IN PATIENTS SCHEDULED FOR PERCUTANEOUS CORONARY INTERVENTION**  
A. A. Saad* (Egypt) - A. M. Abd Elsalam - G. M. Kamal - N. F. Abou El-Ezz - R. S. El-Hagracy

**Thromboembolic Disorders**

Chairperson: Paul Kyrle (Austria)

**PE01**  
**MARKERS OF COAGULATION AND INFLAMMATION IN RELATION TO THE POST THROMBOTIC SYNDROME**  
A. Bouman* (The Netherlands) - J. Smits - H. ten Cate - A. ten Cate-Hoek

**PE02**  
**ALTERNATIVE DIAGNOSES OF PULMONARY EMBOLISM IN PRIMARY CARE**  
P. M. Erkens* (The Netherlands) - W. Lucassen - M. V. Heugten - L. Rietjens - G.-J. Geersing - M. Prins - H. T. Cate - J. Stoffers

**PE04**  
**COMPLIANCE OF RECOMMENDATIONS WITH FRENCH CLINICAL PRACTICE IN THE MANAGEMENT OF THROMBOEMBOLISM IN PATIENTS WITH CANCER: THE CARMEN STUDY**  
M. Sevestre* (France) - D. Farge - P. Debourdeau and Groupe Francophone Thrombose et Cancer

**PE05**  
**D-DIMER AND ULTRASOUND IN COMBINATION ITALIAN STUDY (DULCIS) TO ESTABLISH THE OPTIMAL DURATION OF ANTICOAGULATION FOR VENOUS THROMBOEMBOLISM: PRELIMINARY RESULTS**  
B. Cosmi* (Italy) - C. Legnani - A. Ghiraduzzi - S. Testa - P. Vittorio - E. Favaretto - G. Palareti

**PE06**  
**UNUSUAL THROMBOSES AND THROMBOPHILIA: A CASE-CONTROL STUDY**  
J. Chapin* (USA) - P. Christos - M. T. DeSancho

**PE07**  
**MICROPARTICAL-ASSOCIATED THROMBIN GENERATION IN PATIENTS WITH POSTTHROMBOPHLEBITIC SYNDROME**  
O. Matvienko* (Russian Federation) - Y. Namestnikov - O. Golovina - N. Saltykova

**PE08**  
**ONE YEAR EVENT RATE OF SERIOUS THROMBOSIS AND BLEEDING IN JAPANESE PATIENTS WITH MYOCARDIAL INfarction, STROKE AND ATRIAL Fibrillation**  
ePoster Session

Exhibition hall lower level 17:00 - 19:00

PE10  THE VALUE OF D-DIMER AS A MARKER FOR CARDIOVASCULAR AND ARTERIAL THROMBOTIC EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE; A SYSTEMATIC REVIEW
M.-C. Kleinegris* (The Netherlands) - A. ten Cate-Hoek - H. ten Cate

PE11  VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ELDERLY PATIENTS ADMITTED TO ITALIAN INTERNAL MEDICINE WARDS

PE12  READMISSION AND DEATH RATES FROM VENOUS THROMBOEMBOLISM WITHIN 90 DAYS OF HOSPITAL ADMISSION: WHAT CAN WE LEARN FROM MEASURING REAL OUTCOMES AT A NATIONAL LEVEL?
W. A. Lester* (United Kingdom) - S. Khosla - D. Ray - M. Richardson - D. Pagano and Quality and Outcomes Research Unit, University Hospitals Birmingham

PE13  COFFEE CONSUMPTION AND A REDUCED RISK OF VENOUS THROMBOSIS: MEDIATED THROUGH HEMOSTATIC FACTORS

PE14  VENOUS THROMBOSIS IN A PATIENT WITH CONGENITAL AFIBRINOGENEMIA: CLINICAL IMPLICATIONS AND MANAGEMENT
J. Chapin* (USA) - M. DeSancho

PE15  ACQUIRED AND GENETIC RISK FACTORS ASSESSMENT FOR DEEP VENOUS THROMBOSIS IN 389 OF HOSPITALIZED CHINESE PATIENTS: A SINGLE CENTER EXPERIENCES
M.-Y. Deng* (China) - G.-S. zhang - Y.-Y. luo

PE16  QUALITY OF LIFE IN ACUTE DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
K. Hogg* (Canada) - M. Kimpton - M. Carrier - D. Coyle - P. Wells

PE17  EXPLICIT ASSESSMENT OF THROMBOEMBOLIC RISK AND PROPHYLAXIS FOR MEDICAL PATIENTS IN SWITZERLAND (ESTIMATE): PRELIMINARY RESULTS

PE18  PROPHYLAXIS GUIDELINES AS ASSESSED RETROSPECTIVELY ON A COHORT OF HOSPITAL-ACQUIRED VENOUS THROMBOSIS MEDICAL PATIENTS WITHOUT THROMBOPROPHYLAXIS
**ePoster Session**

**Exhibition hall lower level**  
17:00 - 19:00

**PE19**  
SIGNIFICANCE OF TISSUE FACTOR-POSITIVE MICROPARTICLES IN THE PATIENTS WITH ACUTE PROMYELOCYTOIC LEUKEMIA  
Y. Han* (China) - L. Zhou - X. Bai - D. Wu - Z. Wang - C. Ruan

**PE20**  
SIGNIFICANTLY HIGHER LEVEL OF LIPOPROTEIN (A) AMONG ACUTE CORONARY SYNDROME (ACS) THAN STABLE ANGINA PECTORIS (SAP) PATIENTS OR HEALTHY SUBJECTS IN INDONESIAN POPULATION  
I. Puspitawati* (Indonesia) - S. Setyawati - D. W. Anggrahini - E. H. Herningtyas

**PE21**  
IL-18 AND VASCULAR MINERALIZATION IN CORONARY ARTERY DISEASE PATIENTS  

**PE22**  
STUDY ON GENE MARKERS OF THROMBOSIS IN CORONARY HEART DISEASE BY MULTI-ANALYTE SUSPENSION ARRAY TECHNOLOGY  
W. He* (China) - Y. HU - J. Yu - T. Guo - X. Zhang

**PE23**  
RESULTS FROM THE NATIONAL REGISTRY OF THROMBOPHILIC STATES IN SLOVAKIA  
J. Staško* (Slovakia) - I. Plameňov - J. Sokol - P. Chudy - M. Dobrotov - P. Kubisz

**PE24**  
VENOUS THROMBOEMBOLISM: A REFINED UNITED STATES COST MODEL WITH LONG-TERM ATTACK RATES  

**PE25**  
COAGULATION FACTOR XIII-B HIS95ARG POLYMORPHISM AND THE RISK OF CORONARY ARTERY DISEASE IN A CROATIAN POPULATION  
A. Bronic* (Croatia) - G. Ferencak - R. Bernat - J. Dumi c - S. Dab  

**PE26**  
NO CORRELATION BETWEEN MEAN PLATELET VOLUME AND THE RISK OF RECURRENT VENOUS OR ARTERIAL THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME  

**PE27**  
DEVELOPING ANIMAL MODELS OF HEMOLYTIC UREMIC SYNDROME  
D. Stearns-Kurosawa* (USA) - C. Leibowitz - C. Mayer - S. Kurosawa

**PE28**  
COMPLICATIONS ASSOCIATED WITH PICC INSERTION IN A HOSPITAL FOR HIGH LEVEL OF COMPLEXITY OF THE CITY OF MEDELLIN - COLOMBIA  
J. F. Combariza* (Colombia) - S. Roldan - K. Galvez - V. Olaya - L. ballesteros - V. palacios
ePoster Session

Exhibition hall lower level

17:00 - 19:00

PE29 USING HAEMOSTATIC AND RHEOLOGIC FACTORIALS AS DIAGNOSTIC AND PROGNOSTIC MARKERS OF ACUTE MYOCARDIAL INFARCTIONS IN NIGERIANS
I. O. Ajayi* (Nigeria) - G. Nwaekte - O. E. Ihejirika

PE31 NOVEL HEMOSTATIC MARKERS FOR THROMBOEMBOLIC RISK IN PATIENTS WITH PROSTATE CANCER
M. Toukh* (Canada) - A. Black - R. D. Siemens - M. Othman

PE32 FIBRINOGEN-LIKE PROTEIN 2 (FGL-2) - A NOVEL BIOMARKER FOR CANCER
A. Inbal* (Israel) - E. Rabizadeh - D. Lederfine - E. Rosenbaum - B. Brenner

PE33 CASE SERIES: PATIENTS WITH JAK2 POSITIVE MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED WITH THROMBOTIC EVENTS
J. F. Combariza* (Colombia) - V. Olaya - K. Galvez - L. Ballesteros

PE34 FIBRINOGEN, C-REACTIVE PROTEIN AND INTERLEUKIN-6 IN PREDICTION OF CARDIOVASCULAR COMPLICATIONS AND DEATH IN TYPE 2 DIABETES: THE ADVANCE STUDY

Thrombo-Haemorrhagic Issues in Women & Children

Chairpersons: Paul Monagle (Australia), Sabine Eichinger (Austria)

PEWC01 THE ASSOCIATION OF SMOKING WITH VENOUS THROMBOSIS AND ITS MODIFICATION BY HORMONE REPLACEMENT THERAPY
M. Blondon* (USA) - K. L. Wiggins - K. M. Rice - S. R. Heckbert - B. M. Psaty - N. L. Smith

PEWC02 LONG TERM FOLLOW UP OF HOMOZYGOTE PROTEIN C DEFICIENCY FOLLOWING MULTI MODAL THERAPY
K. E. Monagle* (Australia) - V. Ignatovic - W. Hardikar - F. Newall - P. Monagle

PEWC03 ADMINISTRATION OF ANTITHROMBIN CONCENTRATE IN INFANTS AND CHILDREN ON ECLS IMPROVES ANTICOAGULATION
L. Ryerson - A. A. Bruce* (Canada) - P. M. Massicotte - M. L. Bauman - S. Ghotra - L. Lequier - M. E. Bauman

PEWC04 CLINICAL FINDINGS IN A PROSPECTIVE COHORT OF WOMEN IN CHILDBEARING AGE WITH THROMBOSIS AND/OR PREGNANCY ADVERSE OUTCOMES

PEWC05 ANTICOAGULATION OF CARDIOMYOPATHY IN CHILDREN
K. E. Monagle* (Australia) - S. Jones - I. King - R. Weintraub - P. Monagle - F. Newall
ePoster Session

Exhibition hall lower level 17:00 - 19:00

PEWC06 PREDICTING DEEP VENOUS THROMBOSIS IN PREGNANCY: EXTERNAL VALIDATION OF THE LEFT CLINICAL PREDICTION RULE
M. Righini* (Switzerland) - G. Le Gal

PEWC07 THE ECONOMIC COSTS OF ROUTINE INR MONITORING IN INFANTS AND CHILDREN
J. Gaw - S. Crowley - P. Monagle* (Australia) - S. Jones - F. Newall

PEWC08 CEREBRAL TE IN ITALIAN INFANTS AND CHILDREN: DATA FROM THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (RITI)

PEWC09 PROSPECTIVE STUDY ON INCIDENCE RATE OF NEONATAL AND PEDIATRIC THROMBOEMBOLISM IN A SINGLE TERTIARY CARE HOSPITAL IN ITALY DURING A 5-YEAR PERIOD

PEWC10 OBSTETRICS OUTCOMES ASSOCIATED WITH AN INCREASED LEVEL OF LIPOPROTEIN-A (LP-A) IN THROMBOPHILIC PATIENTS

PEWC11 MOLECULAR BASIS OF TYPE I ANTITHROMBIN DEFICIENCY IN TWO WOMEN WITH RECURRENT VENOUS THROMBOEMBOLISM IN THE FIRST TRIMESTER OF PREGNANCY
Y. Xia* (China) - Q. Ding - X. Wang - Y. Lu - J. Dai

PEWC12 HIGHER DOSES OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ARE NEEDED TO ACHIEVE GOAL ANTI-XA LEVELS IN CRITICALLY ILL CHILDREN

PEWC13 THE EFFECT OF ANTIITHROMBIN CONCENTRATES ON ANGIogenesis IN SERIOUSLY ILL CHILDREN
V. Karlaftis* (Australia) - C. Attard - P. Monagle - V. Ignjatovic

PEWC14 THE PREVALENCE AND ROLE OF ELEVATED COAGULATION FACTORS VIII, IX AND XI IN ARTERIAL THROMBOSIS IN CHILDREN
M. Avila* (Canada) - A. Zanette - T. Canil - S. Williams - W. Kahr - L. R. Brandao and Paediatric Haemostasis Thrombosis

PEWC15 ASSISTED REPRODUCTION TECHNOLOGIES FAILURE AND ACQUIRED THROMBOPHILIA: EXPERIENCE OF A SINGLE SPECIALIZED ARGENTINIAN CENTER
**ePoster Session**

**Exhibition hall lower level**

**Haemorrhagic Disorders (Lab studies) and Von Willebrand disease**

Chairperson: *David Lillicrap (Canada)*

**VWF01** DETECTION OF NON INHIBITORY BINDING ANTIBODIES TO VON WILLEBRAND FACTOR AFFECTING THE CLEARANCE OF VWF:AG IN VON WILLEBRAND DISEASE


**VWF02** BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF 10 ITALIANS PATIENTS AFFECTED BY VON WILLEBRAND DISEASE TYPE 2A/IIE

M. T. Pagliari* (Italy) - I. Garcia Oya - F. Stufano - G. Cozzi - S. La Marca - M. T. Canciani - F. Peyvandi - L. Baronciani

**VWF03** TWO CASES OF CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA ASSOCIATED WITH PREGNANCY

X. Bai* (China) - J. Su - Z. Yu - Z. Wang - C. Ruan

**VWF04** A NEW AUTOMATED CHEMILUMINESCENT METHOD FOR THE DETERMINATION OF VON WILLEBRAND FACTOR RISTOCETIN COFACTOR ACTIVITY (VWF:RCO) AND VON WILLEBRAND FACTOR ANTIGEN (VWF:AG)

K. D. Friedman* (USA) - P. M. Jacobi - M. E. Shaw - J. L. Endres - S. L. Haberichter

**VWF05** HEAD-TO-HEAD COMPARATIVE STUDY OF THE PHARMACOKINETIC BEHAVIOR OF A HIGH-PURITY FACTOR IX CONCENTRATE (ALPHANINE®) AND A RECOMBINANT FACTOR IX (BENEFIX®) IN PATIENTS WITH SEVERE HEMOPHILIA B


**VWF06** GENETIC DIAGNOSIS IN SPORADIC HAEMOPHILIA A FAMILIES IN CHINA

Y. Lu* (China)

**VWF07** PREVALENCe AND TREATMENT OUTCOME OF TRANSFUSION TRANSMITTED INFECTIONS IN HEMOPHILIA A

S. Alkindi - M. Kashoob - A. Balkhair - N. Al Obaidani - A. Pathare* (Oman)

**VWF08** THE MISSING PIECES FOR UNDERSTANDING FVIII INHIBITOR DEVELOPMENT: HEMOPHILIA INHIBITOR PUP STUDY

C. J. Hofbauer* (Austria) - C. Male - D. Brown - E. Santagostino - J. Oldenburg - F. Scheiflinger - B. M. Reipert

**VWF09** PRENATAL DIAGNOSIS FOR CONGENITAL FACTOR VII DEFICIENCY: ONE CASE REPORT

D. Jing* (Canada)

**VWF10** FXI DEFICIENCY: GENOTYPE-PHENOTYPE RELATIONSHIP

ePoster Session

**Exhibition hall lower level**

**17:00 - 19:00**

**VWF11** A MACHINE LEARNING APPROACH TO MERGING AND ANALYZING DATA FROM THE CONDENSED MCMDC1-VWD BLEEDING QUESTIONNAIRE
P. James* (Canada) - J. Grabell - M. Bowman - S. Mollah - B. Coller

**VWF12** P.E1549K: A NEW MUTATION RESPONSIBLE OF VON WILLEBRAND DISEASE TYPE 2M

**VWF13** P.M1304V: A NEW MUTATION IN THE A1 DOMAIN ASSOCIATED TO ATYPICAL VON WILLEBRAND 2B PHENOTYPE

**VWF14** COMPARISON OF RECOMBINANT FVIII UTILISATION IN A COHORT OF UK PATIENTS FOLLOWING A SWITCH FROM A FULL LENGTH TO B-DOMAIN DELETED FVIII: A RETROSPECTIVE ANALYSIS OF HOMECARE DELIVERY DATA
S. Verma* (United Kingdom) - J. Gama

**VWF15** STANDARDIZATION OF AN APTT-BASED FVIII INHIBITOR SCREENING ASSAY
P. Pinto* (India) - S. Shetty - K. Ghosh

**VWF16** INHERITED BLEEDING DISORDERS IN PAKISTANI WOMEN PRESENTING WITH MENORRHAGIA
N. Hossain* (Pakistan) - T. Shamsi - A. Naz - A. James

**VWF17** PHARMACOKINETICS AND SAFETY PROFILE OF A SINGLE INTRAVENOUS DOSE OF RECOMBINANT FACTOR XIII IN PAEDIATRIC PATIENTS WITH CONGENITAL FACTOR XIII A-SUBUNIT DEFICIENCY
M. Williams* (United Kingdom) - C. Stenmo - A. Rosholm - R. Tehranchi

**VWF18** PHARMACOKINETICS OF A NEW RFVIII, TUROCTOCOG ALFA, IN ADULT/ADOLESCENT AND PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA A. DATA FROM THE GUARDIAN* 1 AND GUARDIAN* 3 TRIALS

**VWF19** EFFECT OF APTT REAGENT AND STANDARD ON PLASMA-DERIVED AND RECOMBINANT FACTOR IX POTENCY ESTIMATES
H. Wilmot* (United Kingdom) - J. Hogwood - E. Gray

**VWF20** COMPARISON OF QUALITY OF LIFE IN AN AMISH AND NON-AMISH COHORT AFFECTED WITH VON WILLEBRAND DISEASE
S. Gupta* (USA) - M. Heiman - N. Duncan - P. Yoder - R. Montgomery - J. Hinckley - J. DiPaola - A. D. Shapiro
ePoster Session

Exhibition hall lower level 17:00 - 19:00

PEWC16 HEREDITARY ANTITHROMBIN DEFICIENCY AND PREGNANCY
M. T. Desancho* (USA) - R. Levine - J. Cohen - J. Chapin - R. Kalish - S. Shah

PEWC17 VENOUS THROMBOEMBOLISM IN ITALIAN INFANTS AND CHILDREN: DATA FROM THE ITALIAN REGISTRY OF CHILDHOOD THROMBOSIS (RITI)
C. Gentilomo* (Italy) - P. Saracco - P. Giordano - R. Bagna - A. C. Molinari - M. Grassi - M. C. Putti - D. Lasagni - G. Indolfi - P. Simioni and Italian Group Of Childhood Thrombosis Registry

PEWC18 THROMBOEMBOLIC COMPLICATIONS IN ITALIAN INFANTS AND CHILDREN: COMPARISON OF DATA FROM RITI REGISTRY WITH A SINGLE CENTRE CONSECUTIVE SERIE
P. Saracco - C. Gentilomo* (Italy) - R. Bagna - A. Viano - M. Agostini - P. Simioni and Italian Group Of Childhood Thrombosis Registry

PEWC19 LOW LEVELS OF VITAMIN D IN PREGNANT WOMEN WITH THROMBOEMBOLISM/THROMBOPHILIA

PEWC20 PLACENTAL ABRUPTION AND THROMBOPHILIA

PEWC21 PEDIATRIC THROMBOSIS EDUCATIONAL TOOL (P-TET): AN EDUCATIONAL PROJECT IN DEVELOPMENT FOR CHILDREN RECEIVING ORAL ANTIICOAGULATION
F. R. Cassis - J. D. Carneiro - E. A. D’Amico - L. R. Brandão* (Canada)

PEWC22 THROMBOPROPHYLAXIS WITH TWO DIFFERENT DOSAGES OF LWMH (CALCIC NADROPARIN) IN PREGNANT WOMEN WITH THROMBOPHILIA: A SINGLE CENTER EXPERIENCE
P. Samantha* (Italy) - G. Barillari - U. Venturelli - M. Turello

PEWC23 THE RISK OF VENOUS THROMBOEMBOLIC DURING PREGNANCY
Y. Y. Ouahrhint* (Algeria) - N. Boudjerra - H. Bounecer
To learn about our haematology portfolio, please come and visit our **booth 29**.

Octapharma is specialised in the development and production of high quality human proteins derived from blood plasma and recombinant technologies.

Using cutting-edge purification and viral inactivation techniques we live by our mission of **“the safe and optimal use of human proteins”**.

We provide life saving therapies to our patients worldwide in the treatment of multifarious diseases in Haematology, Immunotherapy and Intensive Care and Emergency Medicine.

We work to the highest standards of quality and safety set by physicians, patients and regulatory authorities.

Octapharma

*For the safe and optimal use of human proteins*
Sponsor and Exhibitor Profiles

**4S DAWN Clinical Software**  
**BOOTH N°20**

The Square, Milnthorpe 4  
Cumbria LA7 7QJ  
United Kingdom

sales@4s-dawn.com  
www.4s-dawn.com

Over 300 clients worldwide use DAWN AC anticoagulation management software with an estimated 500,000 patients. Many of our clients are large healthcare organizations managing many thousands of patients and realize the benefits of the software with increased productivity, improved quality of care and patient safety.

Come and see our new modules for managing:
- New Oral Anticoagulants
- VTE Assessment
- Web Browser based Benchmarking Service
- Clinical Haematology - MPD, Venesection, Haemochromatosis, MGUS and Stable Chronic Leukemia - Anaemia / ESAs - Hepatitis

**AFFINITY BIOLOGICALS, Inc.**  
**BOOTH N°17**

1395 Sandhill Dr.  
Ancaster, Ontario  
L4G 3Z9  
Canada

sales@affinitybiologicals.com  
www.affinitybiologicals.com

Affinity Biologicals, Inc. is a primary manufacturer of products used worldwide in thrombosis and haemostasis research and medical diagnostics. Products include an extensive line of antibodies, conjugates, antibody pairs for immunoassay of human and animal analytes, the VisuLize™ line of complete ELISA kits, and a full line of immuno-depleted human plasma products, VisuCal™ Calibrator Plasma and VisuCon™ Normal & Abnormal Control Plasmas. Services include protein purification, antibody production, assay development, custom lyophilization and custom plasma production.

**ALEXION**  
**BOOTH N°26**

Unit 14 Horizon Business Village  
Brooklands Road, Weybridge 1  
Surrey  
KT13 0TJ  
United Kingdom

alexion.uk@alxn.com

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, often life-threatening, ultra-rare diseases. These diseases may be chronic, progressive, degenerative, and difficult to diagnose and treat.

For further information on relevant disease areas, presenting signs and symptoms, differential diagnosis, and treatment, please visit the Alexion stand at the meeting.
Sponsor and Exhibitor Profiles

AMGEN

240 Cambridge Science Park
Milton Road
Cambridge CB4 0WD
United Kingdom

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from the lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to help improve people’s lives. For more information about Amgen, our pioneering science and our vital medicines, visit:
www.amgen.co.uk

BAXTER HEALTHCARE, Inc.

One Baxter Parkway
Deerfield, IL 60015
United States

www.baxter.com

Bayer Healthcare Pharmaceuticals
13353 Berlin
Germany

www.bayer.com

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is represented in more than 100 countries.
Sponsor and Exhibitor Profiles

BIOGEN IDEC & SWEDISH ORPHAN BIOVITRUM
SPONSOR

133 Boston Post Rd
Weston, MA 02493
United States
www.BiogenIdecHemophilia.com

Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and auto-immune disorders. For additional information about the company, please visit www.biogenidec.com

Swedish Orphan Biovitrum (Sobi)
a leading integrated biopharmaceutical company bringing innovative therapies and services to improve the lives of patients with rare diseases and their families. Based on our long history in hemophilia we continue the search for improved treatment, and now in a successful partnership with BiogenIdec, we are developing the next generation hemophilia therapies. Please visit also - www.sobi.com

BOEHRINGER INGELHEIM LIMITED
BOOTH N°18

Ellesfield Avenue
Bracknell Berkshire
RG12 8YS
United Kingdom
www.boehringer-ingelheim.co.uk

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. A central element of Boehringer Ingelheim’s culture is to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors. For more information please visit: www.boehringer-ingelheim.co.uk

CSL BEHRING
BOOTH N°2

P.O. Box 1230
35002 Marburg
Germany

dieter.pluennecke@cslbehring.com
www.cslbehring.com

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufacturers and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies and inherited respiratory disease. The company’s products are also used in
Sponsor and Exhibitor Profiles

cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com

Daiichi Sankyo Europe has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany. For more information, please visit: www.daiichisankyo.com or www.daiichi-sankyo.eu

DAIICHI SANKYO EUROPE GmbH BOOTH N°14
Zielstattstrasse 48
81379, Munich
Germany
info@daiichi-sankyo.eu
www.daiichi-sankyo.eu

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of more than €8.5 billion, Daiichi Sankyo is one of the world’s 20 leading pharmaceutical companies. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model”, which will respond to market and customer diversity and optimize growth opportunities across the value chain.

Enzyme Research Laboratories provides coagulation and fibrinolytic proteins from human plasma, other source plasmas and platelets. We also offer monoclonal and polyclonal antibodies, immunodepleted plasmas and ELISA reagents. Custom purifications and contract services are also available. r2 Diagnostics strives to provide high quality, innovative and economical products for the hemostasis market. We place major emphasis on the production of optimized and versatile products for the detection of thrombophilia. We offer clot-based kits for quantitation of PC, PS, and Lupus Anticoagulants.

ENZYME RESEARCH/ R2 DIAGNOSTICS
1801 Commerce Drive
South Bend, IN 46628
United States
info@enzymeresearch.com
info@r2diagnostics.com
www.enzymeresearch.com
www.r2diagnostics.com
GSK is dedicated to producing innovations in haematological malignancies that will make profound difference to the lives of patients. Through GSK's revolutionary “bench to bedside” approach we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology/haematology sector. Our worldwide research in this sector includes collaborations with more than 160 cancer centers. GSK is developing a new generation of patient-focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

Haemalogic Technologies, Inc. (HTI) is a manufacturer of research reagents, specializing in the plasma proteins involved in the regulation of blood coagulation and fibrinolysis. Our product line of highly purified proteins includes zymogens, enzymes, cofactors, and inhibitors as well as monoclonal and polyclonal antibodies.

Haemonetics is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.

To learn more about Haemonetics visit our web site at www.haemonetics.com

Helena Biosciences' unparalleled clinical diagnostics experience extends over thirty years, driven by a com-
Sponsor and Exhibitor Profiles

Helena Biosciences

Commitment to excellence, value and the best customer service. Specialising in Clinical Electrophoresis and Haemostasis, Helena Biosciences manufacture and market the most innovative diagnostic products, providing clinicians worldwide with a comprehensive portfolio of blue-chip instrumentation, software and assays.

Helena Biosciences Europe delivers integrated capillary and agarose gel electrophoresis systems - in addition to a range of haemostasis instrumentation and reagents.

**HEMACORE LLC**

34th street of 8 March
125319, Moscow
Russia

mail@hemacore.com
www.hemacore.com
www.thrombodynamics.com

HemaCore LLC - biotech company, develops medical devices and methods for hematology. Main product is Thrombodynamics assay - a new global blood test for monitoring and prognosis of clotting disorders: bleeding and thrombosis. Thrombodynamics assay is highly sensitive both to pro- and anticoagulant changes in hemostatic balance. Thrombodynamics analyzer and disposables sales in Russia will start in November 2012. Planned launch date in Europe is April 2013.

**HERMANSKY-PUDLAK SYNDROME NETWORK UK**

(HPS NETWORK UK)

**BOOTH N°7**

Howards Drive, Hemel Hempstead 49
Herts, HP1 3NW
United Kingdom

chris@hpsnetwork.co.uk
www.hpsnetwork.co.uk

The HPS Network UK was established in 2010. We are affiliated to the US based HPS Network Inc. We are a not-for-profit group working for the benefit of individuals and families affected by Hermansky-Pudlak Syndrome - and those who seek diagnostic testing. We aim to work with health professionals to develop: A) quicker consistent routes to reliable testing, B) standards of care and referral for those affected by HPS. We encourage affected individuals and families to adopt a proactive role in their healthcare by providing information and support. HPS involves: a platelet bleeding disorder, albinism, visual impairment with photophobia and nystagmus, life limiting pulmonary fibrosis, a granulomatous ‘Crohns-like’ colitis, immunodeficiency and HLH (HPS-2 only).
Sponsor and Exhibitor Profiles

**INSPIRATION BIOPHARMACEUTICALS, Inc.**

*SPONSOR*

One Kendall Square, Building 1400 East
Cambridge, MA 02139
United States

www.inspirationbio.com

**Inspiration Biopharmaceuticals**

Inspiration was founded by families with hemophilia, with a mission to improve the lives of people with hemophilia around the world. We are the only biopharmaceutical company focused exclusively on hemophilia. We are working with the community to drive innovation and expand global access to recombinant therapies. Inspiration is led by a management team with extensive experience bringing biopharmaceuticals to market. We have two late-stage products in clinical studies: a recombinant factor IX and a recombinant porcine factor VIII.

**MICROVISK TECHNOLOGIES**

*BOOTH N°22*

Unit 4 Innovation House
Ffordd Richard Davies
St Asaph Business Park
St Asaph, LL170LJ
United Kingdom

info@microvisk.com
www.microvisk.com

Microvisk Technologies is a UK based developer of microviscometry products. First to market are the CoagMax® and CoagLite® point of care coagulation monitoring systems. Currently in the process of final clinical trials it is expected that these will be available for sale under the CE mark shortly and in the US towards the end of the year. The highly patented MEMS (Micro Electro Mechanical System) sensor uses a form of mechanical clot detection to accurately chart the formation of a clot in both whole blood and calcified plasma. CoagMax® is designed for the professional INR tester with the function to upload operator and patient ID’s. The CoagLite® is designed to be as simple as possible for the self-tester and brings the simplicity of blood glucose testing to the point of care INR market for the first time.

**INSTRUMENTATION LABORATORY**

*BOOTH N°27*

Hartwell Road 180
Bedford, MA 01730
United States

www.ilww.com

Instrumentation Laboratory (IL) is passionate about delivering the most innovative solutions to address a range of hemostasis testing needs. The advanced ACL™ family of systems brings complete automation to the hemostasis lab - including the ACL TOP® Family of Hemostasis Testing Systems, featuring the new ACL TOP 300 CTS; and, the ACL AcuStar®, the first fully automated, chemiluminescent analyzer for hemostasis specialty testing. Combined with the HemosIL line of reagents, a comprehensive panel of fully automated assays, IL offers complete disease state management for the hemostasis lab.
predictivity for stent thrombosis after PCI and allows for superior stratification of major bleeding risk and transfusion requirements in cardiac surgery. Multiplate® enables the rapid verification or exclusion of drug induced or disease related platelet disorders. The clinical predictivity of the perioperative use of Multiplate® has been validated in several clinical studies.

Mitsubishi Pharma Europe is the European Headquarters of one of Japan’s largest pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation. Based in London, Mitsubishi Pharma Europe is engaged in the clinical development of new drugs for the European markets. Mitsubishi Pharma Europe is conducting trials in Europe in the following therapy areas; cardiovascular, diabetes, CNS and renal conditions. The staff include regulatory, QA, clinical, biostatistics, medical information, pharmacovigilance, pharmaceutical technology and marketing.

With more than 900 installations Multiplate® is the most widely applied platelet aggregometer in Europe for the monitoring of antiplatelet therapy and the detection of platelet disorders. The POC and laboratory use of Multiplate® delivers superior clinical
Pathway Diagnostics Ltd was established in 1999 as a distribution and manufacturing company specialising in the field of haemostasis. The company is the exclusive distribution partner in the UK and Ireland for Technoclone GmbH and markets their coagulation and fibrinolysis reagents, and instrumentation to clinical, research and industry clients. Pathway Diagnostics markets its own range of haemostasis tests, including assays for Prekallikrein Activator, and those of Unicorn Diagnostics Ltd internationally through local distributors or directly from the UK. The company's product ranges are available in Ireland and Northern Ireland through its Dublin based distributor, LanganBach Services Ltd.

With many years of experience in the IVD industry, Pathway Diagnostics is highly focused on the needs of its customers and in providing the highest quality products and service.
Sponsor and Exhibitor Profiles

PENTAPHARM / DSM  
BOOTH N°16

Postfach  
CH-4002 Basel  
Switzerland

michael.janssen@pentapharm.com  
www.pentapharm.com

The Branch Pentapharm, since 2007 part of DSM, is a manufacturer of haemeostasis diagnostics:
Test kits e.g. Pefakit® APC-R Factor V Leiden, PiCT® (for UFH, LMWH and/or anti-FIIa and FXa drug monitoring), Reptilase Time, in-TDT® (for thrombin generation), or OEM products.
Reagents (from research to bulk quantities) including customer manufacturing n: synthetic chromogenic, fluorogenic and amperogenic substrates, protease inhibitors and snake venom enzymes.
Active pharmaceutical ingredients: aprotinin, peptides and snake venom derived enzymes (Batroxobin, Haemocoagulase) and synthesis of peptides and small organic molecules.

PFIZER  
BOOTH N°25

Pfizer Limited  
IPC 4-1, Walton Oaks,  
Dorking Road, Walton-on-the-Hill,  
Tadworth, Surrey  
KT20 7NS  
United Kingdom

www.Pfizer.co.uk

Pfizer: Working Together for a Healthier World™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

PRECISION BIOLOGIC  
BOOTH N°12

Eileen Stubs Avenue 140  
Dartmouth  
NS, B3B 0A9  
Canada

info@precisionbiologic.com  
www.precisionbiologic.com

Precision BioLogic develops, manufactures and markets diagnostic products used for testing in routine and special coagulation laboratories around the globe. Our unique approach to doing business is built on our superior products, commitment to customer service and attention to detail. Over the past 20 years, our cryocheck™ frozen controls, calibrators and reagents have become synonymous with quality. Today, we are growing our product base to help meet customers’ needs by adding more in vitro diagnostics, including our line of clot-based diagnostic kits. Learn more at www.precisionbiologic.com.
## Sponsor and Exhibitor Profiles

### SANOFI  
**Rue de la Boetie 54**  
75008 Paris  
France  
  
christopher.hunter-ward@sanofi.com  
http://en.sanofi.com/home.asp  

Sanofi a diversified global healthcare leader, focused on patients’ needs Sanofi has core strengths in the field of healthcare with growth platforms: emerging markets, human vaccines, consumer healthcare, diabetes, innovative products and animal health. Through the acquisition of Genzyme, Sanofi has reinforced its footprint in biotechnology and rare diseases. Sanofi’ strategy is based on three key principles in order to deliver long-term sustainable growth: increasing innovation in Research & Development, seizing external growth opportunities, adapt to future challenges and opportunities.  
Sanofi:  
- More than 110,000 employees in 100 countries  
- 2011 net sales: €33.4 billion  
For more information: http://en.sanofi.com/home.asp

### SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GmBH  
**Emil-von-Behring-Straße 76**  
35041 Marburg  
Germany  
  
michael.noeh@siemens.com  
www.siemens.com/healthcare  

Siemens Healthcare Diagnostics offers a comprehensive portfolio of performance-driven systems, unmatched test menu, and information technology solutions for the in vitro diagnostic needs of hospital labs, reference labs, physician office labs, and point-of-care testing. We provide clinicians with the vital information they need for accurate diagnosis, treatment, and monitoring of patients. Our diagnostic solutions - chemistry, immunoassay, automation, hematology, hemostasis, microbiology, diabetes, urinalysis, blood gas, and molecular testing - are designed to streamline workflow, enhance operational efficiency, and support improved patient care.

### STAGO  
**Headquarters**  
Rue des Frères Chausson 9  
92600 Asnières sur Seine  
France  
  
www.stago.com  

Stago dedicates its research and innovative skills to develop and improve the accuracy of the medical diagnostic. The firm formulates manufactures and markets worldwide, a broad range of reagents (routine &
Sponsor and Exhibitor Profiles

Technoclone is a world leading producer of global and special coagulation tests, calibration and control plasmas and Ceveron machines. Ceveron® alpha TGA is not only a fully automated coagulation analyzer for clotting, photometric and immunological, latex based coagulation tests but also offers the unique feature of fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin.

Another innovation is the Ceveron® MFU 500, a micro particle filtration unit which can identify micro particles thrombogenicity in conjunction with the assay Technothrombin® MP. Furthermore Technoclone provides a complete range of ADAMTS13 ELISAs and FXIII assays, as well a complete portfolio for the new anticoagulants such as for Xa inhibitors and direct thrombin inhibitors.

Technoclone

Brunner Strasse 67
1230 Vienna
Austria

sales@technoclone.com
www.technoclone.com

Technoclone is a world leading producer of global and special coagulation tests, calibration and control plasmas and Ceveron machines. Ceveron® alpha TGA is not only a fully automated coagulation analyzer for clotting, photometric and immunological, latex based coagulation tests but also offers the unique feature of fully automated thrombin generation measurement in the routine: CV <5% and assay times <20min Peak Thrombin.

Another innovation is the Ceveron® MFU 500, a micro particle filtration unit which can identify micro particles thrombogenicity in conjunction with the assay Technothrombin® MP. Furthermore Technoclone provides a complete range of ADAMTS13 ELISAs and FXIII assays, as well a complete portfolio for the new anticoagulants such as for Xa inhibitors and direct thrombin inhibitors.
Exhibitors
List correct as at 22 May 2012

<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>4S DAWN Clinical Software</td>
</tr>
<tr>
<td>17</td>
<td>Affinity Biologicals Inc.</td>
</tr>
<tr>
<td>26</td>
<td>Alexion</td>
</tr>
<tr>
<td>19</td>
<td>Amgen</td>
</tr>
<tr>
<td>1</td>
<td>Baxter Healthcare Inc.</td>
</tr>
<tr>
<td>18</td>
<td>Boehringer Ingelheim Limited</td>
</tr>
<tr>
<td>2</td>
<td>CSL Behring</td>
</tr>
<tr>
<td>14</td>
<td>Daiichi Sankyo Europe GmbH</td>
</tr>
<tr>
<td>24</td>
<td>Enzyme Research / r2 Diagnostics</td>
</tr>
<tr>
<td>5a</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td>6</td>
<td>Haematologic Technologies, Inc.</td>
</tr>
<tr>
<td>15</td>
<td>Haemonetics Corporation</td>
</tr>
<tr>
<td>10</td>
<td>Helena Biosciences Europe</td>
</tr>
<tr>
<td>7</td>
<td>Hemacore LLC</td>
</tr>
<tr>
<td>13</td>
<td>HPS Network UK</td>
</tr>
<tr>
<td>27</td>
<td>Instrumentation Laboratory</td>
</tr>
<tr>
<td>22</td>
<td>Microvisk Technologies</td>
</tr>
<tr>
<td>5b</td>
<td>Mitsubishi Pharma</td>
</tr>
<tr>
<td>8</td>
<td>Multiplate - Verum Diagnostica GmbH</td>
</tr>
<tr>
<td>29</td>
<td>Octapharma AG</td>
</tr>
<tr>
<td>16</td>
<td>Pentapharm / DSM</td>
</tr>
<tr>
<td>25</td>
<td>Pfizer</td>
</tr>
<tr>
<td>12</td>
<td>Precision BioLogic</td>
</tr>
<tr>
<td>3</td>
<td>Siemens - Healthcare Diagnostics Products GmbH / Sysmex UK Ltd.</td>
</tr>
<tr>
<td>28</td>
<td>Stago</td>
</tr>
<tr>
<td>23</td>
<td>Technoclone / Pathway Diagnostics Ltd.</td>
</tr>
</tbody>
</table>
Congress Centre Floor Plan

Cityside Entrance

Riverside Entrance
Wiley-Blackwell is proud to publish the Journal of Thrombosis and Haemostasis

Reasons to Read JTH:
It is the number one international specialty journal in the field of thrombosis, bleeding disorders and vascular biology
It offers original research reports, state-of-the-art reviews, commentary and debate on timely topics
With an impact factor of 5.439, it presents highly cited articles written by internationally acclaimed experts in the field
It is yours free when you join ISTH

www.wileyonlinelibrary.com/journal/JTH